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ABSTRACT 
The overall aim of this thesis is to explore aspects of overdiagnosis, i.e. the diagnosis of a tumor that in the 
absence of screening would never have been diagnosed, in prostate cancer (PC) screening. The four papers 
in this thesis all emerge from the Göteborg randomized population-based PC screening trial, in which 
10,000 men were invited to biennial prostate-specific antigen (PSA)-screening between 1995 and 2014 and 
10,000 non-invited constituted a control group. In paper I, the accuracy of cause of death (COD) 
certificates, for men with PC, is evaluated by comparison with the COD as assigned by an independent 
committee after blinded review of medical records. Paper II assesses outcomes for men with screen-
detected PC managed with, so called “active surveillance”. In paper III, organized screening is compared 
with opportunistic screening with respect to effectiveness in reducing PC mortality, measured as the 
number needed to invite (NNI) to screening and overdiagnosis, measured as number needed to diagnose 
(NND) to prevent one man from dying from PC. Paper IV investigates the risk of being diagnosed with PC 
depending on age at screening and the number of screens. The overall agreement between COD 
certificates and the committee was 96%. A large proportion of men screen-detected PC has low-risk PC 
(60%) and could safely be managed with active surveillance, at least with intermediate follow-up. 
Organized screening was more effective in reducing PC mortality and was associated with less 
overdiagnosis than opportunistic screening (NNI 139, NND 13 versus NNI 493, NNI 23). The risk of 
being diagnosed with PC increased dramatically with age but there was no apparent relation to the number 
of screens. From this thesis it can be concluded that Swedish COD certificates have a high accuracy and 
can be used for COD determination for men with PC, at least in the age-range studied (50-64 years old at 
the start of screening). Active surveillance appears safe for men with low-risk PC and should be used as a 
treatment strategy in order to reduce overtreatment. In order to reduce overdiagnosis and improve the 
benefit harm ratio of PC screening, screening should be conducted within the frameworks of an organized 
program where “younger” men could be screened relatively intense but where “older” men are screened 
more selectively.  
Keywords: active surveillance, age, cause of death, opportunistic, organized, overdiagnosis, prostate 
cancer, prostate-specific antigen, risk factors, screening, screening interval 
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 SAMMANFATTNING PÅ SVENSKA 
Bakgrund 
Denna avhandling har som övergripande mål att studera olika aspekter av 
överdiagnostik vid screening för prostatacancer (PC) med blodprovet 
prostataspecifikt antigen (PSA). Med överdiagnostik menas diagnos av en 
cancer som i avsaknad av screening aldrig skulle ha gett symptom eller ha 
upptäckts. Överdiagnostik leder till att ”friska” män får en cancerdiagnos och 
riskerar att behandlas i onödan. Den botande behandlingen för PC (operation 
eller strålbehandling) är förknippad med många biverkningar som till 
exempel nedsatt potens, urinläckage och tarmbesvär. Överdiagnostik och 
dess konsekvenser är huvudanledningen till att allmän screening för PC inte 
har införts i Sverige trots att det finns starka belägg för att PSA-screening 
skulle kunna minska dödligheten i PC. Denna avhandling består av fyra 
delarbeten som alla är sprungna ur en screeningstudie för PC i Göteborg. 
Denna studie startades 1995 då 10,000 män, födda mellan 1930 och 1944, 
lottades till regelbundna PSA-kontroller och 10,000 män lottades till att 
utgöra en kontrollgrupp som inte inbjöds. Våren 2014 avslutades den 10:e 
och sista screeningomgången. Avhandlingens fyra delarbeten syftar till att 
besvara följande frågeställningar:     
• Kan svenska dödsorsaksintyg användas för utvärdering av 
PC dödlighet i screeningstudien i Göteborg trots stor 
skillnad i överdiagnostik mellan armarna? 
• Kan överbehandling minska genom aktiv övervakning?  Är 
aktiv övervakning ett säkert behandlingsalternativ för 
utvalda män med screeningupptäckt PC? 
• Skiljer sig organiserad och opportunistisk screening åt 
avseende effektivitet i att minska dödligheten i PC och 
risken för överdiagnostik?  
• Hur påverkar ålder och antal gånger en man PSA-testas för 
risken att få diagnosen PC? 
Metoder 
I det första delarbetet insamlades journaler och dödsorsaksintyg för alla män 
med PC-diagnos som hade avlidit mellan 1995 och 2008. En 
expertkommitté bestående av tre erfarna urologer granskade sedan 
materialet och fastställde dödsorsaken med hjälp av en algoritm 
(flödesschema). Expertkommitténs utlåtande jämfördes därefter med 
dödsorsaken på dödorsaksintyget. I det andra delarbetet studeras de män 
med screeningupptäckt PC som inte omedelbart genomgick aktiv behandling 
med operation eller strålbehandling, utan som följdes med så kallad aktiv 
monitorering mellan åren 1995 och 2010. Aktiv övervakning är en 
behandlingsstrategi som syftar till att minska onödig behandling av 
screeningupptäckt PC. Med denna strategi följs mannen med regelbundna 
kontroller och först om tumören visar tecken på att växa eller bli mer 
aggressiv går man vidare med operation eller strålbehandling. Förhoppningen 
är att mannen helt kan avstå alternativt skjuta upp, behandling ett antal år 
utan att chansen till bot missas. I det tredje delarbetet jämförs organiserad 
screening med opportunistisk (oorganiserad) screening avseende förmåga att 
minska dödligheten i PC och risken för överdiagnostik. Screeninggruppen i 
Göteborgsstudien har genomgått organiserad screening och kontrollgruppen 
har under samma period exponerats för opportunistisk screening, det vill säga 
PSA-testning på vårdcentralen, i samband med hälsokontroller eller som del i 
utredning av till exempel vattenkastningsbesvär. Genom att jämföra med 
historiska data från 1990-94 (innan PSA var utbrett som screeningtest) kunde 
vi studera hur organiserad och opportunistisk screening påverkat incidens 
(antal nya PC-fall över tid) och dödlighet i PC. I det fjärde arbetet studeras de 
män som deltagit i alla screeningomgångar de inbjudits till, vilket kunde 
variera mellan 3 och 10 screeningtillfällen, beroende på hur gamla de var vid 
studiestart. Eftersom männen hade genomgått olika antal PSA-test vid olika 
åldrar kunde vi jämföra hur stor risken var att bli diagnostiserad med PC, och 
därmed också risken att bli överdiagnostiserad, beroende på ålder och antalet 
gånger en man tagit PSA.      
Resultat och kommentarer 
I: Dödsorsaken angiven på dödsorsaksintygen stämde till 96% överens med 
den dödsorsak som kommittén hade angett. Då de fall där dödsorsaken på 
intyget och kommitténs beslut inte överensstämde var få kunde inte någon 
riskfaktor för ett felaktigt intyg fastställas. Resultaten visar att svenska 
dödsorsaksintyg för män med PC håller hög kvalitet, åtminstone inom ramen 
för den studerade åldersgruppen (50-64 år vid start av screeningen). När 
männen i studien blir äldre ökar annan sjuklighet vilket eventuellt kan 
försämra kvaliteten på dödsorsaksintygen.     
II: En stor andel (60%) av de män som diagnostiserats med screeningupptäckt 
PC har cancer av lågrisktyp. Aktiv övervakning förefaller vara en säker 
monitoreringsstrategi för dessa män, i alla fall under en begränsad tid (i 
denna studie 6 år). För män med tumörer av en högre riskkategori tycks aktiv 
övervakning vara mer riskfyllt. Om en man med denna tumörtyp önskar aktiv 
övervakning bör han tydligt informeras om att det finns risk att missa 
chansen att bli botad vid senarelagd operation eller strålbehandling. 
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 III: Organiserad screening var mer effektiv än opportunistisk screening när 
det gällde att minska dödligheten i PC. Med en uppföljning på 18 år behövde 
139 män bjudas in till organiserad screening för att förhindra ett dödsfall i 
PC, medan motsvarande siffra för opportunistisk screening var att 493 män 
behövde exponerats för denna screeningform. Dessutom resulterade 
opportunistisk screening i mer överdiagnostik än organiserad, 23 män 
behövde diagnostiseras med PC för att förhindra ett dödsfall med medan 
denna siffra var 13 för organiserad screening.   
IV: Risken att bli diagnostiserad med PC var kraftigt beroende av ålder 
medan antalet gånger en man hade tagit PSA-test var av mindre betydelse. 
Om en man till exempel hade kontrollerat PSA fem gånger vid 60 års ålder 
var risken för PC 8.4% medan motsvarande risk vid 65 års ålder var 13% och 
vid 70 år 21%. Resultaten indikerar att risken för överdiagnostik är mer 
kopplad till åldern för när en man slutar kontrollera PSA än hur många 
gånger en man kontrollerat sitt PSA.      
Slutsatser 
Svenska dödsorsaksintyg för män med PC håller hög kvalitet och kan 
användas som underlag för dödsorsaksbestämning i screeningstudier för PC. 
Överdiagnostik är vanligt vid PSA-screening och ökar kraftigt med stigande 
ålder. Om en välinformerad man önskar PSA-testning bör detta ske inom 
ramen för ett organiserat program med täta intervall och noggrann 
uppföljning. Aktiv övervakning bör vara ett alternativ för utvalda män med 
screeningupptäckt lågrisk PC i syftet att minska onödig behandling. Möjliga 
förbättringsområden för PSA-screening som skulle kunna förbättra balansen 
mellan fördelar och nackdelar är: 
-organisera PSA-screeningen inom ramen för ett screeningprogram.  
-screena mer selektivt; undvik screening av äldre män och de med annan 
sjuklighet  
-undvik onödig omedelbar aktiv behandling med operation eller 
strålbehandling för män med cancer av lågrisktyp genom att erbjuda aktiv 
övervakning. 
Framtiden 
Det pågår mycket forskning för att hitta bättre verktyg för screening och tidig 
diagnostik av PC. Nya biomarkörer, genetiska test och bilddiagnostiska 
metoder så som multiparametrisk magnetkameraundersökning verkar lovande 
inför framtiden. Det ultimata screeningtestet/undersökningsmetoden bör vara 
ickeinvasivt, billigt, ha en hög sensitivitet och specificitet för PC och undvika 
att diagnostisera cancer som aldrig skulle gett symptom i frånvaro av 
screening. 
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1 INTRODUCTION 
Modern medicine has strived towards detecting and treating conditions at 
earlier stages. With more sensitive tests and imaging techniques small tumors 
are now being detected, which in the absence of such examinations would 
never have been diagnosed during the lifetime of the host. This is referred to 
as overdiagnosis. Screening has been – and still is – an important strategy for 
early detection, as it enables the detection of a disease at an asymptomatic 
stage. However, during recent years, there has been a growing awareness that 
finding “everything” is not always desirable. The concept of overdiagnosis, 
and the associated concept of overtreatment, has gained attentiveness among 
medical professionals. However, much work remains and overdiagnosis is 
still not a term in Dorland’s Medical Dictionary.[1]  
This strive towards early detection has also influenced the field of urology 
and prostate cancer (hereafter referred to as PC). From being a highly lethal 
disease where most men were beyond the chance of cure by the time of 
diagnosis, the advent of prostate-specific antigen (PSA) as a screening test 
for PC has completely changed the clinical landscape of PC. Today, most 
men are diagnosed with early stage PC. With early diagnosis and treatment 
much suffering from advanced PC and many PC deaths can be prevented. 
However, similar to other forms of early detection strategies, PC screening is 
a double-edged sword; there are both pros and cons. A considerable 
proportion of those diagnosed with screen-detected PC have little to gain 
from being diagnosed or treated, because of the slow growing nature of 
certain PCs and/or from the risks of competing causes of death in older men. 
Whether or not organized screening for PC should be introduced in Sweden 
is an ongoing controversy. The main obstacles for implementing population-
based screening are the high levels of overdiagnosis and overtreatment with 
current screening strategies. This difficult balance of benefits and harms is 
the rationale behind this thesis, which aims at exploring different aspects of 
overdiagnosis in screening for PC with PSA.  
The four papers that constitute this thesis are all based on the Göteborg 
randomized population-based prostate cancer screening study.[2] This study 
started already in 1995 and at the time of writing this thesis the 10th and final 
screening round has just been completed. The Göteborg screening study is 
unique among screening studies for several reasons, mainly because it has a 
long follow up (20 years today). Another factor making the Göteborg study 
unique is the fact that when the study was launched in the mid 1990’s, the 
Swedish male population constituted a previously unscreened population and 
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very few men had had a PSA-test. Therefore, the design of the Göteborg 
study will never be possible to replicate today, since PSA-testing is now 
more or less widespread. Thus, the Göteborg study constitutes an exclusive 
source of information regarding the effects of introducing organized 
screening on a previously unscreened population. 
1.1 The prostate gland 
The prostate is a small gland, normally the size of a walnut, located 
approximately 2 centimeters posterior to the pubic bone right below to the 
bladder. It is shaped like a truncated cone, enclosed by a capsule, with an 
anterior, posterior and lateral surface, a narrowed apex inferiorly and a broad 
base superiorly. The urethra runs through the prostate and the apex of the 
prostate is continuous with the urethral sphincter. Neurovascular bundles 
containing nerves controlling erectile function (potency) runs postero-lateral 
to the prostate in the lateral prostatic fascia making them vulnerable for being 
damaged when the prostate is removed surgically or treated with 
radiotherapy. The vas deferens and the two seminal vesicles are found 
posterior to the prostate and a small space, Denonvilliers fascia, separates 
them and the prostate from the rectal wall. The close contact with the rectal 
wall makes the prostate accessible for digital palpation and transrectal 
biopsies. A shallow groove palpable on rectal examination divides the gland 
in a right and left lobe.[3] 
The prostate is composed of glandular elements and a fibromuscular stroma. 
Histologically it can be divided into three different zones (Figure 1); the 
transition zone from which benign prostatic hyperplasia (BPH) arises and 
where approximately 20% of all PC originate, the central zone where only 1-
5% of all PC originates and the peripheral zone where the majority of the 
glandular tissue in located. This peripheral zone is also the zone where 70% 
of the PC arise and the zone commonly affected by chronic prostatitis.[3] The 
prostate glands consist of a single layer of secretory epithelial cells 
surrounded by a single layer of basal cells and a basal membrane.[4] The 
prostate produces 60% of the ejaculate and the prostatic secretion is believed 
to be important for the motility of the spermatozoa but the overall function of 
the prostate is principally unknown. 
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Figure 1. The prostate gland. (Reprinted with permission from AstraZeneca 
Oncolocy). 
1.2 Prostate cancer 
Prostate cancer is the most common cancer form (excluding non-melanoma 
skin cancer) in Swedish men. Every year, approximately 9000 men are 
diagnosed and PC is a major health concern. The age-adjusted PC mortality 
rate in Sweden is among the highest in the world. Approximately 2400 
Swedish men die from PC every year.[5] What causes PC is largely unknown 
but older age, ethnicity and heredity are well known risk factors.[6] Prostate 
cancer incidence increases strongly with age, and the disease is uncommon 
before the age of 50 years. 
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Figure 2. Prostate cancer, age-specific incidence, 1990-1992 and 2010-2012. Cases 
per 100 000, 3-year mean value. Adapted from: Cancerincidence i Sverige 2012,the 
National Board of Health and Welfare[5] 
The median age at diagnosis in Sweden, as in many other countries with 
wide-spread PSA testing, has decreased from 74 years in 1995 to 69 years in 
2005.[7] The age-span 65-69 years contains the greatest number of new cases 
(Figure 2).[5] Autopsy studies have confirmed the strong association between 
age and PC, showing that PC can be detected as early as in the 3rd decade of 
life. The prevalence of autopsy-detected PCs increases steadily with age, 
reaching 70-80% for men in their 80s.[8, 9] There are large geographic 
variations in both the incidence and mortality of PC. As with many other 
cancer forms heredity and environmental factors interact. A Western lifestyle 
with obesity, a high intake of dietary fat and red meat has been identified as a 
risk factor for developing PC, whereas a high intake of phyto-oestrogens and 
antioxidants have been suggested to have a protective effect. Chronic prostate 
inflammation have also been suggested to have a possible role in the 
development of PC.[6] Exogenous factors most certainly play an important 
role but the evidence available today is too weak and inconclusive to 
recommend any primary preventive measures. As previously mentioned, 
heredity is a very important factor and a large study based on the Swedish 
Family-Cancer Database showed that if the father had PC the risk for his son 
to be diagnosed with PC was 2-fold increased, but if three brothers were 
affected the risk was almost  18-fold increased.[10] True heredity PC, 
defined as three of more relatives with PC, or at least 2 close relatives who 
have developed early onset disease, is however, uncommon (approximately 
9%). Men with hereditary PC usually have disease onset approximately six 
years earlier than spontaneous cases.[11]  
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1.2.1 Incidence and mortality trends 
Prostate cancer is the second most common cancer in men and the sixth 
leading cause of death (COD) in men worldwide but there are large variations 
in incidence and mortality rates and trends over time.[12, 13] Incidence rates 
are highest in the high resource parts of the world such as North America and 
north-western Europe. On the contrary, mortality rates are among the highest 
in low-and medium resource countries such as Trinidad and Tobago and 
Cuba. Scandinavian countries also have high mortality rates. While the 
incidence rate is still increasing in most countries it has started to stabilize 
and decline in those countries which were among the first to adopt a 
widespread use of PSA (e.g. US and Canada). The greatest reductions in 
mortality rates are seen in high resource countries, while mortality is 
increasing in several countries in east and central Europe and South 
America.[13] Sweden is no exception to other high resource countries and in 
Sweden PC constitutes 32% of all cancer diagnosed.[14] Prostate cancer 
incidence was slowly increasing in Sweden until the mid to late 1990s. 
Thereafter the incidence rose dramatically and peaked in 2004 at a level of 
223 new cases per 100 000 men (age-standardized).[15] The incidence now 
appears to have stabilized and even started to decline. Yet one in five 
Swedish men will receive a PC diagnosis during their lifetime.[15] 
 
 
 
 
 
 
 
 
Figure 3. Prostate cancer incidence and mortality in Sweden 1970-2012. Number of 
prostate cancer cases and number of prostate cancer deaths per 100 000 (continuous 
line= incidence, dotted line=mortality). (Adapted from [5]) 
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Prostate cancer mortality has not exhibited the same fluctuation as the 
incidence trend but has remained relatively stable since the 1960s. However, 
a small annual decrease of 2.2% in the age-standardized PC mortality rate has 
been observed during the last decade. The life time risk for PC death for 
Swedish men is 5-6%.[15] 
Several factors contribute to the high PC incidence. An ageing population, 
increased awareness of prostate-related symptoms, better access to health 
care, increased usage of transurethral resection of the prostate (TUR-P) for 
BPH, an increase in the number of biopsy cores taken and a “true” incidence 
increase due to background risks such as exposure to dietary or 
environmental carcinogens are also contributing. However, most importantly, 
there is a direct relationship between the uptake of PSA use and PC 
incidence. Almost the entire incidence increase during the last 15-20 years 
can be explained by the detection of non-palpable (clinical stage “T1c”) 
tumors in parallel with decreased number of men diagnosed with 
metastasized disease. As an example, Sweden’s nationwide National Prostate 
Cancer Registry (NPCR) the proportion of men with low-risk tumors increase 
from 14% in year 1998 to 28% in 2012 while the proportion of men with 
distant metastases at diagnosis decreased from 25% to 13% during the same 
time period.[7] Another indication of earlier diagnosis is that the PSA-level at 
diagnosis has decreased from 23 ng/mL in 1998 to 9 ng/mL in 2012.[7] The 
proportion of men diagnosed with PC after a routine health check-up has 
increased from 29% in 2004 to 46% in 2012.[7] Future incidence trends are 
difficult to foresee as they are depending on future screening policies.  
The decreasing PC mortality trend in the western world also has several 
possible explanations such as early detection with PSA and more aggressive 
treatment of both localized and metastasized disease.[16, 17] To what extent 
the reduction is explained by an effect of screening is debated. Modeling 
studies have indicated that up to 45-70% of the mortality reduction seen in 
the US could be attributed to screening and that changes in treatment could 
explain about a third of the reduction.[16, 17] In the USA, PC mortality has 
decreased by 45% since its peak in 1991.[18] 
1.2.2 Natural course of prostate cancer 
Prostate cancer is a heterogeneous disease where the natural course can range 
from latent, slow-growing disease to fast-growing and aggressive, leading to 
death within a couple of years. Knowing the natural course of untreated PC, 
is important in order to choose the optimal strategy for a man with newly 
diagnosed PC. However, this clinical presentation has changed since the 
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introduction of PSA-testing. Today most cancers are diagnosed at an early 
stage and a substantial proportion of screen-detected tumors are 
overdiagnosed.[19]  Information regarding the natural course of PC can be 
obtained from several different sources.  
Autopsy studies are one important source as they illustrate the true 
prevalence of PC and give an indication on the upper limit of the amount of 
PCs that could potentially be detected with screening. A recent review of 
autopsy studies of white men with no clinical diagnosis of PC during their 
lifetime reported that PC was detected at autopsy in 16% of men in their 50’s 
and 40% of men in their 70’s.[20] It is unknown how large a proportion of 
these latent autopsy cancers that are detected with screening and that 
proportion is probably dependent on factors such as PSA threshold and 
number of biopsy cores taken. Konety et al. reported that the detection rate of 
latent PC at autopsy decreased 3-fold since the introduction of PSA which 
could indicate that PSA-testing detects a proportion of these autopsy 
cancers.[21]  
Information regarding the natural history of PC can also be obtained by 
observing a group of men who remain untreated. However, there are no 
“true” natural history studies for PC, even the observations studies that are 
generally referred to as the “natural history studies of PC” included men who 
received treatment, i.e. endocrine treatment for those with advanced disease. 
Despite these shortcomings, the studies by Chodak, Johansson, and Albertsen 
have contributed greatly to the understanding of the natural history of 
clinically diagnosed PC.[22-24] In 1994, Chodak et al presented a pooled 
analysis of 828 men from six non-randomized studies on deferred treatment 
for clinically localized PC. Men with well- and moderately differentiated 
tumors (cytological grade 1 and 2, corresponding to Gleason score ≤7) had a 
10-year disease specific survival of 87% in comparison to 34% for those with 
poorly differentiated tumors.[22] The Johansson study consisted of 642 men 
with PC in Sweden who did not receive immediate treatment. Prostate cancer 
mortality was associated with grade of differentiation; 15-year PC mortality 
was 6% for highly differentiated tumors, 11% for moderately and 56% for 
poorly differentiated tumors.[23] Albertsen et al. used the Connecticut Tumor 
Registry to identify 767 men aged 55-74 who were diagnosed with localized 
PC between 1971 and 1984 and managed conservatively.[24] In the well-
known Albertsen’s tables he depicted that the risk or dying from PC was 
closely related to Gleason score (for description see paragraph 1.2.3) and age 
at diagnosis. Men with well-differentiated tumors (Gleason score <6) had a 
low-risk (<11%) of dying from PC within 15 years, whereas men with 
moderately differentiated PC (Gleason score 7) had a risk between 42-70% 
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time period.[7] Another indication of earlier diagnosis is that the PSA-level at 
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diagnosed PC. However, this clinical presentation has changed since the 
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introduction of PSA-testing. Today most cancers are diagnosed at an early 
stage and a substantial proportion of screen-detected tumors are 
overdiagnosed.[19]  Information regarding the natural course of PC can be 
obtained from several different sources.  
Autopsy studies are one important source as they illustrate the true 
prevalence of PC and give an indication on the upper limit of the amount of 
PCs that could potentially be detected with screening. A recent review of 
autopsy studies of white men with no clinical diagnosis of PC during their 
lifetime reported that PC was detected at autopsy in 16% of men in their 50’s 
and 40% of men in their 70’s.[20] It is unknown how large a proportion of 
these latent autopsy cancers that are detected with screening and that 
proportion is probably dependent on factors such as PSA threshold and 
number of biopsy cores taken. Konety et al. reported that the detection rate of 
latent PC at autopsy decreased 3-fold since the introduction of PSA which 
could indicate that PSA-testing detects a proportion of these autopsy 
cancers.[21]  
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observing a group of men who remain untreated. However, there are no 
“true” natural history studies for PC, even the observations studies that are 
generally referred to as the “natural history studies of PC” included men who 
received treatment, i.e. endocrine treatment for those with advanced disease. 
Despite these shortcomings, the studies by Chodak, Johansson, and Albertsen 
have contributed greatly to the understanding of the natural history of 
clinically diagnosed PC.[22-24] In 1994, Chodak et al presented a pooled 
analysis of 828 men from six non-randomized studies on deferred treatment 
for clinically localized PC. Men with well- and moderately differentiated 
tumors (cytological grade 1 and 2, corresponding to Gleason score ≤7) had a 
10-year disease specific survival of 87% in comparison to 34% for those with 
poorly differentiated tumors.[22] The Johansson study consisted of 642 men 
with PC in Sweden who did not receive immediate treatment. Prostate cancer 
mortality was associated with grade of differentiation; 15-year PC mortality 
was 6% for highly differentiated tumors, 11% for moderately and 56% for 
poorly differentiated tumors.[23] Albertsen et al. used the Connecticut Tumor 
Registry to identify 767 men aged 55-74 who were diagnosed with localized 
PC between 1971 and 1984 and managed conservatively.[24] In the well-
known Albertsen’s tables he depicted that the risk or dying from PC was 
closely related to Gleason score (for description see paragraph 1.2.3) and age 
at diagnosis. Men with well-differentiated tumors (Gleason score <6) had a 
low-risk (<11%) of dying from PC within 15 years, whereas men with 
moderately differentiated PC (Gleason score 7) had a risk between 42-70% 
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and men with poorly differentiated tumors (Gleason score 7-10) had a high 
risk of dying from PC (70-87%) even if they were diagnosed as late as at age 
74 years. [24]  
The follow-up time is important when reading natural history studies. If 
followed long enough, localized PC that has remained relatively stable for 
10-15 years can shift to become more aggressive and lead to metastasis and 
PC death. Aus et al. reported already in 1995, in a much debated article, that 
PC mortality for men with initially non-metastasized disease was eventually 
as high as 50% if the patient lived long enough.[25] In the Johansson cohort, 
which has an impressive follow up of more than 30 years, PC mortality 
increased three-fold after 15 years but remained relatively stable thereafter. 
The results from these studies could not be corroborated by Albertsen et al. 
who reported on 20 years of follow-up from the Connecticut Tumor Registry, 
in which there was no significant difference in PC mortality rate before and 
after 15 years of follow-up.[26] 
The above mentioned studies were all conducted in the pre-PSA era and the 
study populations consisted mainly of men with palpable tumors (clinical 
stage T2). Therefore it has been questioned how the results can be applied to 
today’s men with screen-detected, non-palpable tumors. Screen-detected 
tumors differ substantially from clinical tumors with respect to the PSA-level 
at diagnosis, grade and stage distribution.[7] Furthermore, an additional 3-12 
years need to be added to survival estimates for screen-detected tumors due 
to lead time, i.e. the time that screening advances diagnosis as compared to 
its clinical presentation. Natural history studies of screen-detected cancers are 
scarce as the majority of men in the PSA era have been curatively treated. 
[27] One study by Lu-Yao et al. reported on the outcome of >14,000 men 
diagnosed between 1992 and 2002 at a median age of 78 years in the 
Surveillance, Epidemiology, and End Results Program (SEER)-database. A 
third of the population had T1c tumors and an additional third was T1a or 
T1b tumors. Ten-year PC-specific mortality was 8.3% for well-differentiated 
(Gleason score 2-4), 9.1% for moderately differentiated (Gleason score 5-7) 
and 25.6% for poorly differentiated tumors (Gleason score 8-10). The 
corresponding 10-year risks of dying from causes other than PC were 59.8%, 
57.2% and 56.5% for each group respectively.[28] Explanations, other than 
lead time, for the improvement in survival for screen-detected cancer include 
overdiagnosis, grade migration and improvements in medical care.  
The 2005 update of the Gleason grading system by the International Society 
of Urological Pathology (ISUP) has also had an effect on prognosis (see 
paragraph 1.2.3). A study by Gulati et al. used three different models to 
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project the risk of clinical detection, progression and PC death for screen-
detected PCs in the absence of any treatment. These risks were closely related 
to age at diagnosis and Gleason score. For example, the risk that men 
diagnosed with a Gleason score 2-7 tumor before the age of 60 would have 
been diagnosed clinically in the absence of screening was 67-93% 
(depending on model) and the risk that they would have died from PC in the 
absence of treatment was 23-34%. For the same age group, but with a 
Gleason score 8-10 tumors, these risks were 90-96% and 63-83% 
respectively.[29]       
Knowledge about the presumed natural history of screen-detected PC can 
also be gained from studies in which PSA has been measured in archived, 
frozen blood samples from men who later develop PC, by calculating the 
time from an elevated PSA-level to clinical diagnosis. These studies can also 
give estimates of lead time. For example, a study by Hugosson et al. 
compared the incidence and outcome of clinically detected PC in a group of 
men, from whom a venous blood sample had been drawn several years 
earlier, with the incidence and outcome of men with screen-detected PC in 
the first screening round of the Göteborg screening trial. With a PSA 
threshold of 3 ng/mL to perform sextant biopsies the detection rate of PC was 
16.2% in the screening group (of those with PSA 3-10 ng/mL), which can be 
compared to the cumulative risk of developing clinical PC after 15 years 
which was 29% for men with a PSA in the range 3-10 ng/mL. The prognosis 
for those with moderately elevated PSA (3-10 ng/mL), who later developed 
clinically detected PC was relatively poor with a chance of survival at only 
50%.[30] An often cited study based on stored serum samples is the study by 
Gann et al. which reported on 366 men in the U.S. Physicians Health Study 
who were diagnosed with palpable PC. For these men, PSA was elevated 4-6 
years before diagnosis.[31] Several studies based on the Malmö Preventive 
Project, which was originally a cardiovascular study in the 1970s and 80s, 
have added further evidence to the strong association between PSA-levels in 
midlife and the future risk of clinical PC. For example, it has been shown that 
a PSA at age 44-50 can predict the risk of developing both palpable and 
advanced PC up to 20 to 30 years later. For men with the highest PSA-levels 
(≈1 ng/mL or higher) the absolute risk of palpable PC was 8-12% and the risk 
of advanced PC was 4-6% after a median follow-up of 23 years. Eighty-one 
percent of advanced PC were found in men with a PSA above the median 
(>0.63 ng/mL) at age 44-50 years.[32] The same group has also reported that 
PSA at age 40-55 years can predict the risk of PC metastasis and mortality. 
Although a PSA below median could not be used to rule out PC death within 
the coming 20-30 years, a PSA below median at the age of 45-49 or 51-55 
years was associated with very low-risk of PC death within 15 years (0.09% 
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and 0.28% respectively).[33] PSA-level at age 60 years has also been shown 
to be predictive of the risk of dying from PC at age 85. Ninety-five percent of 
PC deaths occured in men with a PSA-level above the median (>1 
ng/mL).[34] The studies based on stored serum samples show that there is a 
clear association between the PSA-level and the future risk of clinically 
significant PC. 
Despite these studies the knowledge of the natural course of screen-detected 
PC is limited and additional research is needed in order to optimize screening 
as well as treatment of screen-detected cancers. 
1.2.3 Grading, staging and risk groups 
Prostate cancer is described by its grade and stage and these characteristic, 
together with the PSA-level at diagnosis are used for categorization of PC 
into different risk groups. Risk groups are predictive of prognosis and are 
valuable for guiding treatment decisions. 
Grading: the Gleason score 
In the 1960s, Donald F Gleason (1920-2008) created a grading system for PC 
based on the architectural pattern of the tumor.[35] It consisted of the sum 
(also called score) of the two most common patterns, called grades. Each of 
the grades could vary between 1 (well differentiated) and 5 (poorly 
differentiated), resulting in a sum between 2 and 10. It the most recent update 
by the International Society of Urological Pathology (ISUP) in 2005 it was 
decided that, for prostate biopsy material, pattern 1-2 should rarely, if ever, 
be used, and the Gleason score should instead be the sum of the most 
common grade plus the highest (worst) grade, yielding a summary Gleason 
score ranging between 6 through 10. For radical prostatectomy specimens, 
the Gleason score should still be reported as the two most common patterns 
but with a comment if small foci of higher grade were present.[36]  
The changes in the reporting of the Gleason score has resulted in a relative 
upgrading of PC nowadays, as compared to the reporting done before 2005. 
This has led to an artificial change in prognosis, called the Will-Rogers 
phenomenon.[37] Many tumors that would have been graded as Gleason 
score 6 before the 2005 update would now be graded as Gleason score 7. This 
implies that the prognosis for men with tumors assigned today’s Gleason 
score appears relatively better. This migration has been accompanied by an 
increased concordance between biopsy Gleason score and surgical Gleason 
score from 58% to 72%.[38]  
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Figure 4. Schematic diagram of the Gleason grading system. (Reprinted with 
permission from AstraZeneca).[39] 
Pathological grading is not an exact science; there is substantial intra- and 
inter-observer variability, even for pathologists specialized in urology.[40-42] 
The rumor has it that even Dr Gleason himself admitted that he duplicated his 
previous score about half the time. The European Randomized Study of 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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Screening for Prostate Cancer (ERSPC) is a large randomized trial of PSA 
screening conducted in eight European countries. This study has an 
international pathology committee. This committee performed a quality 
assurance on their own work and reported on the frequency of false-negative 
and false-positives biopsies by comparing the primary pathology reading 
from each ERSPC-center to that of 2 reference pathologists. For sextant 
biopsies false negatives occurred in 4-10% and false-positives 0.36% (cancer 
versus no cancer).[43] 
The Gleason score has shown to be one of the strongest prognostic factors for 
the clinical behavior of PC as well as for treatment response. Gleason score 
in included in all nomograms (a multivariate prediction tool, see chapter 6.1 
for further description) and risk prediction tools for PC.[28, 44] 
Staging 
The extent of the disease is commonly classified according to the Tumor 
Node Metastases (TNM) classification where T denotes the tumor size, N the 
extent of any lymph node involvement and M the presence or absence of 
distant metastases (Table 1). 
Clinical staging can be performed with PSA, digital rectal examination 
(DRE) and transrectal ultrasound (TRUS).[11] A bone scan is performed if 
there is a risk of bone metastases. This examination is sometimes 
complemented with radiology exams, such as computed tomography (CT), 
magnetic resonance imaging (MRI) or positron emission tomography (PET-
CT) in selected cases. Both PSA and DRE are poor predictors of the final 
stage at radical prostatectomy, but the combination of PSA, clinical T-stage 
and Gleason score at biopsy perform better than either variable alone. [45] 
MRI for T-staging has a high specificity (61-100%) for extracapsular 
extension of cancer but is limited by low sensitivity (22-82%) as MRI cannot 
detect microscopic extracapsular cancer growth. MRI can therefore be an 
alternative for T-staging only for selected intermediate and high risk 
cases.[11] 
Examinations with respect for N and M stage should only be performed if the 
outcome of the examination will affect the treatment decision, for example in 
high risk patients when discussing curative treatment. The risk of lymph node 
involvement can be assessed with nomograms or Partin tables.[46, 47] MRI 
and CT are also alternatives for N-staging but are limited by low sensitivity 
(<40% for a 10 mm threshold) and cannot detect microscopic lymph node 
invasion. They are therefore not routinely recommended but can be an 
alternative in high risk patients.[48, 49] 
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Table 1. The 2009 Tumor Node Metastases (TNM) classification for prostate 
cancer. (Adapted from [50]) 
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Table 1. The 2009 Tumor Node Metastases (TNM) classification for prostate 
cancer. (Adapted from [50]) 
 
T-primary tumor  
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T1b Tumor incidental histological finding in >5% of tissue resected 
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T2a Tumor involves one half of one lobe or less 
T2b Tumor involves more than half of one lobe, but not both lobes 
T2c Tumor involves both lobes 
T3 Tumor extends through the prostatic capsule 
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T3b Tumor invades seminal vesicle(s) 
T4 Tumor is fixed or invades adjacent structures other than seminal vesicles 
N-Regional lymph nodes  
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M0 No distant metastasis 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The gold standard for N-staging is pelvic lymph node dissection, that is, 
surgical removal of the lymph nodes in the pelvis.[49] The exact extent of the 
lymph node dissection and for which patients it should be performed is 
debated.  The 2014 European Association of Urology (EAU) Guidelines on 
Prostate Cancer recommends that limited lymph node dissection should not 
be performed as it misses >50% of nodes involved and that extended lymph 
node dissection is not necessary for low-risk patients but is indicated for 
some intermediate risk patients and for high-risk patients.[49] 
M-stage investigations are usually restricted to a bone scan as the skeleton is 
the main site for distant metastases from PC.[51] The diagnostic performance 
of a bone scan is highly dependent on the PSA-level, Gleason score and 
clinical stage and bone scans therefore usually reserved for symptomatic 
patients, or alternatively, asymptomatic patients with a PSA > 10-20 ng/mL 
and/or Gleason score >7.[48, 52] Suspicious “hotspots” on a bone scan can 
be further evaluated with an MRI or CT. 
Risk groups 
Risk groups are used to provide information on prognosis and the risk of 
recurrence after treatment. There are several different definitions (Table 2). A 
recent publication from the NPCR, which reported on long-term mortality of 
men with non-curatively treated PC in Sweden, illustrated the importance of 
a risk group classification. For men diagnosed with PC from 1991 through 
2009 PC mortality varied 10-fold according to risk group and age. For men 
younger than 65 years at diagnosis 15-year cumulative PC mortality ranged 
from 5.5% for those with low-risk PC to 81% for those with distant 
metastases at diagnosis. For the entire study population, 15-year cumulative 
PC mortality was as follows; low-risk 8.9%, intermediate risk 19.6%, high 
risk 35.5%, regionally metastatic 49.1% and distant metastases 69.5%.The 
degree of comorbidity according to the Charlson’s Comorbidity Index[53] 
was strongly associated with the risk of dying from competing causes 
especially for men <65 years. Competing causes of death were common 
across all age and risk groups. The 15-year cumulative risk of dying from 
competing causes ranged from 49.5% for those with low-risk PC to 27.7% 
for men with distant metastases at diagnosis. [54] These figures clearly show 
the variable natural history of PC and the importance of competing causes of 
death; many men with PC, even those with advanced disease, die from causes 
other than PC. 
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Risk groups are also predictive of the risk of biochemical recurrence, that is 
an increase in PSA-level after radical prostatectomy and/or radiation therapy, 
and the prognosis after treatment with curative intent, as was demonstrated in 
the studies by D’Amico et al.[55, 61] The D’Amico criteria are commonly 
used. They have been externally validated and shown to predict disease 
recurrence and survival following radical prostatectomy also in the more 
contemporary era.[62, 63] One limitation with risk group criteria, which 
becomes obvious when reviewing table 2, is that they vary between studies 
and organizations which make direct comparisons of estimates of outcomes 
difficult. 
1.2.4 Treatment alternatives 
Treatment for PC can have a curative intent or be symptomatic and palliative. 
Treatment strategies for PC include active surveillance, radical 
prostatectomy, various forms of radiotherapy, watchful waiting, hormonal 
treatment and a range of palliative chemotherapeutic agents for castration 
resistant PC.   
Radical prostatectomy can be performed with an open retropubic- or, less 
commonly, perineal technique or as a laparoscopic procedure with or without 
robot-assistance. During the procedure the entire prostate gland (between the 
urethra and the bladder), some surrounding tissues and often also the seminal 
vesicles, are removed. A urinary catheter is placed and the urethra is 
reattached to the bladder neck. Whether or not to spare the neurovascular 
bundles (uni- or bilateral nerve-sparing procedure) depends on the size and 
localization of the tumor, the patient’s age, preoperative potency status and 
patient preference. As previously mentioned, a limited lymph node dissection 
is no longer recommended and the indication for extended lymph node 
dissection is debated.[11, 64] However, it may provide important information 
about the prognosis but is associated with increased morbidity with 
complications including lymphoedema, lymphocele, deep vein thrombosis 
and pulmonary embolism.[65, 66]  
Radical prostatectomy is one of few surgical procedures that is considered 
“evidence-based”, i.e. there is level 1 evidence from a randomized controlled 
trial (RCT), the Scandinavian Prostate Cancer Group-4 trial, that this surgery 
provides a benefit in terms of both overall and disease-specific mortality 
compared to watchful waiting (observation). In this landmark study, the 
relative risk of PC death was 0.62 (95% CI, 0.44 to 0.87; P=0.010) with 
radical prostatectomy compared to watchful waiting, after 15 years of follow-
up. The number needed to treat to avoid one PC death was 15 overall and 7 
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for men younger than 65 years.[67] The study population consisted to a large 
extent of clinically diagnosed cancers – only 12% were clinical stage T1c 
(non-palpable tumors). The results of SPCG-4 could not be corroborated in 
the PIVOT trial, where the study population consisted predominately of men 
with PSA-detected clinically localized PC (50% T1c tumors). After a median 
follow-up of 10 years, there was no significant difference in overall- or PC 
mortality between radical prostatectomy compared to observation (HR, 0.88; 
95% CI, 0.71-1.08; p=0.22 and HR, 0.63; 95% CI, 0.36-1.09; p=0.09 
respectively).  However, a reduction in overall mortality was seen for men 
with PSA >10 ng/ml and possibly also for men with intermediate and high-
risk disease. [68] At the time of writing this thesis there has been no high-
quality randomized or prospective observational study that has been able to 
show that robot-assisted radical prostatectomy is superior to retropubic 
radical prostatectomy with regards to oncological and functional outcome. 
However, robot-assisted radical prostatectomy is associated with less blood-
loss and lower transfusion rates as well as shorter hospital stay, but comes at 
a higher monetary cost.[69-74] Post-operative incontinence and erectile 
dysfunction are the two most common side-effects regardless of operative 
technique. The experience and skills of the individual surgeon have been 
shown to be very important for functional and oncologic outcomes.[75-77]      
Radiotherapy can be given as external beam radiotherapy (EBRT), as low- 
(LDR) or high-dose rate (HDR) brachytherapy or as a combination or EBRT 
and HDR brachytherapy. Evolving techniques such as three-dimensional 
conformal radiotherapy and intensity-modulated external-beam radiotherapy 
have increased the precision of the radiation and therefore enabled dose-
escalations up to 78-80 Gray (Gy). The standard for ERBT in Sweden today, 
is to give 78 Gy/39 fractions.[64] These higher doses have in several studies 
shown to provide superior long-term cancer control.[78, 79] LDR 
brachytherapy is only performed at a few clinics in Sweden. Radioactive 
seeds of iodine or palladium are permanently implanted in the prostate. 
During a period of months these seeds deliver a high dose of radiation to the 
gland with limited damage to the surrounding tissues. HDR brachytherapy is 
given in combination with EBRT. After a series of EBRT, the HDR 
brachytherapy is given by placing hollow needles filled with radioactive 
material (iridium). Results from observational studies suggest that the effect 
regarding cancer control for the different strategies of radiotherapy is 
comparable.[80-82] Radiation to pelvic lymph nodes is generally not 
recommended as randomized trials have failed to show a beneficial effect of 
this procedure.[83] Several studies, including the Swedish SPCG-7 trial have 
shown that radiotherapy combined with hormonal treatment is superior to 
radiotherapy alone for intermediate and high-risk PC.[84-87]. Therefore, 
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androgen deprivation therapy is recommended before and after radiotherapy 
for high-risk PC.[64] Neoadjuvant hormonal treatment before radical 
prostatectomy is not recommended as it deranges the histological picture and 
makes it difficult to decide on the need for adjuvant treatment.  Radiotherapy 
can be given adjuvant to radical prostatectomy for those with a high risk of 
local recurrence or as “salvage radiation” after biochemical recurrence (2 
consecutive PSA values of >0.2 ng/mL post-operatively).  
Active surveillance is a relatively new treatment strategy, introduced in the 
last decade. It aims at reducing overtreatment of screen-detected PCs by 
postponing, or in some instances completely avoiding, curative treatment. In 
contrast to watchful waiting AS has a curative intent. Active surveillance 
implies that selected men with a low-risk PC are closely monitored with 
regular clinical examinations, PSA-tests and repeat biopsies. If there are signs 
of disease progression, treatment (radical prostatectomy or radiation therapy) 
is recommended with the intention to cure the patient. The challenge with 
active surveillance is to find the right candidates and the right signs of disease 
progression, so that the window of cure is not missed. Up to this day, there 
has been no RCT comparing active surveillance with other treatment 
strategies. The results from a large trial in the UK, the Prostate testing for 
cancer and Treatment (ProtecT)-trial, which has randomized men age 50-69 
years with localized PC to radical prostatectomy, radiation therapy or active 
surveillance, are awaited in 2016. There are several large active surveillance-
cohorts around the world which up to this date have reported medium-term 
outcomes (see subchapter 5.1 table 16 and 17). There are no evidence-based 
criteria for inclusion to active surveillance, how these patients should be 
followed or what should trigger intervention. Reported cohorts all have 
slightly different inclusion criteria but all are variations of very low and low-
risk PC and generally include: clinically confined PC (T1-2), Gleason score 
<7, PSA <10-15 ng/mL and some volume criteria in biopsies. Some series 
also include selected men with intermediate risk cancer (see subchapter 5.1 
table 15 and 16). 
Watchful waiting is a strategy where symptomatic treatment (endocrine 
treatment, trans-urethral resection of the prostate (TUR-P), and/or radiation 
therapy for bone metastasis) is initiated only if the cancer progresses and 
causes symptoms. It was a common strategy in the pre-PSA era and before 
radical prostatectomy became a wide-spread procedure. It has palliative 
intent and is mainly a treatment alternative for men with limited life-
expectancy due to age and/or a high degree of co-morbidity.  
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Endocrine treatment is generally reserved for advanced PC. The rationale 
behind endocrine treatment is that PC cells are dependent on testosterone for 
growth and perpetuation. The testes, controlled by the hormones LH and 
FSH, which in turn are controlled by the hormone LNRH, are the main 
sources of androgens but the adrenal glands also produce smaller amounts. 
Androgen deprivation can be achieved by suppressing the production by 
surgically removing the testes or by inhibiting LNRH secretion with agonists 
(negative feedback) or antagonists. The effect of androgens can also be 
blocked at the receptor level by anti-androgens.     
Choice of treatment is determined by tumor risk group, the patient’s general 
health, life-expectancy and patient preference. Various nomograms can be 
used to predict different PC outcomes.[88] The first assessment to make is 
whether the cancer is localized and potentially curable. Prostate cancer is 
believed to be beyond cure if there are distant metastases, lymph node 
involvement, if the PSA-level is above 100 ng/ml and if the tumor is clinical 
stage T4.[64] For these patients surgery or radiotherapy are not treatment 
options. In addition, treatment with curative intent is seldom recommended if 
the patient has a remaining life expectancy of less than 10 years, regardless of 
risk group. For men who are not candidates for curative treatment, the 
decision is when, or if, to start hormonal therapy. Hormonal treatment is 
generally recommended when symptoms arise. As there are no RCTs that 
have compared different curative treatments for PC with one another, the 
treatment decision is largely based on patient preference. Some cohort studies 
suggest that surgery is superior to radiotherapy in terms of oncological 
whereas other show similar results for the two treatment options.[89-92] 
Patients with very low-risk and low-risk tumors can be candidates for active 
surveillance. Surgery is the preferred alternative for those with higher risk 
tumors and larger prostates and radiotherapy is generally the first option for 
those with locally advanced tumors, clinical stage T3. The side-effects of 
various treatments and their effect on quality-of-life (QoL) are discussed in 
depth in paragraph 1.6.4. 
1.3 Prostate-specific antigen 
PSA is the most commonly used tumor marker in oncology. The early 
research on what would later be called PSA was performed by Flocks, Ablin 
and Hara in the 1960’s and 70’s. The initial research work on PSA in semen 
was carried out to assess PSA’s properties as a forensic marker for rape 
victims. In 1979 Wang was the first to purify PSA from the prostate[93] and 
in 1987 Stamey reported that PSA was a more sensitive marker for PC than 
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prostatic acid phosphatase which had previously been used.[94] Work by 
several researchers in the early 1990’s including Catalona, Labrie and Brawer 
showed that PSA could be used to assess risk of PC.[95-98] The U.S. Food 
and Drug Administration (FDA) approved the use of PSA for monitoring 
treatment response and disease recurrence and in 1994 it was approved as a 
screening tool for early detection of PC in asymptomatic men.[99]   
PSA is a serine protease produced by the luminal cells of the prostatic 
epithelium. It is a member of the kallikrein gene family and is secreted in 
high concentration into the seminal fluid which is mixed with the semen 
during ejaculation. PSA lyses the protein semenogelin and this process 
liquefies the ejaculate, hence improving the motility of the sperm. PSA 
expression is strongly influenced by androgens and PSA starts becoming 
measurable at puberty. PSA is normally found in low concentrations in serum 
where it circulates in both free and bound form (bound to alfa-1-
antichymotrypsin, alfa-2-macroglobulin and alfa-1-antitrypsin).[4] It is 
believed that disruption of the normal prostatic architecture with breakage of 
the basal cell layer and the basal membrane, caused by for example 
inflammation, BPH, PC or trauma (i.e. prostate surgery, biopsies, cystoscopy 
and urine retention) allows PSA to leak out to the circulation where it can be 
measured as a PSA elevation.[4] The characteristics of PSA as a screening 
test for PC are discussed in depth in chapter 1.5.1. 
1.4 Screening 
1.4.1 Definitions and strategies 
Screening, as defined by the World Health Organization, is “the use of simple 
tests across a healthy population in order to identify individuals who have a 
disease but do not yet have symptoms”.[100] It is a form of secondary 
prevention, which aims at finding individuals who are likely, or unlikely, to 
have the disease of interest so that the individual can be the subject to further 
work-up. The concept of screening is based on the assumption that early 
diagnosis and treatment will improve prognosis as compared to later 
diagnosis and treatment at a symptomatic stage.  The main goal of cancer 
screening is to reduce disease-specific mortality.  Screening can be performed 
with three different strategies: mass screening (screening the entire 
population), selective screening (e. g. screening only high-risk individuals), 
or opportunistic screening (non-organized screening, e. g. an individual 
having a certain test as part of a laboratory work-up performed in clinical 
practice or a test as part of a physical examination).[101]  
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According to the International Agency of Research of Cancer (IARC) an 
organized screening program is defined by [101]: 
• a written policy stating the target population, method of 
screening and screening interval 
• a defined target population 
• a management team responsible for implementation 
• a health care team responsible for decisions and care 
• a quality assurance structure 
• a method for detecting cancer occurrence in the target 
population 
1.4.2 Characteristics of a suitable disease 
To be suitable for screening a disease must have a preclinical (asymptomatic) 
phase when it can be detected by a screening test, and in addition, be such 
that is progresses over time. The preclinical phase starts with the biological 
onset of the disease. At some point during this process the disease becomes 
theoretically detectable by the screening test and the preclinical detectable 
phase starts. This point in time depends both on the characteristics of the 
disease and the characteristics of the test. The proportion of a population 
being in the preclinical detectable phase depends on the incidence of the 
disease, the average duration of the preclinical phase for that disease and any 
prior screening activity in the population.[102] If repeated screening takes 
place, the prevalence of the preclinical phase is determined mainly by the 
incidence of the disease. Generally, a disease is thought to be suitable for 
mass screening if the preclinical detectable phase is long enough and the 
prevalence of the preclinical detectable phase is high enough. In addition, the 
disease should have sufficient public health importance. As previously 
mentioned, early treatment must result in better prognosis and reduce disease-
specific mortality, in comparison to diagnosis when symptoms arise, for 
screening to be effective.[101] 
1.4.3 Characteristics of a suitable test 
A suitable screening test must be cheap, ubiquitous in the population and 
acceptable for the individual, i.e. reasonably free from discomfort and risks. 
It must also be reliable and valid. Reliability of a test is its “capacity to give 
the same results – positive of negative, whether correct or incorrect – on 
repeated application in a person with a given level of disease”.[102] Factors 
that affect reliability are the biological variability of the disease being 
screened for, the variability of the equipment and the intra- and inter-observer 
variability.[103] 
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Validity is the ability to correctly identify those who have and those who do 
not have the disease. The validity can be expressed by the test’s sensitivity 
and specificity (Table 3).[101, 103] Sensitivity is the probability to correctly 
classify people who have the disease. It is often difficult to estimate 
sensitivity of screening tests, since as a definitive, confirmatory, diagnostic 
test to find all those who have the disease (cells a+c in table3) is usually not 
performed on the screening population. One strategy of dealing with this 
limitation is to follow all individuals and to observe the number of cases that 
develop among the screening negative and to regard them as false-negatives 
(interval cancers, i.e. cancers that are detected between screening intervals). 
However, it is often difficult to know whether these are “true” false-negatives 
or new cases of fast growing cancers. Specificity of a test is the probability to 
correctly classify individuals without the disease. An optimal screening test 
would have 100% sensitivity and 100% specificity which is never the case. 
The results of the screening test for individuals with and without disease 
often overlap if the screening test is continuous, for example PSA and the cut 
off value for positive versus negative test result has the be somewhat 
arbitrary chosen.  In reality, there is often a trade-off between sensitivity and 
specificity.[101]  
Moreover, a screening program also has to be feasible. Two estimates of 
feasibility are the positive predictive value (PPV) and the negative predictive 
value (NPV).[101, 103] PPV is the proportion of individuals who tests 
positive who have the disease and NPV is the proportion of individuals who 
test negative who are disease-free. A high PPV is important for a screening 
test to be considered useful as it indicates that the test detects many cases 
among those with a positive test and that diagnostic resources for further 
work up are not spent unnecessarily on disease-free individuals. PPV and 
NPV for a given screening test are influenced by sensitivity, specificity and 
disease prevalence and are therefore not fixed characteristics of a test. 
Specificity has a greater effect on PPV than sensitivity, but the opposite is 
true for NPV. Specificity determines the number of false positives and as 
most people in a population are disease-free, a small decrease in specificity 
might have a large effect on the absolute number of false positives, which can 
results in large drop in PPV. PPV also increases with sensitivity and 
prevalence. A screening program can therefore improve its PPV by focusing 
on high-risk individuals (higher prevalence).[101, 103] 
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Table 3. Sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV)  
In 1968 Wilson and Jungner (then Chief of the Clinical Chemistry 
Department at Sahlgrenska sjukhuset) wrote a report entitled “Principles and 
practice of screening for disease” for the WHO in which they summarize ten 
criteria that need to be met in order for a disease to be suitable for screening. 
These criteria have become classic and are often cited.[104]  
Wilson and Jungner classic screening criteria 
 
• The condition sought should be an important health problem 
• There should be an accepted treatment for patients with 
recognized disease 
• Facilities for diagnosis and treatment should be available 
• There should be a recognizable latent or early symptomatic 
stage 
• There should be a suitable test or examination 
• The test should be acceptable to the population 
• The natural history of the condition, including development 
from latent to declared disease, should be adequately 
understood 
• There should be an agreed policy on whom to treat as 
patients 
• The cost of case-finding (including diagnosis and treatment 
of patients diagnosed) should be economically balanced in 
relation to possible expenditure on medical care as a whole 
• Case-finding should be a continuing process and not a “once 
and for all” project 
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Truth/gold standard  
Test result Disease No disease  
Positive a true positive b false positive a/a+b=PPV 
Negative c false negative d true negative d/c+d=NPV 
 a/a+c=sensitivity d/b+d=specificity  
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As screening generally is directed towards healthy people, the medical and 
ethical demands must be higher than for diagnosis and treatment for 
individuals with disease signs and symptoms. As the field of medicine has 
evolved with an increasing focus on evidence-based medicine, patient 
autonomy, cost-effectiveness and quality control several adaptions to the 
classical criteria have been suggested. Andermann et al., also on behalf of the 
WHO,  published ten new criteria, as a summary of  the requirements that 
have emerged during the last 40 years.[105] 
Andermann’s revised screening criteria 
• The screening program should respond to a recognized need 
• The objectives of screening should be defined at the outset 
• There should be a defined target population 
• There should be scientific evidence of screening program 
effectiveness 
• The program should integrate education, testing, clinical 
services and program management 
• There should be quality assurance, with mechanisms to 
minimize potential risks of screening 
• The program should ensure informed choice, confidentiality 
and respect for autonomy 
• The program should promote equity and access to screening 
for the entire target population 
• Program evaluation should be planned from the outset 
• The overall benefits of screening should outweigh the harm 
1.4.4 Evaluation of screening 
The main goals of a screening program are to reduce morbidity and mortality 
of the disease being screened for. Other important measures are process 
measures, such as the number of persons being screening and the number of 
cases detected. Intermediate measures that can be evaluated before mortality 
data is available are stage migration and case fatality. Stage migration implies 
that screen-detected cases are diagnosed at an earlier stage than clinically 
diagnosed cases and is an indication of screening effectiveness. Case fatality 
is the number of deaths among cases.[101] The effectiveness of a screening 
program can be evaluated with different study designs such as experimental 
(e.g. a RCT), cohort, case-control and ecological studies.[102, 103]  
There are several forms of biases that must be considered when evaluating 
screening. If survival is evaluated, a phenomenon called lead time bias may 
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occur. Lead time is the time by which screening advances diagnosis, i.e. the 
time from screen-detection to when the disease would have appeared 
clinically (Figure 5).[102] If survival is measured from time of diagnosis, 
survival of men with screen-detected cancer will appear longer, even if they 
do not actually live longer simply because they are diagnosed earlier. 
Another form of bias is length time bias, which is a form of selection bias. 
This can occur because screening tends to diagnose slow-growing, less 
aggressive tumors with a long preclinical detectable phase rather than the 
fast-growing and potentially lethal tumors (Figure 6). Volunteer bias is a 
third form of bias which occurs if people who volunteer for screening differ 
from those who do not.[103] Lead time and length time biases can be 
controlled for if screening is evaluated in RCTs of sufficient size where 
patients are randomized to screening versus no screening, where mortality is 
studied rather than survival, where all outcomes are counted regardless of 
method of detection (screen-detected and interval cancers) and where 
outcomes are compared for the entire study population and not just the 
participants.[102, 103]  
Figure 5. Lead time 
Prostate Cancer Screening 
24 
As screening generally is directed towards healthy people, the medical and 
ethical demands must be higher than for diagnosis and treatment for 
individuals with disease signs and symptoms. As the field of medicine has 
evolved with an increasing focus on evidence-based medicine, patient 
autonomy, cost-effectiveness and quality control several adaptions to the 
classical criteria have been suggested. Andermann et al., also on behalf of the 
WHO,  published ten new criteria, as a summary of  the requirements that 
have emerged during the last 40 years.[105] 
Andermann’s revised screening criteria 
• The screening program should respond to a recognized need 
• The objectives of screening should be defined at the outset 
• There should be a defined target population 
• There should be scientific evidence of screening program 
effectiveness 
• The program should integrate education, testing, clinical 
services and program management 
• There should be quality assurance, with mechanisms to 
minimize potential risks of screening 
• The program should ensure informed choice, confidentiality 
and respect for autonomy 
• The program should promote equity and access to screening 
for the entire target population 
• Program evaluation should be planned from the outset 
• The overall benefits of screening should outweigh the harm 
1.4.4 Evaluation of screening 
The main goals of a screening program are to reduce morbidity and mortality 
of the disease being screened for. Other important measures are process 
measures, such as the number of persons being screening and the number of 
cases detected. Intermediate measures that can be evaluated before mortality 
data is available are stage migration and case fatality. Stage migration implies 
that screen-detected cases are diagnosed at an earlier stage than clinically 
diagnosed cases and is an indication of screening effectiveness. Case fatality 
is the number of deaths among cases.[101] The effectiveness of a screening 
program can be evaluated with different study designs such as experimental 
(e.g. a RCT), cohort, case-control and ecological studies.[102, 103]  
There are several forms of biases that must be considered when evaluating 
screening. If survival is evaluated, a phenomenon called lead time bias may 
Rebecka Arnsrud Godtman 
25 
occur. Lead time is the time by which screening advances diagnosis, i.e. the 
time from screen-detection to when the disease would have appeared 
clinically (Figure 5).[102] If survival is measured from time of diagnosis, 
survival of men with screen-detected cancer will appear longer, even if they 
do not actually live longer simply because they are diagnosed earlier. 
Another form of bias is length time bias, which is a form of selection bias. 
This can occur because screening tends to diagnose slow-growing, less 
aggressive tumors with a long preclinical detectable phase rather than the 
fast-growing and potentially lethal tumors (Figure 6). Volunteer bias is a 
third form of bias which occurs if people who volunteer for screening differ 
from those who do not.[103] Lead time and length time biases can be 
controlled for if screening is evaluated in RCTs of sufficient size where 
patients are randomized to screening versus no screening, where mortality is 
studied rather than survival, where all outcomes are counted regardless of 
method of detection (screen-detected and interval cancers) and where 
outcomes are compared for the entire study population and not just the 
participants.[102, 103]  
Figure 5. Lead time 
Disease onset
Disease onset
Clinical diagnosis
Clinical diagnosis
Death
Death
TimeDisease detectable 
by screening
Screen-detection
Survival with clinical diagnosis
Survival with screen-detection
Lead time
Sojourn time
Mean lead time
Preclinical phase
N
o 
sc
re
en
in
g
Sc
re
en
in
g
Prostate Cancer Screening 
26 
 
 
 
 
 
 
 
 
 
 
Figure 6. Length time (Adapted from [106]) 
When a cancer screening program is introduced in a population, the observed 
cancer incidence is expected to increase as screening advances diagnosis 
(lead time) but also because in the prevalence screen (the first screening 
round) tumors are detected from a pool of small, preclinical and sometimes 
latent tumors. When lead time is over, cancer incidence should drop to a level 
below the predicted incidence without screening if no overdiagnosis is 
present. This is because screening has advanced the time of cancer diagnosis. 
However, in a situation with overdiagnosis, the observed incidence will not 
fall below the expected but remain at a new and higher level. Overdiagnosis 
can, as previously mentioned, be defined as detection of a tumor with 
screening, which in the absence of screening, would never have been 
diagnosed. If a screening program is directed towards finding pre-cursor 
lesions, e.g. cervical cancer screening, the cancer incidence should decrease 
after the introduction of this screening program. 
1.5 Screening and diagnosis of prostate 
cancer 
Whether or not to screen for PC is one of the most controversial issues in 
urology. There is evidence from high-quality studies that organized PSA 
screening reduces PC mortality [2, 59] but opponents argue that the harms of 
screening outweigh the benefits.[107, 108] The recommendations from 
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various organizations therefore differ. The Swedish National Board on Health 
and Welfare do not recommend population-based screening for PC but states 
that PSA-testing should be an individual decision and that well-informed men 
who wish to have the PSA-test should be given this possibility after receiving 
written information.[109] The European Association of Urology (EAU) 
recommends an individualized, risk-adapted strategy where well-informed 
men with a life-expectancy of at least 10-15 years can be offered a PSA-test. 
They recommend the baseline PSA-level be used to determine the screening 
interval.[11] There are also several different American organizations that 
have issued screening guidelines. For example, the American Association of 
Urology (AUA) recommends shared-decision making about screening for 
men 55-69 years and recommends against screening for men <40 years and 
against routine screening for men 40-54 and >70 years. They also state that a 
screening interval of  ≥2 years may be preferred but that a baseline PSA can 
be used to determine the screening interval.[110] The National 
Comprehensive Cancer Network (NCCN) recommends that healthy, well-
informed men 50-70 years of age be offered screening and that screening 
above the age of 70 years should be individualized.[111] The US Preventive 
Services Task Force (USPSTF) updated their recommendation on PSA 
screening in 2012 and came to the controversial conclusion to give a Grade D 
recommendation against PSA screening for men of all ages.[107] Their 
recommendation has been heavily criticized.[112, 113] In summary, most 
organizations recommend shared-decision making for men with at least a 10-
year remaining life-expectancy but recommendations regarding starting age 
and screening interval differ. 
1.5.1 Screening tools 
Digital rectal examination 
DRE has long been used as a screening tool for PC, and it was the only 
screening method available before the advent of PSA. The examination has 
the advantages of being a simple, quick and cheap method without serious 
side-effects. However, the examination is subjective and the test performance 
is dependent on the skill of the examiner. Moreover, many tumors, even life-
threatening, will never be palpable. Tumors in the peripheral zone (the 
majority of the tumors) are said to be palpable when the volume exceeds 0.2 
mL.[11] Screening with DRE alone has never been investigated in a 
randomized trial but several studies have reported that the combined use of 
PSA and DRE increases detection rate.[98, 114, 115] For example, in the 
Dutch center of the ERSPC the PPV of suspicious DRE in conjunction with 
an PSA above 3 ng/mL was 49% compared to a PPV of 22% for those with a 
normal DRE but an elevated SPA.[115] An abnormal DRE has also been 
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mL.[11] Screening with DRE alone has never been investigated in a 
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PSA and DRE increases detection rate.[98, 114, 115] For example, in the 
Dutch center of the ERSPC the PPV of suspicious DRE in conjunction with 
an PSA above 3 ng/mL was 49% compared to a PPV of 22% for those with a 
normal DRE but an elevated SPA.[115] An abnormal DRE has also been 
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shown to be associated with a more aggressive cancer (Gleason score ≥7) and 
should therefore prompt prostate biopsy.[115-117]  
Prostate-specific antigen 
PSA is, as previously mentioned, the most commonly used tumor marker in 
oncology but as a screening test it is far from perfect. Nevertheless, it is 
currently the best screening test available. Although PSA can be found in 
small amounts in certain cancers and tissues other than the prostate gland, 
there is no other significant source of serum PSA. Thus, PSA can be 
considered prostate-specific, from a clinical perspective. PSA elevations 
often indicates a prostatic disease but are not cancer-specific.[4] There is an 
overlap in PSA-levels between healthy men, men with BPH and those with 
PC. In BPH the amount of PSA is proportional to the prostate size. Prostate 
cancer cells, on the other hand, produce less PSA than normal prostate cells 
but the PSA-level is proportional to the number of cancer cells. Men with 
metastasized PC can therefore have PSA-levels reaching several thousands. 
PSA is measured in a venous blood sample, and like any other laboratory 
test, reliability is affected by measurement errors and variations between 
different laboratory assays. The variation between different laboratories in 
Sweden is approximately 6% and measurement errors within each method 
range between 2-6%. There is also an intra-individual variation, and PSA-
level can vary by 15% within a few weeks also for a person without prostatic 
disease.[64] It is therefore recommended that a man have a second PSA test 
within a couple of weeks after an elevated test.[118]    
Estimating the sensitivity, specificity, PPV and NPV for PSA is difficult 
since not all men will undergo a biopsy and prostate biopsies are not the 
perfect “gold standard” but have a certain level of false negatives (depending 
on the number and location of biopsy cores). Also, the test performances of 
PSA depend on laboratory assays and methods, PSA threshold, number of 
biopsy cores, PC prevalence and whether or not overdiagnosed cancers are 
included. Cancer detection rate (number of cancer/number of men screened), 
however, is relatively easy to calculate, but is also dependent on both test and 
population characteristics. For example, in the Göteborg screening study, the 
detection rate in the first screening round for a PSA threshold 3ng/mL was 
2.5%.[119]    
There are several different approaches to estimate the sensitivity of PSA. 
From the Finnish arm of the ERSPC Auvinen et al. estimated sensitivity with 
the incidence method where sensitivity was calculated by comparing the 
incidence of cancers in screen negative men (interval cancers) to the 
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incidence in the control arm (expected incidence in the absence of screening). 
Men who were diagnosed with interval cancers were regarded as false 
negatives. With this method, test sensitivity for PSA >3 ng/mL was 
89%.[120] Another approach was used in the Prostate Cancer Prevention 
Trial (PTCP).The PCPT was conducted to study the use of the 5-alfa-
reductase inhibitor finasteride for the prevention of PC, and randomized men 
with PSA <3 ng/mL and normal DRE to either finasteride or placebo. The 
trial protocol included annual PSA and DRE, and a biopsy was recommended 
in case of PSA > 4.0 ng/mL and/or a DRE suspicious of cancer. In addition, 
at the end of the trial, all participants without PC were biopsied. In this low-
risk population (all had PSA <3 ng/mL and normal DRE at entry), PSA 
sensitivity for a cut off of 4.1 ng/mL was 20.5% and specificity was 93.8%. 
The PCPT clearly showed that PSA could not be treated as a dichotomous 
variable; instead, there was a continuum of risk for PC at all PSA-
levels.[121] Prostate cancer was found among 15% of those who had never 
had a PSA above 4 or an abnormal DRE during the study, and 15% of these 
tumors were Gleason score ≥7.[122] A third approach to estimate sensitivity 
was used by Gann et al. In an unscreened population, using stored serum 
samples, sensitivity for clinically detected PC within a 4-year period for a 
PSA cut-off of 4 ng/mL was 73%.[31] 
Specificity has also been estimated in the Finnish section of the ERSPC for a 
PSA cut-off of 4 ng/mL and an ancillary test (DRE or free-to-total, F/T PSA) 
for PSA 3.0-3.9 ng/mL. Specificity was calculated as the proportion of 
screen-negative (true negative) men among those who were regarded as 
disease-free (true negative + false positive). False positives were those with 
an elevated PSA and/or abnormal DRE but no cancer in subsequent biopsies. 
With this method specificity for PSA > 4 ng/mL was 93% in the first 
screening round and essentially the same in the second round. Specificity 
decreased slightly with age.[123] One limitation with this method is that it 
assumes that men with a PSA below the threshold do not harbor cancer. As 
they were not biopsied, and even if they were, this cannot be known for sure. 
As with sensitivity, specificity can be calculated using stored serum samples. 
These studies, which were conducted in the pre-PSA era, have the advantage 
of being uninfluenced by overdiagnosis as they only included clinical 
cancers. Similar estimates of specificity have been reported from such studies 
(91%).[31]               
The American Cancer Society performed a systematic review of the literature 
assessing PSA performance and reported pooled estimates for PSA 
thresholds of 4 ng/mL and 3 ng/mL (Table 4). In their calculation they also 
assumed that screen negatives were true negatives.[124] 
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Table 4. Pooled estimates for PSA performance (Adapted from [124]) 
These figures clearly show that there is balance between sensitivity and 
specificity and if the threshold for biopsy is lowered more cancers will be 
diagnosed but at the cost of more false positives (decreased specificity) 
leading to unnecessary biopsies. False positives are common, as indicated by 
the low PPV of PSA; most men with a PSA above 3 or 4 ng/mL do not have 
cancer. In the Göteborg screening study 24% of those with a PSA above 
3ng/ml had PC at biopsy (PPV).[119] The NPV of PSA was estimated in the 
PCPT and for a PSA-level of ≤4 ng/mL, NPV was 85%.[122]  
This suboptimal specificity of PSA, especially among men with moderately 
elevated PSA-levels (4-10 ng/mL), has led to a search for new ways of trying 
to improve upon the performance with i.e. PSA-density, F/T PSA and PSA 
kinetics. PSA density relates the PSA-level to the volume of the prostate 
measured by TRUS. As PC cells express more PSA per volume than BPH, a 
PSA density below 0.1-0.15 ng/mL/cm3 is believed to be more likely to be 
indicative of BPH rather than PC.[125, 126] The ratio of F/T PSA has the 
advantage that it is not user-dependent as no TRUS is required. The 
proportion of free PSA is lowered in men with PC, and the lower the ratio the 
greater the risk of PC.[127, 128] The F/T PSA ratio is generally used together 
with PSA density and PSA kinetics in men with elevated PSA to determine 
indication for biopsy. PSA kinetics are measures of the change in PSA over 
time and can be calculated in a number of ways; as PSA velocity, PSA 
doubling time or percent change. Lately it has been questioned whether PSA-
kinetics add any predictive information compared to PSA alone in predicting 
risk of low-risk PC on biopsy.[129, 130] A review article by Vickers et al. 
assessed the evidence from 87 published articles on PSA kinetics and 
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concluded that there was little evidence that PSA velocity or doubling time 
adds any predictive information in predicting risk of for untreated patients 
beyond that provided by the absolute PSA-level alone.[129] 
Transrectal ultrasound and prostate biopsies 
TRUS is a rapid and generally well-tolerated procedure. The classic image of 
PC on TRUS is a hypoechoic area in the peripheral zone of the prostate, 
however the sensitivity for such a lesion being PC is only 25-30%.[131] 
TRUS cannot be used as a primary screening tool because of a limited 
sensitivity and specificity for PC but has an important role in the visualizing 
the prostate and the seminal vesicles, in measuring prostate volume and in 
guiding the biopsy needle. 
TRUS-guided prostate biopsy is the clinical standard for a definitive PC 
diagnosis. Biopsies with a transrectal approach are most common but they 
can also be performed transperineal. During the transrectal approach an 
ultrasound-guided periprostatic block of local anesthetics is given to reduce 
procedural pain and antibiotic prophylaxis, commonly with ciprofloxacin, is 
given to reduce the risk of infectious complications. During the last 30 years, 
there has been a strong trend of increasing the number of biopsy cores 
sampled; from four cores in the early 1980’s, to laterally directed sextant 
biopsies which was the standard for many years, to around 12 cores today. 
However, because sextant biopsies miss up to 34% (false negatives) of all PC 
and since the cancer detection rate of 10-12 cores is approximately 30% 
higher than sextant biopsies,[132] the current EAU and AUA 
recommendation are that a minimum of 8-12 cores be sampled.[11, 133]  
Several studies have reported on the limitations of TRUS-guided biopsy in 
accurately grading PC. This is crucial as Gleason score is important for 
proper treatment selection and prediction of PC prognosis. For instance, for 
men being considered for active surveillance, upgrading on an early repeat 
biopsy occurs in approximately 20-30%.[134-136] This is likely a reflection 
of under sampling at the first biopsy rather than true disease progression, 
considering the long natural history of PC. A proportion of men eligible for 
active surveillance also has a negative biopsy or down-grading (20-45%) on 
their repeat biopsy which further indicates that the biopsy results are not a 
perfect reflection of the tumor burden but only mirror small parts of the 
prostate.[134, 136] The concordance between biopsy results and the 
patoanatomical review of prostatectomy specimens is highly dependent on 
the number of biopsy cores taken. The concordance rate for extended biopsy 
schemes (10-12 cores) range from 52% to 80% compared to 41% to 63% for 
sextant biopsies.[133] Various extended biopsy schemes such as saturation 
>4 ng/mL >3 ng/mL 
Cancer detection rate 3% 4% 
Sensitivity 21% 32% 
Specificity 91% 85% 
PPV 30% 28% 
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biopsy (32 cores) or template guided mapping biopsies, where the entire 
prostate gland is covered with biopsies at 5 mm interval, have therefore been 
proposed, for example when selecting candidates for active 
surveillance.[137-139] The exact number of cores and their location is an on-
going controversy. It is a balance between an adequate cancer detection rate 
with a high pathology concordance versus low levels of overdetection and 
side-effects at a reasonable cost. In a comprehensive review by Eichler et al. 
it was concluded that biopsy schemes with 12 cores (a sextant biopsy plus 
laterally directed cores) detected 31% more cancer than sextant biopsy, but 
increasing the number of cores to 18-24 did not detect significantly more 
cancers than 12. There was no difference in adverse events between sextant 
and 12 core biopsies.[140]  
1.5.2 The evidence for prostate cancer screening 
The question of whether or not to screen for PC with PSA has for years been 
heavily debated and is still controversial. Many hoped that the controversy 
surrounding PSA screening would be settled when the long-awaited first 
mortality reports from the Prostate, Lung, Colorectal, and Ovarian Cancer 
Screening Trial (the prostate section of this trial will hereafter be referred to 
as PLCO) and ERSPC were published in 2009, in the same issue of the New 
England Journal of Medicine. On the contrary, the debate became even more 
polarized as the two studied reported contrasting results. In addition, in 2012 
the USPSTF published their Grade D recommendation against PSA 
screening and the 2013 Cochrane metaanalysis came to the conclusion that 
PSA screening did not significantly reduce PC mortality.[107, 108] This 
conclusion was reached by pooling the results of five very different studies. 
Below follows a short summary of these five randomized and the Göteborg 
screening trial which was not included in the analysis.    
The Quebec trial 
The Quebec trial randomized more than 46 000 men aged 45-80 years to 
annual screening with PSA and DRE versus no screening. A PSA above 3 
ng/mL and/or a positive DRE were regarded as positive screening tests and 
led to TRUS-guided biopsies. A 62% reduction in PC mortality was reported 
after a median of 8 years.[141, 142] However, the data analysis has been 
heavily criticized as it did not follow the intention-to-screen principle; only 
men who actually were screened (23.6% of those randomized to screening) 
were compared to those who were not screened regardless of allocation arm 
at randomization. It is therefore difficult to assess the value of these reported 
results.  
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The Norrköping trial 
The Norrköping trial was initially designed as a feasibility study of PC 
screening. Of 9026 men aged 50-69 years in Norrköping, Sweden, every 
sixth man was selected to a screening group (n=1494) and the remaining 
population constituted a control group. Men were screened every third year; 
during the first two rounds only with DRE and thereafter PSA was added. A 
suspicious DRE and/or a PSA above 4.0 ng/mL led to a recommendation of a 
sextant biopsy. After a total follow-up of 15 years, more PCs were detected in 
the screening group than amongst controls and screen-detected tumors tended 
to be more localized, but there was no significant difference in PC mortality 
between the groups.[143]  
The Stockholm trial 
In the Stockholm trial, 2400 men 55-70 years were randomized to a single 
screen with PSA, DRE and TRUS and the remaining source population (n= 
24,202 men) constituted controls. A PSA >10 ng/mL and/or abnormal 
findings on DRE or TRUS led to quadrant biopsy. After a median of 12.9 
years there was no difference in PC or overall mortality between the 
screening and control group. However, non-attendees in the screening group 
had a higher overall mortality than the attendees. The increased risk of death 
among non-attendees was due to non-PC mortality.[144]  
The PLCO trial     
The PLCO trial is a large randomized controlled cancer screening trial 
conducted in 10 different centers in the USA.[145] The prostate section of the 
trial randomized more than 76 000 men in a 1:1 ratio to screening or control. 
The screening group in the PLCO was offered annual DRE and PSA tests for 
4 years and only PSA for another 2 years. A PSA >4ng/mL and/or an 
abnormal DRE led to recommendations for further diagnostic evaluation 
which was not part of the study protocol but was at the discretion of the 
patient and his primary physician. After 10 years of follow-up more PC was 
diagnosed in the screening group than the control group (rate ratio 1.22; 95% 
CI 1.16-1.29).[146] There was no sign of stage-shift between the groups; the 
number of men with in advanced disease was similar. There was no 
statistically significant reduction in PC mortality between the groups at 10 
years. Fifty men died due to PC in the screening group compared with 44 
among controls resulting in a rate ratio of 1.13 (95% CI 0.75-1.70).[146] 
Results after 13 year of follow up have also been published. At 13 years, the 
relative risk of PC diagnosis between the groups had decreased to 1.12. 
Again, there was no statistically significant reduction in PC between the 
groups (rate ratio 1.09, 95% CI 0.87-1.36).[147]  
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biopsy (32 cores) or template guided mapping biopsies, where the entire 
prostate gland is covered with biopsies at 5 mm interval, have therefore been 
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cancers than 12. There was no difference in adverse events between sextant 
and 12 core biopsies.[140]  
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at randomization. It is therefore difficult to assess the value of these reported 
results.  
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The ERSPC trial 
The ERSCP was initiated in the 1990’s to evaluate the effect of PSA 
screening on PC mortality. Belgium, Finland, France, Italy, the Netherlands, 
Portugal, Spain, Sweden and Switzerland were initially participating but 
Portugal discontinued their participation in 2000 and France did not join until 
2001, hence the French data were not included in the 2009 publication. A 
total of 182160 men 50-74 years old underwent randomization of which 162 
387 were in predefined core age group of 55-69 years. Recruitment and 
randomization procedures differed between countries following national rules 
and legislation. Men in the screening arm (n= 82 816) were invited for 
screening with PSA every fourth year (Sweden every second year). The 
screening algorithm varied somewhat between centers and could include 
DRE, TRUS and F/T PSA ratio as ancillary test but most centers used ≥3.0 
ng/mL as the PSA cut-off for biopsy. Results have been published for 9-, 11- 
and 13-years of follow-up. After 9 years of follow up, the cumulative PC 
incidence in the screening and control group was 8.2% and 4.8% 
respectively. Of those randomized to screening 82% attended at least once 
and the average rate of compliance with biopsy recommendations was 86%. 
The incidence of localized PC was higher in the screening group while the 
incidence of metastasized disease was higher in the control group. In the core 
age group there were 214 PC deaths in the control group and 326 PC deaths 
in the control group at a median follow-up of 9 years.  The rate ratio for PC 
death was 0.80 (95% CI, 0.65 to 0.98; P = 0.04). In order to prevent one PC 
death 1410 men needed to be invited to screening (NNI) during 9 years and 
48 men needed to be diagnosed (NND) with PC.[148] In 2012, updated 
results with 11-years of follow-up were published. The rate ratio for PC 
incidence was 1.63; 95% confidence interval (95%CI 1.57-1.69). A relative 
reduction of 21% in PC mortality was reported (0.79; 95% CI, 0.68 to 0.91; 
P=0.001) which corresponded to a NNI of 1055 and NND of 37.[149] The 
recently published 13-year follow-up confirmed previous results that 
screening with PSA substantially reduces PC mortality. The rate ratio for PC 
incidence between screening and control arm had decreased to 1.57 (1.51-
1.62) after 13 years and the rate ratio for PC mortality remained stable at 0.79 
(95% CI 0.69-0.91). This resulted in improved estimates of NNI and NND 
which after 13 years of follow-up were 781 (95% CI 490-1929) and 27 (95% 
CI 17-66) respectively.[59]        
The PLCO and the ERSPC have both been criticized, but for separate 
reasons. The criticism of PLCO has been focused on the following points:  
-the population was heavily pre-screened; approximately 44% in each arm 
had at least one PSA-test before study start.[146]  
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-there was a high degree of contamination (PSA-testing) in the control group; 
after 6 years, 52% of the control group had been screened with PSA.[150]  
-in the screening group only 40% of those with a PSA above threshold were 
in fact biopsied.[151]  
It has been questioned whether the study had enough power to find a 
difference in PC mortality at these levels of contamination and 
compliance.[152]   
Those who have criticized the ERSPC have argued that it is a multicenter 
study with different populations and different screening algorithms and that 
the distribution of different treatments has not been the equal between the 
study arms.[153]   
The Göteborg trial 
The Göteborg randomized population-based prostate cancer screening trial, 
which constitutes the study base for the four papers in the present thesis, was 
initiated in 1994.[2] It was planned as an independent study and became part 
of the ERSPC in 1996, with men in the core age group 55-69 years at 
randomization, without any changes in the protocol. As of today, the 
Göteborg trial is the study that has reported on the largest reduction in PC 
mortality due to PSA screening. The study population and screening 
algorithm if the Göteborg screening trial is described in depth in chapter 
3.The first mortality results of the Göteborg screening study were published 
in the Lancet Oncology in 2010. Of the 9952 men in the screening arm, 76% 
attended at least once and among those with a PSA above threshold, 93% had 
at least one biopsy. After 14 years of follow-up the cumulative incidence of 
PC was 12.7% in the screening arm and 8.2% in the control arm, 
corresponding to a hazard ratio of 1.64 (95% CI 1.50-1.80). There was a 
stage migration with more low-risk cancers detected in the screening arm and 
more metastasized cancers in the control arm. At 14 years, a total of 44 men 
had died due to PC in the screening arm compared to 78 men in the control 
group. The rate ratio of PC death between men in the screening arm and 
controls was 0.56 (95%CI 0.39-0.82). NNI was 293 and NND 12. 
1.6 Harms of prostate cancer screening 
The introduction of PSA as a screening tool for PC has led to a substantial 
increase in the number of men diagnosed with PC. In addition, a substantial 
proportion of these cancers would never have caused symptoms or death. If 
organized PSA screening were to be introduced, even more PCs would be 
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study with different populations and different screening algorithms and that 
the distribution of different treatments has not been the equal between the 
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of the ERSPC in 1996, with men in the core age group 55-69 years at 
randomization, without any changes in the protocol. As of today, the 
Göteborg trial is the study that has reported on the largest reduction in PC 
mortality due to PSA screening. The study population and screening 
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1.6 Harms of prostate cancer screening 
The introduction of PSA as a screening tool for PC has led to a substantial 
increase in the number of men diagnosed with PC. In addition, a substantial 
proportion of these cancers would never have caused symptoms or death. If 
organized PSA screening were to be introduced, even more PCs would be 
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detected. The mortality benefit of an organized screening program has to be 
weighed against a number of negative effects. The potential harms of 
screening are present in all stages of the screening process and further 
downstream following curative treatment for PC. Overdiagnosis and its 
consequences are, by many, regarded the primary harms  
1.6.1 Lead time and overdiagnosis in prostate 
cancer screening 
Lead time and the rate of overdiagnosis are closely connected. Lead time, as 
previously described, is the time that screening advances diagnosis, from 
screen-detection to when the tumor would have been clinically diagnosed. 
Overdiagnosis can be viewed from different perspectives; one can adopt an 
epidemiological view and define overdiagnosis as detection of a cancer that 
in the absence of screening would never have been diagnosed.[19] With this 
definition, it is impossible to know if a patient is overdiagnosed at the time of 
treatment; the only way to find out would be to leave the cancer untreated 
and follow the patient for his remaining life-time, and observe what he would 
die from. For obvious reasons, this is rarely an alternative. Therefore, this 
definition is not particularly helpful when trying to decide on the right 
treatment strategy for a patient. Another, more clinical way of looking at 
overdiagnosis is trying to identify tumor features that determine prognosis 
and to define tumors as clinically significant or insignificant. Overdiagnosis 
is then all cancers defined as clinically insignificant. 
Most would agree that a 55-year old man with a large Gleason 4+5 tumor 
have a clinically significant tumor but if he would end up dying in a car crash 
soon after diagnosis, from an epidemiological perspective he could be 
regarded as overdiagnosed.  
With either definition, overdiagnosis is a major problem in PC screening. A 
large study based on the nationwide SCR and the US SEER Program found 
that PC accounted for 52% of all deaths among PC patients in Sweden 
compared to 30% in the United States during the essentially the same time 
period (1961-2008 in Sweden and 1973-2008 in the US). Among men with a 
PC diagnosis the 10-year cumulative risk of dying from PC was 43% in 
Sweden and 20% in the United States. [154] The advent of PSA has led to a 
stage shift, and today most men are diagnosed with T1c tumors with very-
low or low-risk features with excellent long term prognosis.[28]   
Lead time cannot be measured directly for a single case but the lead time 
distribution can be estimated. The maximum lead time is the sojourn time 
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(duration of the preclinical detectable phase). It is assumed that on average 
the lead time is half of the sojourn time if the cancer is detected in the first 
screening round and shorter if the cancer is detected in subsequent rounds. 
Lead time distribution in a screening study can be estimated by comparing 
the frequency of diagnosed cases in the screened and unscreened population 
where the lead time distribution is the area between the two curves. The lead 
time distribution depends on the sensitivity of the screening test, screening 
interval, incidence of the disease and the duration of the preclinical detectable 
phase.[102] 
Lead time can also be viewed as a measure of the quality of a screening test 
where a long lead time indicates an effective screening test, showing that 
screening can advance diagnosis effectively. However, lead time is 
intertwined with sensitivity, screening interval and overdiagnosis which 
makes the interpretation difficult. For PCs detected by PSA screening, the 
mean lead time has been reported to be up to 12 years.[19] However, this 
estimate is the mean lead time of all screen-detected tumors including the 
overdiagnosed ones. Overdiagnosed tumors have a preclinical detection 
phase that exceeds the remaining lifetime of the individual and their lead time 
is therefore infinity. These cases therefore inflate lead time estimations. Lead 
time for clinically significant tumors are probably much shorter, otherwise a 
screening interval of 10 years would be adequate, assuming a perfect 
screening situation. Studies have reported a wide range of mean lead times 
from 3-12 years. Draisma et al. suggested that there are at least three reasons 
for this: 1. the screening context i.e. the population at risk and the screening 
algorithm; 2. the definition of lead time and overdiagnosis used; 3. the 
method used for calculating the estimates.[155] Draisma et al. defined three 
different types of lead time: non-overdiagnosed lead time, censored lead time 
and uncensored lead time. They suggested that the type of lead time should 
be defined in future studies. Non-overdiagnosed lead time can only be 
calculated for non-overdiagnosed cancer (clinical diagnosis precedes death). 
Censored lead time can be calculated for both overdiagnosed and non-
overdiagnosed cancers (lead time for overdiagnosed cancers are censored at 
time of death from other causes). Uncensored lead time can also be calculated 
for both overdiagnosed and non-overdiagnosed cancers but with the 
difference that the overdiagnosed lead time is not censored at the time of 
death from other causes. The conclusion from this work is that an estimated 
lead time applies exclusively to the situation from which it was derived.   
Several studies have investigated non-overdiagnosed lead time using 
information obtained from stored serum samples, where the time from an 
elevated PSA to clinical PC diagnosis is measured. These studies have 
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reported lead time estimates ranging between 3 and 12.8 years.[30, 31, 156-
158] One limitation with this type of study design is that it is assumed that 
the cancer would have been detected at the time of the raised PSA and that 
only cancers that would have surfaced clinically are detected (100 % 
sensitivity and 100% specificity). Another limitation is that the results are 
dependent on the length of follow-up. If the follow-up is not long enough, 
such that all cancers have had time to surface clinically, lead time will appear 
shorter than it really is. 
Lead time can also be estimated as the prevalence:incidence ratio, where the 
calculation is based on the formula P=D*I (P=prevalence of preclinical 
detectable phase, D=mean sojourn time and I=incidence) and prevalence is 
estimated from detection rate (DR) at first screening and sensitivity (s) of the 
test (P=DR/s). [159-161] One limitation with the prevalence:incidence ratio 
is that it assumes  that incidence can be treated as a constant which has not 
been the case for PC. Instead, the “catch-up time method” or incidence:risk 
ratio has been suggested as an alternative. With this method mean lead time 
is calculated as the time required for the cumulative incidence in the 
unscreened group to catch up with the detection rate in the first screening 
round.[161, 162] Applying this method to the five largest centers in the 
ERSPC, Finne et al. calculated the mean lead time in the ERSPC to 6.8 
years.[162] Opportunistic screening in the control arm (contamination) can 
affect lead time so that it appears shorter than it is. 
Lead time can also be estimated with computer simulation models. Modeling 
studies have several advantages; it is possible to control for e.g. 
contamination in the control arm, various secular trends and different 
screening strategies (by varying PSA thresholds, screening interval etc) can 
be investigates. For example, simulation models based on the Dutch section 
of the ERSPC estimated mean lead times and rates of overdiagnosis for 
screening at various ages and screening intervals. Mean lead time varied from 
12.3 years for a single screen at age 55 to 6.0 years for a single screen at age 
75.[19] Other studied have used US screening and PC incidence patterns to 
estimate mean lead times between 4.5 to 7 years [163, 164] Differences in 
these lead time estimates can partly be explained by different PSA-thresholds 
for biopsy and biopsy compliance rates.   
As previously mentioned lead time and the rate of overdiagnosis are closely 
connected. Similar to lead time, overdiagnosis is difficult to calculate, 
however, it can theoretically be calculated as the absolute difference in the 
number of cancer cases between the study arms in a randomized controlled 
study where all study participants are followed for their life-time and there 
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has been no screening in the control group. Estimates of overdiagnosis in 
PSA-screening vary greatly across studies and range between 2.9-88.1%.[19, 
155, 163-173] An article by Etzioni et al. discussed the reasons for this wide 
range of estimates and identified several different reasons described below. 
[174]  
-Definitions and methods of measuring overdiangosis: From a study aiming 
at interpreting different overdiagnosis estimates in mammography screening 
de Gelder et al cited seven different ways of measuring overdiagnosis. 
Depending on which denominator was used and depending on which phase 
of screening was assessed the estimates could vary by a factor of 3.5 and 4, 
respectively.[175] Overdiagnosis has been reported as: 1) the fraction of 
screen-detected tumors, 2) the fraction of all tumors detected in the screening 
group and 3) the fraction of all men invited to screening. Other measures can 
be number of cases per adverted PC death (NND) or, number of 
overdiagnosed tumors relative to the number of cases expected without 
screening – for the entire population, or for the screening population. 
Overdiagnosis can also be expressed as the relative risk of cancer with 
screening compared with the relative risk of cancer without screening.[175]  
-Screening context: the screening strategy has a large effect on the risk of 
overdiagnosis. The PSA threshold, the number of biopsy cores, screening 
interval, and age at screening will all affect the risk of overdiagnosis. A low 
PSA threshold and frequent screens will increase the risk of overdiagnosis. 
The incidence of PC in the comparison group, whether it is a control group or 
the expected PC incidence in the background population, will also affect the 
risk of overdiagnosis. For example, if there is widespread opportunistic 
screening in the comparison group, the overdiagnosis estimate in the 
screening group relative to the comparison group will be lower. If the 
background population has been opportunistically screened, the pool of latent 
cancers that can be detected by screening and the risk of overdiagnosis will 
be smaller.[174] 
-Estimation approaches: “excess incidence approach” and “lead time 
approach” are the two main approaches for estimating overdiagnosis. The 
rationale behind the excess incidence approach lies in the observation of 
incidence patterns that follow an introduction of screening where the cancer 
incidence first increases and then declines to a new, higher level which 
indicates the amount of overdiagnosis. However, the estimates from this 
method are highly dependent on at which point in time the analysis is 
performed. If the introduction phase (“the prevalence round”) of a screening 
program is included, the estimates will be higher than if the estimates are 
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reported lead time estimates ranging between 3 and 12.8 years.[30, 31, 156-
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ERSPC, Finne et al. calculated the mean lead time in the ERSPC to 6.8 
years.[162] Opportunistic screening in the control arm (contamination) can 
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these lead time estimates can partly be explained by different PSA-thresholds 
for biopsy and biopsy compliance rates.   
As previously mentioned lead time and the rate of overdiagnosis are closely 
connected. Similar to lead time, overdiagnosis is difficult to calculate, 
however, it can theoretically be calculated as the absolute difference in the 
number of cancer cases between the study arms in a randomized controlled 
study where all study participants are followed for their life-time and there 
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The incidence of PC in the comparison group, whether it is a control group or 
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screening in the comparison group, the overdiagnosis estimate in the 
screening group relative to the comparison group will be lower. If the 
background population has been opportunistically screened, the pool of latent 
cancers that can be detected by screening and the risk of overdiagnosis will 
be smaller.[174] 
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rationale behind the excess incidence approach lies in the observation of 
incidence patterns that follow an introduction of screening where the cancer 
incidence first increases and then declines to a new, higher level which 
indicates the amount of overdiagnosis. However, the estimates from this 
method are highly dependent on at which point in time the analysis is 
performed. If the introduction phase (“the prevalence round”) of a screening 
program is included, the estimates will be higher than if the estimates are 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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calculated when a screening program has reached “steady state”. During the 
introduction phase of screening, when the prevalence screens are performed, 
the excess incidence will include both overdiagnosed and non-overdiagnosed 
cancers, compared to when the screening program has reached a steady state 
and the excess incidence only consists of overdiagnosed tumors. The age 
groups included in the analysis are also important. Screening should cause a 
“compensatory drop” in incidence in the older age groups, which have 
completed screening. If these age groups are not included in the analyses, 
overdiagnosis will be over-estimated. The “lead time approach” uses 
mathematical models to predict lead time and overdiagnosis based on the 
pattern of excess incidence. A third approach is to relate the excess incidence 
caused by screening to the cancer-specific mortality reduction, by calculating 
the NND. This estimate can give a picture of the harms-to-benefit balance of 
screening, but is strictly speaking not an estimate of overdiagnosis. Published 
estimates of NND have ranged between 5 and 48 (Table 5). Similar to the 
other excess incidence approaches, estimates of NND are highly time-
dependent measures, which partly explain the wide range.  
Published estimated of overdiagnosis is summarized in table 5. When 
reviewing these estimates, it becomes obvious that they are not directly 
comparable due to the reasons listed above. For example, many of the US 
estimates are lower than the European, which can be partly explained by 
higher PSA thresholds and lower compliance with biopsy following a 
positive screening test in the US. In addition, it is clear that PC screening 
with PSA results in substantial overdiagnosis, regardless of how it is 
estimated.  
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introduction phase of screening, when the prevalence screens are performed, 
the excess incidence will include both overdiagnosed and non-overdiagnosed 
cancers, compared to when the screening program has reached a steady state 
and the excess incidence only consists of overdiagnosed tumors. The age 
groups included in the analysis are also important. Screening should cause a 
“compensatory drop” in incidence in the older age groups, which have 
completed screening. If these age groups are not included in the analyses, 
overdiagnosis will be over-estimated. The “lead time approach” uses 
mathematical models to predict lead time and overdiagnosis based on the 
pattern of excess incidence. A third approach is to relate the excess incidence 
caused by screening to the cancer-specific mortality reduction, by calculating 
the NND. This estimate can give a picture of the harms-to-benefit balance of 
screening, but is strictly speaking not an estimate of overdiagnosis. Published 
estimates of NND have ranged between 5 and 48 (Table 5). Similar to the 
other excess incidence approaches, estimates of NND are highly time-
dependent measures, which partly explain the wide range.  
Published estimated of overdiagnosis is summarized in table 5. When 
reviewing these estimates, it becomes obvious that they are not directly 
comparable due to the reasons listed above. For example, many of the US 
estimates are lower than the European, which can be partly explained by 
higher PSA thresholds and lower compliance with biopsy following a 
positive screening test in the US. In addition, it is clear that PC screening 
with PSA results in substantial overdiagnosis, regardless of how it is 
estimated.  
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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As previously mentioned, overdiagnosis can also be viewed from a clinical 
perspective, trying to identify tumors that are unlikely to cause disease-
specific morbidity or mortality even without treatment. Several attempts have 
been made trying to describe overdiagnosed cases, with synonyms such as 
“minimal”, “focal”, “insignificant” and “indolent disease”. In many scientific 
papers, the definition of “indolent disease” is often based on strict 
pathological criteria, whereas the definition of “insignificant disease” also 
takes patient age and comorbidity into consideration. According to a review 
article, the most commonly used definition of “insignificant PC” is based on 
pathology at radical prostatectomy and includes: organ-confined disease (no 
extraprostatic extension, no seminal vesicle invasion and no lymphnode 
involvement), no Gleason pattern 4 or 5 and a maximum tumor volume of 0.5 
mL.[181] The tumor volume threshold of <0.5 ml is based on a study by 
Stamey et al. with incidentally detected PCs in a cystoprostatectomy series 
from the 1990s. The authors hypothesized that the largest tumors were the 
most aggressive. Because the lifetime risk of clinically diagnosed PC was 
8%, the authors chose the largest 8% of the tumors (destined to surface 
clinically during a man’s lifetime) which all had a volume above 0.5 mL – 
hence, the cut-off 0.5 mL to define significant versus insignificant PC.[182] 
Another frequently cited paper is a series of 157 consecutive radical 
prostatectomies, where Epstein et al. defined “insignificant PC” as organ-
confined, Gleason score <7 with a tumor volume <0.2 mL. The same authors 
also defined “minimal disease” as a tumor volume <0.5 mL and with the 
same criteria as for “insignificant disease”.[183] However, it has been 
questioned whether this volume thresholds are applicable to screen-detected 
cancers. In addition, PC is oftentimes a multifocal disease, that is, a man can 
have not only one focus of PC, but several foci.[184] A more recent study 
based on the first screening round in the Rotterdam section of the ERSPC 
reported a total tumor volume threshold for the index tumor of 0.55 mL and a 
total tumor volume threshold of 0.7 mL. When accounting for tumor grade 
and stage these figures became higher, 1.3 and 2.5 mL respectively.[185]  
A number of nomograms exist that help predict the risk of insignificant 
cancer. For men with a high probability of insignificant cancer, a 
conservative management such as active surveillance can be the first 
treatment strategy whereas men with a low probability (for example less than 
30%) can be advised immediate curative treatment.[186] However, these 
probability cut-offs are arbitrary and should be set individually depending on 
patient characteristics and preferences. In the radical prostatectomy series by 
Epstein et al. discussed above, the model that best predicted insignificant PC 
included; PSA density (PSAD) <0.1 ng/mL, Gleason score <7, <3 cores with 
cancer, and ≤50% cancer in any core. These criteria could identify 
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insignificant cancer (organ-confined, no Gleason 4 or 5, and tumor volume 
<0.2 mL) with a PPV of 95%, NPV 66%, and an overall predictive value of 
73%.[183] An updated version of the preoperative Epstein criteria was 
presented in 2004, based on a series of T1c tumors. The combination of 
PSAD<0.15 ng/mL, Gleason score ≤6, <3 cores with cancer and ≤50% 
cancer in any core correctly identified 91.6% as organ-confined at radical 
prostatectomy.[187] Current nomograms for predicting insignificant PC are 
based on findings at radical prostatectomy; this is, however, a surrogate 
endpoint for more long-term endpoints such as disease progression and 
disease-specific mortality. Three commonly used nomograms are the ones by 
Kattan, Steyerberg, and Nakanishi.[188-190] These nomograms use 
pretreatment clinical characteristics to predict insignificant disease at radical 
prostatectomy. For example, for a 60 year old man diagnosed with a T1c 
cancer, PSA 4 ng/mL, prostate volume 40 mL and 5 mm cancer in one biopsy 
core, these nomograms predict the probability of insignificant cancer ranging 
from 22-65% (lowest value Kattan and highest value Steyerberg).[191] These 
nomograms are based on different populations; some are based on patients 
referred to a urology clinic and others on the general population in a 
screening setting. This should be kept in mind when interpreting the different 
results and is also a reason for questioning the generalizability of these tools. 
1.6.2 Why overdiagnosis a particular problem in 
prostate cancer screening 
The lifetime risk for a Swedish man of being diagnosed with PC is 
approximately 16%, which can be compared to the lifetime risk of dying 
from PC for a Swedish man which is 5-6%.[192] This incidence:mortality 
ratio for PC is indicative on the presence of overdiagnosis. So why is 
overdiagnosis such a large problem for PC and PSA screening? 
Tare several factors promoting overdiagnosis, and the most important are 
discussed here.   
Firstly, of all, there is a large reservoir of latent, silent cancers that can 
potentially be detected with screening. As previously mentioned, autopsy 
studies of men who died from causes other than cancer have shown that PC 
can be detected as early as the 3rd decade of life and the prevalence of PC 
increases with age. Among men in their fifties and sixties, that is, men in the 
potential screening age, 30-60% harbor PC.[8, 9] Similar proportions of PC 
have also been reported from cysto-prostatectomy series where PC is found 
in up to 50% of the specimens.[193] Increased diagnostic activity with PSA, 
of both asymptomatic men and those with mild lower urinary tract symptoms 
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(LUTS), risks detecting these tumors which would otherwise have been 
diagnosed. The reported incidence of insignificant PC in radical 
prostatectomy specimens varies from 2.3-25% depending on the patients 
included.[181] In a screened population, Postma et al. reported minimal 
cancer (organ-confined, Gleason score ≤6 and tumor <0.5 mL) in 32-42% of 
radical prostatectomy specimens.[194]         
Secondly, as already mentioned, PC incidence increases with age. Many parts 
of the world have an ageing population and men’s life expectancy is 
increasing. For example, Swedish 65 year-olds have a remaining life 
expectancy of more than 18 years.[195] Similar estimates can be seen in 
other parts of the Western world.[196] The benefits of early diagnosis are 
probably smaller for older men compared to younger.[197] Increasing age is 
associated with an increased number of comorbidities and the risk of dying 
with PC rather than from it increases. Several studies have reported that age is 
an important risk factor for overdiagnosis of PC.[172, 173, 198] 
Thirdly, PSA is highly specific for prostatic tissue but it is not cancer-
specific. PSA as a screening tool have several limitations, see paragraph 
1.5.1. Inflammation/infection, BPH and trauma can cause PSA elevations and 
poorly differentiated, highly lethal, cancers sometimes do not even produce 
PSA and are therefore no accompanied by increased PSA-levels which makes 
detection difficult. In addition PSA cannot differentiate between low- and 
high-risk cancers. The limited specificity implies that many men will have to 
undergo biopsies with the risk of detecting insignificant cancer that have no 
relation to the PSA elevation. In addition, screening is associated with length 
time bias and risks detecting a dis-proportional amount of less aggressive, 
slow-growing tumors, which may not pose a threat to life, while missing the 
aggressive tumors for which screening was intended. 
1.6.3 Consequences of overdiagnosis 
Overdiagnosis has consequences on all levels; for the individual patient as 
well as for society as a whole. The psychological consequences of 
overdiagnosis are obvious; “healthy” men, who in the absence of screening 
would never have been aware of their PC, are turned into patients. More men 
will have to go through work-up following a positive screening test including 
the discomfort and risk of complications of prostate biopsy. Thereafter 
follows a period of waiting for the biopsy results and a substantial portion of 
these men will subsequently receive a cancer diagnosis. The harms of PC 
screening, which would affect more men if screening were to be introduced, 
due to overdiagnosis, are: 
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• PSA blood test. From the PLCO it was reported that 
complications following a PSA blood test was seen at a rate 
of 26 per 10 000 screens. There were only minor 
complications reported such as dizziness and, bruising and 
hematoma from the blood draw.[146] 
 
• Biopsy. Common complications following prostate biopsy 
include hematospermia, hematuria, hematochezia, fever, 
urinary tract infections and urine retention. Bleeding 
complications (hemostospermia, hematuria, hematochezia) 
are often mild and self-limiting. Macroscopic hematuria is 
common with reported rates of up to 84%, but hematuria 
requiring hospitalization occurs in less than 1%.[199] From 
the Dutch arm of the ERSPC hematuria lasting longer than 3 
days, hematospermia and rectal bleeding were reported after 
22.6%, 50.4%  and 1.3% of the procedures, respectively. 
Other series have reported rectal bleeding in 30-40%. 
Although massive rectal bleedings are uncommon they can 
be life-threatening and require intervention.[200] Despite 
local anesthetics, some men find the procedure painful and 
unpleasant but the majority rate these symptoms as a minor 
problem and would be willing to undergo a repeat biopsy, if 
necessary.[200, 201]   Infectious complications including 
urinary tract infections, epididymitis, fever and sepsis have 
increased, most likely due to microbial antibiotic 
resistance.[202, 203] Most infectious complications are 
caused by the gram negative bacteria Escherichia Coli.[204] 
Infectious complications requiring hospitalization have also 
increased and up to 6.3% of men undergoing a biopsy 
require hospital admission within 3 days, most for febrile 
infections.[199, 205] A recent report from the Prostate 
Cancer Data Base (PCBaSe), Sweden showed that infectious 
complications are increasing also in Sweden and 1% of 
biopsied men were hospitalized for a post-biopsy infection. 
The strongest risk factors for an infections complication not 
requiring hospitalization were a history of UTI and severe 
comorbidity. Infectious complications requiring 
hospitalization increased with time (from 2006 to 2011) and 
were more likely in men with a high comorbidity 
score.[203] Acute urinary retention is uncommon (<2%) but 
worsening LUTS are reported in <25% of patients.[199]  
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Recently there has been a growing concern that prostate 
biopsies, especially repeated biopsies and extended biopsy 
schemes may cause erectile dysfunction. The hypothesis is 
that biopsies may cause inflammation that may temporarily 
damage the neurovascular bundles because of their 
anatomical proximity to the prostate, and/or that biopsy may 
hit the nerves and cause direct damage. Psychological 
effects of undergoing work-up for cancer may also play a 
role. The scientific evidence is sparse but there seems to be a 
trend towards increasing erectile dysfunction during the first 
month but that these changes resolve with longer follow-
up.[199] The long-term effects of repeated biopsies for men 
on active surveillance need further investigation. The risk of 
a fatal complication following prostate biopsy is extremely 
low and men selected for prostate biopsy are healthier than 
the general population.[203, 206, 207] 
 
• Anxiety. A review by Hewitson concluded that health-related 
quality-of-life (HRQoL), psychological distress and anxiety 
were not dramatically increased for asymptomatic men 
during the screening process.[208] Carlsson et al. 
investigated the level of anxiety in men with a positive 
screening test (PSA ≥3 ng/mL) in the Göteborg screening 
study and showed that levels of anxiety were generally low; 
66% reported no anxiety while awaiting the PSA result and 
45% reported no anxiety associated with prostate biopsies. 
There was no significant association between the PSA-level 
and anxiety levels. However, for a small subgroup of 
patients, screening was associated with severe anxiety.[209] 
Several other studies have reported similar results.[210, 211] 
Wade et al. recently reported from the ProctecT-trial that 
levels of anxiety and depression associated with prostate 
biopsy were low and comparable with those of the general 
male population with the exception of two groups of 
patients; those with problematic post-biopsy side-effects and 
those who received a cancer diagnosis.[212]  
 
Many patients receive the receipt of a cancer diagnosis as a 
death sentence. The psychological consequences of living 
with a cancer diagnosis have been studied in both qualitative 
and quantitative studies, albeit the psychological harms of 
overdiagnosis are less well studied than the physical 
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consequences. Several studies have reported increased rates 
of anxiety, depression, post-traumatic stress disorder, 
cardiovascular events and even suicide for men living with a 
PC diagnosis.[213-216] Physicians need to be aware of these 
potential consequences of living with a cancer diagnosis, in 
order to offer appropriate counseling and/or pharmacological 
treatment of anxiety and depression, when indicated. 
  
• False positive results. Men with false positive PSA results 
have more PC specific worry both in the short and long term 
than men with true negative results.[217] Men with false 
positive results also have more subsequent PSA testing and 
visits to a urologist.[218] False positive tests also lead to 
unnecessary biopsies. It is therefore important to minimize 
this rate. The rate of false positive tests depends on the PSA 
cut-off and the number and location of biopsies. In the 
Göteborg screening trial, using a PSA cut-off ≥3ng/mL, the 
PPV was 24% meaning that 76% of those with a positive 
screening test had negative biopsies.[119]    
  
• False negative result. False negative results occur due to a 
false negative PSA results, i.e. a PSA below threshold 
despite cancer in the prostate, or due to a false negative 
biopsy, i.e. a PSA above threshold and PC present in the 
prostate but PC is not detected in the biopsy. The rate of 
false negative PSA results is dependent on PSA threshold 
and the rate of false negative biopsies depend on the biopsy 
technique and the number of sampled biopsy cores. For 
sextant biopsies, false negatives range between 15-34%. 
[133]. A false negative screen can result in delayed 
diagnosis and in the worst case, a missed chance of cure.  
 
• The economic consequences. The economic consequences of 
overdiagnosis have been very little studied. The costs of 
introducing a screening program, as performed in the Dutch 
section of the ERSPC (age 55-75, PSA threshold 3 ng/ml, 
sextant biopsy, screening interval 4 yrs), have been 
estimated with the MISCAN model. Compared to a situation 
with no screening at all, health care costs for PC would be 
doubled if screening (100% attendance rate) was 
implemented. Only 10% of the additional costs would be 
due to the screening program itself whereas diagnosis and 
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Recently there has been a growing concern that prostate 
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treatment of overdiagnosed men would account for almost 
40% of the total cost. Screening with a 4 year interval up to 
the age of 75 was the most expensive screening strategy, 
both annual and biennial screening up to 70 years were less 
expensive.[219]  
 
1.6.4 Overtreatment and quality-of-life issues 
In addition to increasing health-care costs and the many potentially negative 
psychological consequences of living with a cancer diagnosis, overdiagnosis 
may lead to subsequent overtreatment, which is believed to be the major 
problem with overdiagnosis.  Many patients receive treatment and end up 
being treated for a cancer that would never have surfaced clinically, which is 
synonymous to overtreatment. This would be less of a problem if the 
treatments did not have side-effects. However in the case of PC, treatments 
with curative intent (radical prostatectomy and radiotherapy) have long-term 
side-effects with consequences for QoL. In addition, as screening advances 
diagnosis, men have to live longer with these side-effects. The largest 
reduction in HRQoL occurs within the first 1-2 years after treatment and 
stabilizes thereafter. Differences in the effects on various HRQoL domains 
between treatment alternatives tend to attenuate over time.[220] Common 
long-term side-effects following curative treatment for PC are urinary 
incontinence, impotence and bowel disturbances. Radical prostatectomy has a 
greater effect on sexual and urinary function while radiation therapy had a 
larger effect on bowel function, at least during the first 5 years.[221, 222] 
Reported rates of postoperative incontinence (0-65%) and impotence (29-
100%) vary greatly in different reports.[223] Baseline function, patient age 
and operative skills of the surgeon all have an important influence on the 
functional (and oncological) outcomes. Historically, erectile dysfunction used 
to occur in almost all patients post radical prostatectomy but with the advent 
of the nerve-sparing technique [224] some men are potent postoperatively. In 
the SPCG-4 trial, which compared radical prostatectomy to watchful waiting, 
84% reported erectile dysfunction and 41% urinary leakage post-operatively 
after a median follow up of 12 years, compared to 80% and 11% for watchful 
waiting patients.[225] Urinary incontinence is at its worst the first moths 
postoperatively and then improves. Carlsson et el. recently published a paper 
on the effect of surgical variability on the functional and oncological outcome 
of men undergoing open radical prostatectomy at the Sahlgrenska University 
Hospital in Göteborg, Sweden. Of men reported to be potent at baseline, 19% 
reported being potent 18 months postoperatively, and of those reporting to be 
continent at baseline 85% were continent 18 months postoperatively. There 
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was a large heterogeneity between surgeons with respect to urinary 
continence, with incontinence rates ranging between 7% and 30%, depending 
on which surgeon performed the operation.[75] To this date, no RCT has 
demonstrated any difference in functional and oncological outcomes between 
open radical prostatectomy and robot-assisted radical prostatectomy.[11, 64] 
In a study from the Göteborg screening trial it was shown that if screening 
were to be implemented, the “cost” of saving one man from PC death is 4 
men impotent and less than one man incontinent.[226] The 30-day mortality 
after radical prostatectomy is low at 0.1-0.5%.[227]  
During the last decade there have been significant improvements in the 
planning and delivery of radiotherapy, which has reduced complication rates. 
Complications are usually divided in acute and late toxicity (≥ 6 months post 
treatment). Acute toxicities occur in about 50% of patients and include LUTS 
(mainly irritative symptoms), hematuria, diarrhea, rectal bleeding or mucus 
discharge and anal irritation. These are usually self-limiting and respond well 
to symptomatic treatment. Late toxicities are also mainly gastrointestinal and 
genitourinary symptoms and include increased bowel frequency, rectal 
bleeding, urethral strictures, LUTS, hematuria (ranging from minor hematuria 
to severe hemorrhagic cystitis), erectile dysfunction and secondary 
malignancies such as rectal cancer. The exact mechanism behind erectile 
dysfunction after radiotherapy is unclear but might be due to vascular damage 
and scarring. Acute and late complications are often classified according to 
the Radiation Therapy Oncology Group (RTOG)/European Organization for 
Research and Treatment of Cancer (EORTC) morbidity scale which is graded 
from 1 to 4 (1=mildest, 4=fatal). In an EORTC trial, late toxicity after 
external radiation (70 Gy) was reported for 377 men with T3-4 tumors. A 
total of 22.8% had grade ≥2 urinary or intestinal complications or edema in 
the lower extremities (legs). Grade 3 or 4 complications occurred in <5% of 
patient but 4 of the 377 men died due to grade 4 complications.[228]  
Side effects from treatment also have consequences for various aspects of 
QoL. A large prospective study by Sanda et al. investigated factors that were 
associated with changes in QoL radical prostatectomy and radiotherapy 
reported by patients and their partners. Each treatment alternative resulted in 
a distinct pattern of changes on QoL related to the various side-effects. The 
degree of satisfaction, for patients and their partners, regarding treatment 
outcomes was significantly associated with changes in QoL domains 
affected.[229]  
A recent paper by Schaake et al. investigated the impact of radiation-induced 
toxicity on HRQoL. They found that also mild, grade 1 toxicity, had negative 
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effects on HRQoL. Urinary incontinence affected all HRQoL scales and the 
effect was most pronounced 6 months after therapy, but the negative impact 
decreased thereafter. Rectal discomfort was common (18%) and had a major 
impact on HRQoL. The proportion of men who experience any rectal 
discomfort was stable over time, but the level of discomfort decreased. There 
was no significant association between HRQoL and radiotherapy technique, 
adjuvant hormonal treatment or patient characteristics.[230]      
From the PLCO trial, Davis et al. reported on long-term side-effects of PC 
treatment and effects on cancer-related and general QoL. Urinary, sexual, and 
bowel side effects were independently associated with cancer-related QoL. 
Urinary and bowel side-effects were also associated with general QoL. Bowel 
side effects had the strongest association with all QoL outcomes. Treatment 
related side-effects were present and affected QoL up to 10 years post-
treatment.[231]        
With data from the ERSPC trial Heijnsdijk et al. used the MISCAN model to 
predict quality adjusted life-years (QALYs) gained after introducing 
organized PSA-screening compared to a situation without screening. Over the 
lifetime of 1000 men, who would be screened annually between 55-69 years, 
there would be nine fewer PC deaths and 73 life years gained. However, this 
figure would have to be adjusted by -23% due to loss in QoL, resulting in 56 
QUALYs gained. The main reasons for the loss in QoL were overdiagnosis 
and side-effects from curative treatment. The model also predicted that over 
the life-time of the 1000 men, 45 men would be overdiagnosed and 
overtreated and there would be a loss of 1134 PC-free years (lead time years). 
[170]      
Active surveillance has emerged as a treatment strategy with the aim of 
reducing the overtreatment of screen-detected PCs as described in paragraph 
1.2.4. The challenges of active surveillance are discussed in depth in the 
discussion section of paper II. 
1.7 Screening and overdiagnosis in other 
fields of medicine 
Overdiagnosis and overtreatment are not unique for prostate cancer 
screening. Both phenomena are common in many field of modern medicine. 
Not all individuals who receive an intervention, whether it is a screening test, 
a medication or an operative procedure will benefit from it. A certain level of 
overdiagnosis and/or overtreatment has to be accepted. For example, when 
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treating mild to moderate hypertension with thiazide diuretics, 122 patients 
need to be treated during 5 years to prevent one cardiovascular event.[232]  
Mammography 
The benefits and harms of breast cancer screening with mammography have 
been debated extensively during the last decades. Similar to any cancer 
screening, the benefit of a reduction in disease-specific mortality has to be 
weighed against a number of potential negative consequences. Some women 
find the examination painful and unpleasant. The psychological effects of a 
false-positive examination are well-studied.[233]  False positives occur at a 
rather high rate in breast cancer screening. According to a Cochrane review; 
200 women will receive a false-positive result were further investigations 
will show that they do not have cancer if 2000 women are screened during a 
10 year period.[234]   
Analogous with PC screening, there is potential for overdiagnosis with 
mammography. There is a “disease reservoir” of asymptomatic cancers that 
can be detected with screening but that might never have surfaced clinically. 
Autopsy studies have shown that undetected breast cancer lesions are 
common and found in 7-39% of middle-aged women.[235] Since the 1960’s 
a number of RCTs of mammography have been published, several of which 
have been conducted in Sweden.[234]   
The USPSTF updated their recommendations for breast cancer screening in 
2009. For women age 50-74 they recommend biennial screening with 
mammography. Their decision was based on a meta-analysis of six trials 
among women age 50-59 years that showed a RR for breast cancer death of 
0.86 (CI 0.75-0.99) and NNI 1339 (CI 322-7455) and two trials among 
women aged 60-69 years that gave a pooled RR of 0.68 (CI 0.54-0.87) and 
NNI 377 (CI 230-1050). For women for women 39-49 of age they concluded 
that the net benefit was small (NNI of 1904) and therefore recommended 
against screening. They found only one study that reported results for women 
older than 70 years. This study could not show a reduction in breast cancer 
mortality.[236, 237] A 2011 Cochrane review by Gøtzsche et al. was more 
pessimistic about mammography and concluded that screening likely reduces 
breast cancer mortality by 15% but with approximately 30% overdiagnosis 
and overtreatment and that it is unclear whether breast cancer screening does 
more good than harm.[234] An independent expert panel in the UK reviewed 
the benefits and harms of breast cancer screening and published their 
conclusions in the Lancet in 2012. They estimated that screening with 
mammography reduces breast cancer mortality by 20% (RR 0.80, CI 0.73-
0.89) and that approximately 19% of the cancers detected in the screening 
Prostate Cancer Screening 
52 
effects on HRQoL. Urinary incontinence affected all HRQoL scales and the 
effect was most pronounced 6 months after therapy, but the negative impact 
decreased thereafter. Rectal discomfort was common (18%) and had a major 
impact on HRQoL. The proportion of men who experience any rectal 
discomfort was stable over time, but the level of discomfort decreased. There 
was no significant association between HRQoL and radiotherapy technique, 
adjuvant hormonal treatment or patient characteristics.[230]      
From the PLCO trial, Davis et al. reported on long-term side-effects of PC 
treatment and effects on cancer-related and general QoL. Urinary, sexual, and 
bowel side effects were independently associated with cancer-related QoL. 
Urinary and bowel side-effects were also associated with general QoL. Bowel 
side effects had the strongest association with all QoL outcomes. Treatment 
related side-effects were present and affected QoL up to 10 years post-
treatment.[231]        
With data from the ERSPC trial Heijnsdijk et al. used the MISCAN model to 
predict quality adjusted life-years (QALYs) gained after introducing 
organized PSA-screening compared to a situation without screening. Over the 
lifetime of 1000 men, who would be screened annually between 55-69 years, 
there would be nine fewer PC deaths and 73 life years gained. However, this 
figure would have to be adjusted by -23% due to loss in QoL, resulting in 56 
QUALYs gained. The main reasons for the loss in QoL were overdiagnosis 
and side-effects from curative treatment. The model also predicted that over 
the life-time of the 1000 men, 45 men would be overdiagnosed and 
overtreated and there would be a loss of 1134 PC-free years (lead time years). 
[170]      
Active surveillance has emerged as a treatment strategy with the aim of 
reducing the overtreatment of screen-detected PCs as described in paragraph 
1.2.4. The challenges of active surveillance are discussed in depth in the 
discussion section of paper II. 
1.7 Screening and overdiagnosis in other 
fields of medicine 
Overdiagnosis and overtreatment are not unique for prostate cancer 
screening. Both phenomena are common in many field of modern medicine. 
Not all individuals who receive an intervention, whether it is a screening test, 
a medication or an operative procedure will benefit from it. A certain level of 
overdiagnosis and/or overtreatment has to be accepted. For example, when 
Rebecka Arnsrud Godtman 
53 
treating mild to moderate hypertension with thiazide diuretics, 122 patients 
need to be treated during 5 years to prevent one cardiovascular event.[232]  
Mammography 
The benefits and harms of breast cancer screening with mammography have 
been debated extensively during the last decades. Similar to any cancer 
screening, the benefit of a reduction in disease-specific mortality has to be 
weighed against a number of potential negative consequences. Some women 
find the examination painful and unpleasant. The psychological effects of a 
false-positive examination are well-studied.[233]  False positives occur at a 
rather high rate in breast cancer screening. According to a Cochrane review; 
200 women will receive a false-positive result were further investigations 
will show that they do not have cancer if 2000 women are screened during a 
10 year period.[234]   
Analogous with PC screening, there is potential for overdiagnosis with 
mammography. There is a “disease reservoir” of asymptomatic cancers that 
can be detected with screening but that might never have surfaced clinically. 
Autopsy studies have shown that undetected breast cancer lesions are 
common and found in 7-39% of middle-aged women.[235] Since the 1960’s 
a number of RCTs of mammography have been published, several of which 
have been conducted in Sweden.[234]   
The USPSTF updated their recommendations for breast cancer screening in 
2009. For women age 50-74 they recommend biennial screening with 
mammography. Their decision was based on a meta-analysis of six trials 
among women age 50-59 years that showed a RR for breast cancer death of 
0.86 (CI 0.75-0.99) and NNI 1339 (CI 322-7455) and two trials among 
women aged 60-69 years that gave a pooled RR of 0.68 (CI 0.54-0.87) and 
NNI 377 (CI 230-1050). For women for women 39-49 of age they concluded 
that the net benefit was small (NNI of 1904) and therefore recommended 
against screening. They found only one study that reported results for women 
older than 70 years. This study could not show a reduction in breast cancer 
mortality.[236, 237] A 2011 Cochrane review by Gøtzsche et al. was more 
pessimistic about mammography and concluded that screening likely reduces 
breast cancer mortality by 15% but with approximately 30% overdiagnosis 
and overtreatment and that it is unclear whether breast cancer screening does 
more good than harm.[234] An independent expert panel in the UK reviewed 
the benefits and harms of breast cancer screening and published their 
conclusions in the Lancet in 2012. They estimated that screening with 
mammography reduces breast cancer mortality by 20% (RR 0.80, CI 0.73-
0.89) and that approximately 19% of the cancers detected in the screening 
Prostate Cancer Screening 
54 
group during the screening years were overdiagnosed. For women invited for 
screening during a period of 20 years starting at the age of 50 years NNI was 
235.[238]  
When Sweden introduced population-based mammography screening in 1986 
it was as one of the first countries in the world. Since 1997, mammography is 
offered nationwide in Sweden. The National Board of Health and Welfare 
recommends screening for breast cancer with mammography every 18-24 
months in women aged 40-74.[239] Critical voices have been raised that the 
invitations for mammography in Sweden are not detailed enough and should 
better state the advantages and disadvantages of screening, and that many 
women do not perceive the invitation as voluntary but rather as something 
mandatory.[240] The National Board of Health and Welfare is currently 
working on a revision of the invitation letter.     
In summary, breast cancer screening with mammography reduces breast 
cancer mortality by 15-25%. The amount of overdiagnosis is difficult to 
estimate but ranges between 11-30% depending on method of calculation and 
the composition of the underlying population in which it is being studied. 
NNI varies between different reports from 100 to 2000 women, depending on 
age, duration of screening and length of follow-up.[238] 
Colorectal cancer screening 
The majority of colorectal cancer tumors develop from precancerous 
adenomas to carcinomas, a process that takes several years. Screening for 
colorectal cancer aims at detecting these precancerous lesions with fecal 
occult blood-testing (FOBT) and/or endoscopy (flexible sigmoidoscopy or 
colonoscopy). FOBT can be tested with the guaiac-method or with a human-
specific immunochemical test.[241]  
Four RCTs have investigated whether screening with FOBT followed by 
endoscopy reduces colorectal cancer mortality. [242-245] A Cochrane review 
combining the results of these four trials reported a reduction of 16% in 
colorectal cancer mortality (RR 0.84, CI 0.78-0.90) after 11-18 years of 
follow-up. There was no significant difference in all-cause mortality. [246] 
NNI for biennial screening with FOBT range between 600-1200 with up to 
17 years of follow-up.[247] 
Flexible sigmoidoscopy has also been shown to reduce disease-specific 
mortality, in five separate RCTs by 22-31%.[248-252] As colorectal cancer 
screening reduces the incidence of invasive cancer through detection and 
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removal of adenomas overdiagnosis cannot be estimated as NNT/NND.[249, 
250, 252]        
Negative aspects of colorectal cancer screening includes false negative tests 
(polyps that do not bleed or that do not bleed at the time of the test), false 
positive FOBTs leading to unnecessary endoscopies, overdiagnosis of polyps 
that would never have developed to invasive cancer and complications of 
endoscopic procedures (perforation, bleeding).[246] 
In Sweden there is an ongoing screening program for colorectal cancer with 
FOBT in the Stockholm/Gotland region since 2008, and since 2013 the 
Swedish National Board of Health and Welfare recommends screening for 
colorectal cancer with FOBT for men and women aged 60-74. An almost 
nation-wide screening study is launched in 2014 comparing screening with 
FOBT and endoscopy.[253]  
Cervical cancer screening 
Screening for cervical cancer with Papanicolou (Pap) smear has a long 
history. Already in 1928 Papanicolou published a report indicating that 
cervical cancer could be diagnosed from exfoliated cells. Exposure to certain 
strains of human papilloma virus (HPV) has an important role in the 
development of cervical cancer and the majority of cases are preceded by a 
history of HPV-infection resulting in cellular abnormalities. However, most 
episodes of HPV infection are transient and would never develop into high-
risk lesions or cancer. Screening for cervical cancer with Pap-smear and/or 
HPV-testing aims at diagnosing precancerous lesions and preventing them 
for develop into invasive cancer and thereby reducing cervical cancer 
incidence and mortality. The effectiveness of Pap smear screening has never 
been demonstrated in a RCT. Evidence comes from observational studies and 
by studying trends in cervical cancer incidence and mortality following the 
introduction of screening, which has shown that organized screening with 
Pap smear can reduce cervical cancer mortality by up to 80%.[254-257] The 
Nordic countries introduced organized screening at different times; Finland 
was first in 1963, soon followed by Iceland and Sweden. Denmark also 
launched a program already in 1964 but has had problems reaching an 
adequate coverage in the population; the attendance rate was only 45% as late 
as in 1991. In Norway, screening was opportunistic until 1994 when an 
organized screening program was introduced. As expected Iceland, Finland 
and Sweden have had the most pronounced incidence and mortality 
reductions, 55-75% and 60-76%, respectively, while the corresponding 
figures for Denmark and Norway have been lower.[256] NNS to prevent one 
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removal of adenomas overdiagnosis cannot be estimated as NNT/NND.[249, 
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cervical cancer death has been estimated to 1140 after 10 years for regular 
Pap smears.[258]           
Similar to other screening method, there are potential harms with screening 
and treatment for cervical cancer. Abnormal tests can lead to more frequent 
testing and invasive procedures (colposcopy, cervical biopsy) resulting in 
bleeding, pain and infections.[259] An abnormal test can also lead to a short-
term increase in anxiety and distress. The potential harms of treatment 
include adverse pregnancy outcomes such as preterm delivery.[260] There is 
also a risk of overdiagnosis. Many precancerous lesions will never develop to 
invasive cancer but regress and other lesions are slow-growing and will never 
become symptomatic during the woman’s lifetime. Similar to colorectal 
cancer screening, cervical cancer screening aims at reducing the incidence of 
cervical cancer screening by removal of precursors, therefore NNT/NND 
cannot easily be estimated.  
The USPSTF recommends screening for cervical cancer with cytology (Pap 
smear) every three years for women aged 21-65, alternatively screening every 
5 years with a combination of cytology and HPV-testing for women aged 30-
65.[261] The Swedish national screening program for cervical cancer is 
currently reviewed. Today, women are regularly invited (every 3-5 years) for 
a Pap smear between the ages of 23 to 60. In some parts of the country, 
testing for HPV is also part of the screening program. As a complement to 
the national screening program Swedish girls (10-12 years) are offered 
vaccination against HPV strains number 16 and 18, which are most strongly 
associated with increased risk of cervical cancer, as part of the vaccination 
program for children in Sweden. 
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2 AIM 
The overall aim of this thesis was to explore different aspects of 
overdiagnosis in screening for PC with PSA. The specific aims of each paper 
were as follows: 
Paper I 
To investigate the accuracy of Swedish COD certificates for men with PC to 
ensure that these can be used for endpoint evaluation in screening studies for 
PC and to investigate whether overdiagnosis affected accuracy. 
Paper II 
To evaluate whether active surveillance can be used as a treatment strategy 
for screen-detected PC to reduce overtreatment. 
Paper III 
To investigate the effectiveness of organized compared to opportunistic 
screening in reducing PC mortality, measured as number needed to invite, as 
well as risk of overdiagnosis, measured as number needed to diagnose 
Paper IV 
To investigate the effect of age and number of screening visits on the risk of 
being diagnosed with PC. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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3 PATIENTS AND METHODS 
3.1 Population 
The Göteborg randomized population-based PC screening study is the base 
for all four papers (I-IV) in this thesis. This trial was initiated in 1994 
following approval from the ethical review committee at the University of 
Göteborg. As of Dec 31 1994, there were 32,298 men born between 1930 and 
1944 (age 50-64, median 56 years) and living in the city of Göteborg, 
according to the Population Registry. Using computer randomization, 10,000 
men were randomized to a screening group and 10,000 men to a control 
group. A total of 101 men were excluded (50 in the screening group and 51 in 
the control group); 56 men had prevalent PC, 34 had deceased and 10 had 
emigrated but had not been removed from the Population Register at the time 
of randomization; another man in the control group refused participation 
(Figure 7). No informed consent was deemed necessary for men in the 
control group. Men in the screening group received a letter with information 
regarding PSA and its advantages and disadvantages together with an 
invitation for PSA-testing every second year. The mean upper age limit for 
invitation was 69 years (67-71). The PSA threshold that led to a 
recommendation for further urological work-up was initially 3.4 ng/mL but 
has been lowered on two occasions for consistency with other ERSPC sites 
and due to a change in assay-calibrator ( in 1999 to 2.9 ng/mL and in 2005 to 
2.5 ng/mL). The urological work-up consisted of a DRE, TRUS and prostate 
biopsies. Laterally directed sextant biopsies were the standard up to year 
2009, thereafter a ten-core biopsy scheme has been used. Men with a PSA 
below the threshold and men with benign biopsy were re-invited for PSA-
testing after 2 years. The treatment strategy following a PC diagnosis was not 
specified in the study protocol, but was at the discretion of the patient and the 
treating physician. The vast majority of men in both the screening and control 
arm has been followed and treated by the same team of urologists at 
Sahlgrenska University hospital in Göteborg, Sweden.  
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Figure 7. Consolidated Standards Of Reporting Trials (CONSORT) diagram 
showing the screening algorithm of the Göteborg randomized population-based 
prostate cancer screening study 1995-Jun 30, 2014 
In all men with a PC diagnosis, both in the screening and control group, all 
available medical information regarding tumor stage, treatment and disease 
course was continuously entered into a study database. This database was 
linked every third month to the Regional Cancer Register (since 2009 also to 
the Swedish National Cancer Register, SCR) and the Swedish Population 
Register (SPR) to obtain information on PC diagnosis, mortality and 
emigration outside Sweden. In addition, for all deceased men, a copy of the 
COD certificate was obtained. COD in all men with a PC diagnosis was 
determined by an independent COD committee as described below.   
As of spring 2014 the 10th and final screening round was completed when all 
age cohorts had reached the upper age-limit for invitation. However, the 
study data-base continues to be regularly linked to the SCR and the SPR to 
retrieve information regarding PC diagnosis and deaths. 
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Total male population in Göteborg on 31 December, 
1994 aged 50-64 years (n=32 298) 
20 000 men randomized to screening or control group in 
a 1:1 ratio 
50 men excluded before invitation 
28 men with prevalent PC 
22 men who had emigrated 
or deceased 
51 men excluded before invitation 
27 men with prevalent PC 
23 men who had emigrated or 
deceased 
1 man refused participation 
 
9950 men in the screening group, invited 
every 2 years for a PSA test 
3739 complete attendees 
3914 attendees 
  
2297 non-attendees 
  
9949 men in the control group (not invited) 
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3.2 Registers 
Several different Swedish registers have served as important sources of 
information for the Göteborg screening study and for the four papers in the 
present thesis. Nordic countries, Sweden included, are known to have a high 
quality of their official registers. The Swedish 10-digit personal identity 
number, which is a unique personal identifier, is given to all individuals who 
are registered in Sweden. It is an important tool for linking medical registers 
and enables almost 100% coverage in many Swedish registers.[262] 
Cause of death register - Dödsorsaksregistret 
Sweden has a long history of population registers. Way back in 1749 a 
population register, “Tabellverket”, covering the entire country, was 
established. At that time, the clergy was responsible for the reports. COD 
determination for all causes of death has been mandatory in Sweden since 
1911, and since then, the National Board of Health and Welfare publishes a 
statistical summary report entitled “Causes of death” every year. Previously, 
cause of death was recorded in churches’ funeral books and summaries were 
sent monthly to the district medical officer who reported to Statistics’ 
Sweden. In 1991 the certificate was divided in two parts; one death certificate 
(sv. “Dödsbevis”) which is sent to the Swedish Tax Agency as well as the 
Population Register, and another COD certificate (sv. “Dödsorsaksintyg”) 
which is sent to the National Board of Health and Welfare that constitutes the 
base for COD statistics. Both certificates should be issued by a medical 
doctor.[263]  
The COD certificate has two parts. Part I has four lines (A-D) and the bottom 
line (lined) should state the underlying COD and any other conditions entered 
on line A-C should be a direct consequence of the underlying COD stated on 
D. The underlying COD is the condition that started the chain of events 
leading to death, for example: PC  deep venous thrombosis  pulmonary 
embolism. Part II should state any other conditions that might have 
contributed to death, but which are not related to or a direct consequence to 
the COD, e. g. hypertension. Incomplete or inconclusive certificates are 
returned to the certifier for supplementation (2.7% of all certificates in 2008). 
If no COD certificate is issued, a reminder is sent to the doctor who issued 
the death certificate. The COD certificate was not issued in 1.84% of all 
deaths, despite reminders. In these instances the COD is coded as R99.9. 
Trained coders at the National Board of Health and Welfare code all deaths 
according the International Classification of Diseases - 10 (ICD-10) and enter 
the information in the COD registry. The reported underlying COD is 
changed from what is stated on the certificate in 20% of all cases.[264]  
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The autopsy frequency is the proportion of deaths where the COD is based on 
an autopsy (clinical or forensic). Autopsy is believed to be the most thorough 
examination to confirm a COD; declining autopsy rates over time may lead to 
more inaccurate COD determinations in national statistics. Since 1970, the 
autopsy frequency in Sweden has declined from 50 % to 12% in 2011. The 
autopsy frequency was 7% for women and 15% for men in 2011.[265]  
The Swedish Cancer Register - Cancerregistret 
The SCR was started in 1958 and is, since the 1980’s, divided into six 
regional cancer registers which are managed by the Regional Cancer Centers 
(RCC). The RCCs are responsible for registration, coding, data check and 
correction work. Every health care provider is obliged, by Swedish law, to 
report every newly diagnosed cancer to the RCC, regardless of the mode of 
diagnosis (clinical, morphological, based on laboratory test or on 
autopsy).[266] The SCR is generally considered to be of high quality with 
99% of all cancers morphologically verified [266] and an almost complete 
coverage. The completeness of the SCR was investigated in a sample survey 
in 1998. Possible underreporting was investigated by comparing the Hospital 
Discharge Resister with the SCR. The degree of underreporting was site-
specific and increased with age. Underreporting for urological cancers was 
low. In total, underreporting was estimated at 3.7% of all reported cases.[267] 
The Swedish Population Register -Folkbokföringsregistret 
The Tax Agency (sv. “Skatteverket”) is responsible for the SPR. The register 
contains information about people who live in Sweden and where in the 
country they reside. The first time a person is registered in the Population 
register he or she receives a personal identification number. The register 
receives information regarding migration within the country and emigration 
to other countries. When a person has deceased, the register receives a death 
certificates. 
Paper I 
This paper evaluated the quality of Swedish COD certificates in men with 
PC, to ensure that death certificates can be used for endpoint evaluation in a 
PC screening study. As PC mortality is the main endpoint in the Göteborg 
screening trial, an accurate COD determination is crucial. All men with a PC 
diagnosis (PC as underlying COD on the death certificate or identified 
through linkage with the SCR) and who deceased during the study period 
(Jan 1, 1995 - Dec 31, 2008) were included. Men lacking an analyzable death 
certificate were excluded (n=7, 2.5%). Swedish COD certificates have, as 
previously described, two parts. In this analysis, PC was only regarded as the 
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diagnosis (clinical, morphological, based on laboratory test or on 
autopsy).[266] The SCR is generally considered to be of high quality with 
99% of all cancers morphologically verified [266] and an almost complete 
coverage. The completeness of the SCR was investigated in a sample survey 
in 1998. Possible underreporting was investigated by comparing the Hospital 
Discharge Resister with the SCR. The degree of underreporting was site-
specific and increased with age. Underreporting for urological cancers was 
low. In total, underreporting was estimated at 3.7% of all reported cases.[267] 
The Swedish Population Register -Folkbokföringsregistret 
The Tax Agency (sv. “Skatteverket”) is responsible for the SPR. The register 
contains information about people who live in Sweden and where in the 
country they reside. The first time a person is registered in the Population 
register he or she receives a personal identification number. The register 
receives information regarding migration within the country and emigration 
to other countries. When a person has deceased, the register receives a death 
certificates. 
Paper I 
This paper evaluated the quality of Swedish COD certificates in men with 
PC, to ensure that death certificates can be used for endpoint evaluation in a 
PC screening study. As PC mortality is the main endpoint in the Göteborg 
screening trial, an accurate COD determination is crucial. All men with a PC 
diagnosis (PC as underlying COD on the death certificate or identified 
through linkage with the SCR) and who deceased during the study period 
(Jan 1, 1995 - Dec 31, 2008) were included. Men lacking an analyzable death 
certificate were excluded (n=7, 2.5%). Swedish COD certificates have, as 
previously described, two parts. In this analysis, PC was only regarded as the 
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underlying COD if it was mentioned on the first part (line A-D) of the 
certificate.  
All available medical information was retrieved for men in the study. This 
included hospital charts, reports from outpatient clinics, x-rays, 
histopathology reports and autopsy protocols. A COD committee, consisting 
of three experienced urologists, reviewed all collected material and decided 
on the COD using a pre-specified algorithm. This algorithm has been used in 
the whole of the ERSPC for cause of COD determination.[268] It consists of 
a hierarchy of questions that need to be answered by the committee members. 
The first set of questions is:  
1. Were clinical metastases present and if so, were these PC 
metastases? The answer should be based on: clinical picture, 
PSA-level, x-ray, scans, treatment or no treatment, and 
pathology. Were there signs of progressive disease? The 
answer should be based on the same parameters as stated 
above. Was metastatic, progressive PC the COD?  If in 
doubt or negative the next question is: 
2. When in doubt or negative, the next set of questions is: Was 
there a progressive clinical recurrence? Was the progressive 
local recurrence the COD?  
3. When in doubt or negative the next set of questions is: 
Where complications of primary treatment the COD? If 
negative, were complications of screening or biopsy the 
COD? 
4. When still in doubt or negative, the last question is: Was the 
specific COD known and did PC contribute to this other 
COD?   
The algorithm can lead to eight different endpoints; definitely PC death, 
probable PC death, definitely intervention-related death, possible PC death, 
unlikely PC death, PC as a contributory factor to death, definitely not PC 
death and pending, if information for deciding on COD were lacking.  
In paper I, the COD was regarded as a dichotomous variable where definitely 
PC-, probable PC-, and intervention-related deaths were classified as “PC 
death” and all remaining endpoints as “other CODs”. Each committee 
member followed the algorithm and independently reached one endpoint. In 
cases of disagreement, consensus was reached by discussion in most cases 
but if no consensus could be reached the COD was a majority decision. Cases 
of special interest could also be discussed at a meeting with COD committees 
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from the other ERSPC centers. The committee was blinded for information 
regarding study arm in the majority of cases and only had access to the COD 
certificates in extraordinary cases where there was no other medical 
information available. 
Sensitivity was calculated as the proportion of deaths correctly coded as PC 
deaths and specificity as the proportion of correctly coded non-PC death, 
with the committee’s decision as reference.  
Agreement between members in the COD committee was classified as total 
agreement, minor disagreement or major disagreement. Total agreement was 
when all three committee members had classified COD as the exact same 
endpoint, minor disagreement was when one or two of the members had 
classified different endpoints but where the final endpoint was the same, for 
instance if two members had classified COD as definitely PC and the third 
member had classified COD as probable PC (all classified as PC death in the 
final evaluation). Major disagreement was when committee members did not 
agree on the COD in the final evaluation. For example, two members had 
classified COD as definitely PC and one member as unlikely PC (final 
evaluation 2 PC deaths and 1 non-PC death).   
To investigate factors that potentially could affect COD determination, all 
medical records were manually reviewed by the author of this thesis. We 
choose to register the presence of other malignancies (at the time of death or 
in the medical history), serious comorbidity, place of death and whether or 
not an autopsy had been performed.  
After paper I was published in 2011, the COD committee has finalized the 
evaluation of COD for all men with PC up to Dec 31, 2012. Therefore, 
results up to this date are also presented in this thesis.     
Paper II 
This second paper assessed outcomes for men managed with active 
surveillance. All men who had active surveillance as the primary treatment 
strategy between Jan 1, 1995 and Dec 31, 2010 in the Göteborg screening 
study were included. The treatment strategy was not determined by the study 
protocol, but at the discretion of the patient and his treating physician. The 
reason for choosing active surveillance was in the majority of cases, a 
presumed low-risk cancer but could also be due to comorbidities or patient 
preference. There was no protocol determining the exact interval between 
follow-ups or indications for re-biopsy but follow-up was determined by the 
biopsy outcome, disease activity, patient’s age and degree of comorbidity. All 
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men included in this study were managed by a small group of urologists, 
working under the same treatment policies, at a single university clinic. 
Typically, men were followed every 3-12 months with PSA and clinical 
examination, but the interval between follow-ups depended on disease 
activity and age. Most men were followed with active surveillance (curative 
intent) but as men grew older and comorbidities surfaced, active surveillance 
could gradually transcend into watchful waiting (symptomatic treatment). An 
early re-biopsy was performed if the initial biopsy contained a very small 
volume of cancer (<2 mm). Re-biopsy was also performed if there were signs 
of disease progression or typically, every two to three years in men with 
stable disease. Patients were recommended to remain on active surveillance 
as long as they felt comfortable with this management strategy, and as long 
as there were no signs of disease progression. Progression of PSA, grade or 
stage or led to a recommendation for a switch in treatment strategy to radical 
prostatectomy, radiation therapy or hormonal treatment. The patient himself 
could also request a change in treatment strategy. Follow-up continued every 
3-6 months after treatment.  
Tumors were divided in to risk groups (Table 6); the risk group definitions 
were a modified version of the D’Amico criteria.[55]A very low-risk group 
was also defined, based on the Epstein criteria for insignificant cancer.[183]  
Table 6. Risk group definitions 
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Endpoints were overall survival, PC-specific survival, treatment-free and 
failure-free survival. Failure after active surveillance was defined as death 
from PC, development of PC metastases, initiation of hormonal therapy or 
PSA recurrence following surgery or radiation. PSA recurrence was defined 
as PSA ≥0.2 ng/mL after radical prostatectomy with or without salvage 
radiation and as the PSA nadir + 2 ng/mL after radiation therapy. 
Paper III 
This paper aimed at investigating the effectiveness of organized versus 
opportunistic screening in reducing PC mortality, measured as NNI, and the 
amount of overdiagnosis, measured as NND. The screening group in the 
Göteborg screening study has, as previously mentioned, been invited to 
organized PSA screening every second year since 1995. In contrast, men in 
the control group have not been invited to such screening and have been 
unaware of their participation in a screening trial for PC. However, since the 
study started in 1995 opportunistic PSA screening has increased dramatically 
in Sweden.[269, 270] This implies that men in the control arm have also been 
exposed to these increasing levels of opportunistic screening. In the study 
data-base, information regarding the method of detection was prospectively 
registered for both the screening and control group.  
In 1990-94 PSA-usage as a screening test was close to non-existing in 
Sweden. Based on PC incidence data from the SCR and mortality data from 
the SPR for this pre-PSA-era years, we were able to estimate how the 
expected PC incidence and mortality could have developed, in the absence of 
any screening. By comparing the observed and expected incidence and 
mortality in the screening group – with organized screening versus without 
any screening – NNI and NND for organized screening could be calculated. 
In the same way, by comparing the observed and expected incidence and 
mortality in the control group – with opportunistic screening versus without 
any screening – NNI and NND for opportunistic screening could be assessed. 
The study period was from Jan 1, 1995 to Dec 31, 2012. NNI and NND for 
organized screening were calculated for the last seven years of follow-up, but 
NNI and NND for opportunistic screening could only be calculated after 15 
years, as this was the first time the observed mortality was lower than the 
expected. 
Paper IV 
This paper investigated the effect of age at screening and the number of 
screening visits (“screens”) on the risk of being diagnosed with PC. The 
screening arm of the Göteborg screening study contributed the study 
population (Figure 7). Men in the screening arm were defined as “attendees” 
 PSA Gleason score T stage Biopsy result 
Very low PSA density 
<0.15 ng/mL 
≤6 T1c <3 cores with 
cancer and 
≤50% cancer in 
any core 
Low <10 ng/mL ≤6 T1 - 
Intermediate <20 ng/mL ≤7 T1-2 - 
High <100 ng/mL ≥8 T1-4 - 
Advanced ≥100 ng/mL - M1 and/or N1 - 
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Paper IV 
This paper investigated the effect of age at screening and the number of 
screening visits (“screens”) on the risk of being diagnosed with PC. The 
screening arm of the Göteborg screening study contributed the study 
population (Figure 7). Men in the screening arm were defined as “attendees” 
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if they attended at least once and as “complete attendees” if they accepted all 
screening invitations without any interval interruption. Men who never 
attended were defined “non-attendees”. Complete attendees who were 
diagnosed with PC, who emigrated or who deceased between screening 
rounds (within 2 years of their last screen) were also included in the group of 
complete attendees. The maximum number of screens in each age cohort is 
shown in table 7.  
Table 7. Maximum number of screens for each age cohort 
The study period was from Jan 1 1995 to Jun 30, 2014. Men born 1944 were 
excluded from analysis in the paper IV due to short follow-up. In addition, 
the screening algorithm in the 10th round, which only included men born 
1944, was different from the previous rounds, with MRI used as a 
complementary screening test. Prevalent cases of PC (who were excluded 
from invitation, figure 7) were not evenly distributed in the age cohorts but 
were more frequent in the older age cohorts. We therefore added these cases 
to the each corresponding age cohort when calculating cumulative incidences 
of PC among complete attendees. Data regarding the number of PC deaths in 
the male Göteborg population born 1930-44 between 1980 and 1994 was 
obtained from the National Board of Health and Welfare.  
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3.3 Statistical considerations 
In the four papers that constitute this thesis several different statistical 
methods have been applied. These methods are discussed here below, and a 
summary of the methods used in each paper is presented in table 8. 
The Wilcoxon’s rank-sum test/Mann-Whitney U test was used to test 
differences in medians between groups for variables that were not normally 
distributed, for example median age at diagnosis or death in paper I. In 
paper I, Cohen’s kappa coefficient was calculated to measure agreement 
between COD certificates and the COD committee. The Kappa statistics is 
used to calculate agreement between two or more independent observers. As 
compared to a “simple” calculation of the proportion of agreement, the 
Kappa statistic takes into account that agreement can occur by chance. The 
calculation is based on the difference in the observed agreement compared to 
how much agreement could be expected by chance alone. Kappa can range 
from -1 to1, where 1 is perfect agreement, 0 is what would be expected by 
chance and a negative value would indicate systematic disagreement. A value 
between 0.81 and 0.99 is generally considered almost perfect 
agreement.[271] In paper I, confidence intervals (CI) for proportions 
(agreement, sensitivity and specificity) were calculated according to the 
efficient-score method with correction for continuity.[272, 273] The CI for 
the kappa statistics was calculated using an analytical method for 
dichotomous variables.[274] 
Survival analyses 
Different forms of survival analyses have been used in all four papers. 
Survival analysis is a branch in statistics that focuses on the time it takes for 
some event to occur, it other words, survival analyses typically deal with so 
called “time to event” data. These types of analyses enable study participants 
to be followed for various lengths of time and allow so called “censoring”. 
Survival times are censored if the period of observation is cut before the 
event/endpoint could potentially occur. Reasons for censoring can be that 
individuals are lost to follow-up, emigrate or die from unrelated causes, since 
these individuals are no longer “at risk” for the outcome of interest if they are 
no longer alive, or we would never be able to accurately find out whether 
they experienced the event or not if they were lost to follow-up or emigrated 
and we lost track of them. These individuals can contribute with valuable 
information regarding time at risk even though they have not experienced the 
event of interest, since we know for certain that they were event-free during 
the time that we could follow them.[275]The different forms of survival 
analysis used in this thesis are explained in brief and discussed below. 
Age cohort Maximum number of screens 
1930-31 3 
1932-33 4 
1934-35 5 
1936-37 6 
1938-39 7 
1940-41 8 
1942-43 9 
1944 10 
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The Kaplan Meier estimator of the survival function: The Kaplan Meier 
estimator or the product limit estimator is the probability of surviving or 
being event-free at a certain time considering time in many small 
intervals.[275] For each time interval the survival probability is calculated as 
the number of persons being event-free divided by the number of persons at 
risk. Those who are censored are no longer at risk. The cumulative 
probability of being event-free at a certain point in time is a chain of 
conditional probabilities where the probabilities of being event-free at all 
time-intervals preceding that point are multiplied.[275] There are some 
assumptions that should be met when using the Kaplan Meier method; those 
who are censored should have the same survival probability as those who 
continue to be followed and the survival probability should not be dependent 
on the time of recruitment (those who are recruited early have the same 
survival probability as those recruited later on). In addition, it must be 
possible to register the date of the event.[276] Survival analysis can also be 
used to estimate the probability of having experienced an event at a certain 
time. The cumulative probability or the cumulative incidence of an event can 
be estimated as 1 –  the Kaplan Meier estimator. To statistically test whether 
there is a statistical difference between the groups in the probability of the 
event at a certain time point, the log rank test can be applied. It is a 
hypothesis test where the null hypothesis is that the survival distributions are 
equal at all follow-up times. It compares the observed number of events in 
each group to the number of expected events if the survival function were the 
same, taking in to account differences in the length of follow-up between the 
groups.[277]  
-In paper I the cumulative incidence of death due to all causes, death due to 
PC and death due to non-PC causes in the screening and control group were 
plotted as 1 – the Kaplan Meier estimator. Time was calculated from date of 
diagnosis to date of death, emigration of last follow-up (Dec 31, 2008), 
whichever came first. The log rank test was used to test if there were 
significant differences the probability of death (from all causes, PC and other 
causes) between the screening and control group. 
-In paper III median time to PC diagnosis in the screening and control group 
was calculated with the Kaplan Meier method. Time to diagnosis was 
calculated from study start (Jan 1, 1995) to date of diagnosed. Men who did 
not experience an event were censored at date of death, emigration or Dec 31, 
2012, whichever came first. The log rank test was used to test the difference 
in time to diagnosis between the study arms.       
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Actuarial or life table analysis: This type of analysis is similar to the 
Kaplan Meier analysis but is used to describe data where the results are 
grouped into time intervals instead of the exact time that the events occur, as 
in the Kaplan Meier analysis. For the calculation, the number of persons at 
risk who enter the time interval, the number of events and the number 
censored during the interval are needed. The cumulative incidence can then 
be estimated as 1 – the actuarial survival estimate. Life tables can also be 
used to estimate the survival curve for a cohort of people from birth using age 
and sex specific mortality rates.[275]   
-In paper III life-table analysis was performed to estimate the observed 
cumulative PC incidence and mortality in the screening and control group, 
calculated as 1 – the actuarial survival estimate. Follow-up time was 
calculated from study start (Jan 1, 1995) to date of an event (PC diagnosis or 
death). Men who did not experience an event were censored at date of death, 
emigration or last follow-up (Dec, 31 2012). Standard errors (SE) were 
calculated according to a method by Greenwood [278] and CI were 
calculated on the log cumulative hazard scale and then transformed back to 
the survival scale.  
Cox proportional hazard regression analysis: This type of analysis can be 
used to explore the relationship of multiple predictors to a right-censored, 
time-to event outcome.[277] The hazard function is related to the survival 
function and the hazard can be interpreted as the instantaneous risk of having 
an event, assuming being event-free up to the time of interest.[275] The Cox 
proportional hazard model can test the independent effect of a number of 
explanatory variables, which can be continuous or categorical, on the hazard 
of the event. However, this analysis assumes that the relative hazard (the ratio 
of the hazards between the groups that are compared) is constant over time; 
the “proportional hazards assumption”. This can be tested and addressed if 
the assumption is violated.[277]           
          
Survival analysis in the presence of competing risks: A fundamental 
assumption in standard survival analysis, as mentioned above, is that 
censoring is not associated with an altered chance of having the event. Events 
that cause censoring and which are associated with an altered chance of 
experiencing the event are called competing risks.[279, 280] In the presence 
of competing risks the cumulative incidence calculated with the Kaplan 
Meier method (1 – Kaplan Meier estimator) will overestimates the 
cumulative incidence of the event; the magnitude of overestimation depends 
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The Kaplan Meier estimator of the survival function: The Kaplan Meier 
estimator or the product limit estimator is the probability of surviving or 
being event-free at a certain time considering time in many small 
intervals.[275] For each time interval the survival probability is calculated as 
the number of persons being event-free divided by the number of persons at 
risk. Those who are censored are no longer at risk. The cumulative 
probability of being event-free at a certain point in time is a chain of 
conditional probabilities where the probabilities of being event-free at all 
time-intervals preceding that point are multiplied.[275] There are some 
assumptions that should be met when using the Kaplan Meier method; those 
who are censored should have the same survival probability as those who 
continue to be followed and the survival probability should not be dependent 
on the time of recruitment (those who are recruited early have the same 
survival probability as those recruited later on). In addition, it must be 
possible to register the date of the event.[276] Survival analysis can also be 
used to estimate the probability of having experienced an event at a certain 
time. The cumulative probability or the cumulative incidence of an event can 
be estimated as 1 –  the Kaplan Meier estimator. To statistically test whether 
there is a statistical difference between the groups in the probability of the 
event at a certain time point, the log rank test can be applied. It is a 
hypothesis test where the null hypothesis is that the survival distributions are 
equal at all follow-up times. It compares the observed number of events in 
each group to the number of expected events if the survival function were the 
same, taking in to account differences in the length of follow-up between the 
groups.[277]  
-In paper I the cumulative incidence of death due to all causes, death due to 
PC and death due to non-PC causes in the screening and control group were 
plotted as 1 – the Kaplan Meier estimator. Time was calculated from date of 
diagnosis to date of death, emigration of last follow-up (Dec 31, 2008), 
whichever came first. The log rank test was used to test if there were 
significant differences the probability of death (from all causes, PC and other 
causes) between the screening and control group. 
-In paper III median time to PC diagnosis in the screening and control group 
was calculated with the Kaplan Meier method. Time to diagnosis was 
calculated from study start (Jan 1, 1995) to date of diagnosed. Men who did 
not experience an event were censored at date of death, emigration or Dec 31, 
2012, whichever came first. The log rank test was used to test the difference 
in time to diagnosis between the study arms.       
Rebecka Arnsrud Godtman 
69 
Actuarial or life table analysis: This type of analysis is similar to the 
Kaplan Meier analysis but is used to describe data where the results are 
grouped into time intervals instead of the exact time that the events occur, as 
in the Kaplan Meier analysis. For the calculation, the number of persons at 
risk who enter the time interval, the number of events and the number 
censored during the interval are needed. The cumulative incidence can then 
be estimated as 1 – the actuarial survival estimate. Life tables can also be 
used to estimate the survival curve for a cohort of people from birth using age 
and sex specific mortality rates.[275]   
-In paper III life-table analysis was performed to estimate the observed 
cumulative PC incidence and mortality in the screening and control group, 
calculated as 1 – the actuarial survival estimate. Follow-up time was 
calculated from study start (Jan 1, 1995) to date of an event (PC diagnosis or 
death). Men who did not experience an event were censored at date of death, 
emigration or last follow-up (Dec, 31 2012). Standard errors (SE) were 
calculated according to a method by Greenwood [278] and CI were 
calculated on the log cumulative hazard scale and then transformed back to 
the survival scale.  
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function and the hazard can be interpreted as the instantaneous risk of having 
an event, assuming being event-free up to the time of interest.[275] The Cox 
proportional hazard model can test the independent effect of a number of 
explanatory variables, which can be continuous or categorical, on the hazard 
of the event. However, this analysis assumes that the relative hazard (the ratio 
of the hazards between the groups that are compared) is constant over time; 
the “proportional hazards assumption”. This can be tested and addressed if 
the assumption is violated.[277]           
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on the incidence rate of the competing risk. For competing risk data, the log 
rank test is also inappropriate but corresponding hypothesis test for 
competing risk data exists. The Cox regression analysis also becomes invalid 
when competing risks are censored. There are competing risk regression 
models, that can distinguish between individuals who are still alive and those 
who have failed due to competing risks. The most common competing risk 
regression is the one by Fine and Gray.[281]   
-In paper II the cumulative incidence of treatment and failure were 
calculated with both Kaplan Meier method and competing risk analysis in 
order to estimate the magnitude of overestimation with the Kaplan Meier 
method. In paper II, we also investigated the association between risk group 
and age at diagnosis with the hazard of failure after active surveillance. Due 
to the presence of competing risks, we performed both a Cox regression 
analysis and competing risk regression according to the method by Fine and 
Gray.[281] Follow-up time was calculated from the date of diagnosis to date 
of the event. Men who did not have an event were censored at the date of 
death (in the Kaplan Meier analysis and Cox regression), date of emigration 
of date of last clinical follow-up. For men with multiple events, i.e. PSA 
recurrence, PC metastases and PC death, time was calculated to the first 
occurring event.   
-In paper IV, cumulative incidence of PC in the different age cohorts and at 
different ages was calculated as 1 – the Kaplan Meier estimator and with 
corresponding competing risk estimates. Time was calculated from study 
start to date of PC diagnosis. Men who were not diagnosed with PC were 
censored at date of death (in the Kaplan Meier analysis), date of emigration 
of last follow-up (Jun 30, 2014).        
Ederer II method: In paper III, we sought to project PC incidence and 
mortality in the absence of opportunistic or organized screening. This was 
performed by calculating the expected PC incidence and mortality with 
something called the Ederer II method, based on historical data from years 
1990 to 1994.[282] These years constitute the pre-PSA era when the usage of 
PSA as a screening tool for PC was close to non-existing. The Ederer II 
method is commonly used to assess expected survival when calculating 
relative survival or excess mortality. The expected survival can be thought of 
as being calculated for a cohort from the general population that is matched 
to the study cohort.[283] In paper III, the expected cumulative PC incidence 
and mortality were estimated as 1 – the Ederer II estimator. To match the 
age-distribution in the screening and control group when calculating the 
expected estimates we used 1-year age strata. The calculations of the 
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expected incidence and mortality were based on the entire male population in 
Göteborg.  Alternative methods for calculating expected survival are Ederer I 
and the Hakulinen method. The three methods differ regarding how long each 
matched individual is considered to be at risk for the purpose of calculating 
expected survival.[283]      
Number needed to screen (NNS) and number needed to treat (NNT): In 
paper III, we calculated NNS and NNT for organized and opportunistic 
screening. The statistics “number needed to screen” was first described by 
Rembold in 1998 and is a further development of the NNT by Cook and 
Sackett.[284, 285] NNS is calculated as 1 divided by the absolute risk 
reduction of the endpoint of interest between the study arms. In our study, 
NNS was calculated from an intention-to-treat analysis, that is, a comparison 
between all men in the two randomized arms, regardless of whether men in 
the screening group actually attended screening or not. Therefore, NNS 
referred to the number of men needed to be invited, and thus NNS was 
renamed number needed to invite (NNI). Number needed to treat (NNT) in a 
screening trial can be calculated as 1 divided by the absolute PC mortality 
reduction multiplied by the excess PC incidence. In the case of PC screening, 
a large proportion of those diagnosed with screen-detected cancer do not 
receive immediate treatment and NNT thus rather reflects the number of men 
needed to diagnose. NNT was therefore renamed number needed to diagnose 
(NND). Other authors have called this statistic number needed to manage 
(NNM) for the same reason. For studies with time to event outcomes, the 
calculation of NNS needs to take into account different length of follow-up 
and censoring, especially if censoring varies between the study groups. This 
can be done by calculating NNS from for example survival estimates from a 
Kaplan Meier analysis or the cumulative hazard function from the Nelson 
Aalen estimator.[286-288] In paper III, we calculated NNI and NND for 
organized and opportunistic screening, respectively. NNI for organized 
screening was calculated as 1 divided by the absolute difference in 
cumulative PC mortality between the observed PC mortality in the screening 
group compared to the expected pre-PSA era projected PC mortality rate. For 
opportunistic screening, NNI was calculated in the same way but by 
calculating the difference in the observed PC mortality for the control group 
compared to the expected pre-PSA era projected PC mortality rate. The 
absolute difference in PC incidence was calculated in the exact same fashion. 
NND was then calculated as NNI multiplied by the excess (increased) 
incidence between screening compared to pre-PSA era projected rates and 
control compared to pre-PSA era projected rates. In these calculations, 
cumulative PC incidence and mortality were calculated with the life-
table/actuarial method and with the Ederer II method. Confidence intervals 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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for NNI was calculated with a method described by Altman et al.[288] Both 
NNI and NND are highly time dependent time dependent and citing only one 
estimate can be misleading, without also mentioning the follow-up time at 
which these metrics are calculated.[178]  
In paper III, when calculating confidence intervals for the absolute and 
relative risk reduction the SE for the expected values was assumed to be zero 
as the expected incidence was based on the whole male population in 
Göteborg. The 95% CI for the absolute risk reduction was calculate as 
expected – observed cumulative incidence +/- 1.96 x SEobserved. The 95% CI 
for the relative risk reduction was calculated as 100 x (1 minus the quote 
between the limits of the 95 % CI for the observed and the expected 
cumulative incidences. 
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4 RESULTS 
Paper I 
This paper investigates the accuracy of Swedish COD certificates for men 
with PC to ensure that they can be used for determining the COD in the 
Göteborg screening study. During the follow-up of this study (Jan 1, 1995 to 
Dec 31, 2008), a total of 285 men diagnosed with PC deceased. Of these 
men, 278 had analyzable COD certificates and were included in the analysis 
in paper I.  
Men in the screening arm were significantly younger at diagnosis compared 
to controls (64.9 versus 66.0 years, p=0.004) but there was no significant 
difference in the median age at death between the study groups (69.8 versus 
70.3 years, p=0.89). As men in the screening group were diagnosed at a 
younger age, median follow-up from date of diagnosis was longer for the 
screening group than for the control group (6.7 versus 4.3 years, p<0.001). 
The vast majority of cases had a morphologically diagnosed PC (96%). 
Multiple malignancies (28%) and serious comorbidity were common (55%). 
Almost half (48%) of all deaths occurred in a hospital and 17 percent of the 
deaths resulted in an autopsy (medical or forensic). 
The COD, as coded by the COD committee, is shown in table 9.  
The certificates and the committee were in agreement regarding the COD in 
267 of 278 cases, corresponding to an overall agreement of 96% (95% CI 
92.8-97.9). Agreement, sensitivity, specificity, and kappa score are listed in 
table 10. 
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Table 9. Coding of cause of death from the cause of death committee with 
follow-up until Dec 31, 2008 and Dec 31, 2012. (Within parenthesis, number 
of men who lacked an analyzable death certificate but where cause of death 
was possible to establish for the committee based on information from 
medical records). 
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Definition of 
COD 
Number of 
cases, follow 
up until Dec 
31, 2008 
Number of 
cases, follow 
up until Dec 
31, 2012 
In the 
final 
evaluation 
classified 
as 
Definitely PC 119 (1) 197 (2) PC 
Probable PC 1 1 PC 
Definitely 
intervention-
related 
1 1 PC 
Possible PC 2 2 Other 
COD 
Unlikely PC 1 (1) 4(1) Other 
COD 
PC as a 
contributory 
COD 
4 19 Other 
COD 
Definitely not 
PC 
150 (5) 314(11) Other 
COD 
Pending 0 (1)  
Total 278 (7) 538 (15)  
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Table 10. Measurements of agreement 
There were 11 cases of disagreement, four cases in the screening group and 
seven cases in the control group. However, disagreement went in both 
directions with an incorrect PC as the COD in five cases and an incorrect 
other COD in six cases. The discordant cases were a diverse group and it was 
difficult to find any feature that distinguished them from the remaining cases. 
To further validate the COD certificates, the cumulative overall-, PC-
specific- and non-PC-specific mortality were estimated with the Kaplan 
Meier method. The screening group appeared to have a lower overall 
mortality compared to the control group but this difference was probably due 
to a lower PC mortality as the cumulative risk of dying from non-PC causes 
was similar in the two groups.   
An updated review of the COD committee’s work until Dec 31, 2012, which 
was not available at the time of publication of paper I has been added to 
tables 9, 10 and 11. With an extra four years of follow-up, the total number of 
men who had died with a PC diagnosis amounted to 553 men, of whom 538 
had analyzable death certificates and were thus available for a comparative 
analysis. Median age at diagnosis in this population was 66.3 years 
(screening group 65.3 years, control group 67.4 years, p<0.001) and the 
median age at death was 72.9 years (screening group 73.1, control group 
72.7, p=0.98). In total, there were 30 cases of disagreement up to Dec 31, 
2012, corresponding to an overall agreement of 94%. There were 15 
discordant cases in the screening arm and 15 cases among controls. There 
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were 17 cases with PC inaccurately assigned as the COD on the certificate 
where the committee had assigned other COD, and 13 cases where the COD 
was inaccurately coded as other COD on the certificate. The number of PC 
deaths in the screening and control arm as assigned by the COD certificate 
and the committee respectively, is shown in table 11. 
Table 11. Number of prostate cancer deaths in each study group according to 
cause of death certificates and committee  
The members of the committee were in total agreement regarding the COD in 
84% (466/553). In 12% (65/553) there was minor disagreement between the 
members and in 4% (22/553) there was major disagreement. 
Paper II 
This paper investigated outcomes for men managed with AS in the Göteborg 
screening study. 
In the Göteborg screening trial, almost half (45.7%, 442/968) of all men with 
a screen-detected PC were primarily managed with active surveillance. Three 
men were excluded; two men moved to another area in Sweden and another 
man refused active treatment and follow-up, resulting in a study population 
of 439 men. Median age at diagnosis was 65.4 years and median follow-up 
from diagnosis was 6.0 years (range 0.08-15.1 years). Of all screen-detected 
cases, very low-risk and low-risk constituted 60%, and in the active 
surveillance cohort these groups constituted 78%. Men with intermediate risk 
PC were a relatively large group and amounted to 21% of those on active 
surveillance.  
During follow-up, a total of 162 men switched treatment strategy from active 
surveillance to radical prostatectomy (n=106), radiotherapy (n=32) and 
hormonal treatment (n=24). The 5- and 10-year cumulative risk of receiving 
 Agreement, follow-up to Dec 31 3008 Overall 
agreement, 
follow-up 
Dec 31 2012 
 Overall Screening 
group 
Control 
group 
Agreement 96% 
(267/278) 
97% 
(143/147) 
95% 
(124/131) 
94% 
(508/538) 
 
Kappa score 92% 94% 89% 88% 
Sensitivity 96%  98% 95% 92% 
Specificity 96% 97% 94% 96% 
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to a lower PC mortality as the cumulative risk of dying from non-PC causes 
was similar in the two groups.   
An updated review of the COD committee’s work until Dec 31, 2012, which 
was not available at the time of publication of paper I has been added to 
tables 9, 10 and 11. With an extra four years of follow-up, the total number of 
men who had died with a PC diagnosis amounted to 553 men, of whom 538 
had analyzable death certificates and were thus available for a comparative 
analysis. Median age at diagnosis in this population was 66.3 years 
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were 17 cases with PC inaccurately assigned as the COD on the certificate 
where the committee had assigned other COD, and 13 cases where the COD 
was inaccurately coded as other COD on the certificate. The number of PC 
deaths in the screening and control arm as assigned by the COD certificate 
and the committee respectively, is shown in table 11. 
Table 11. Number of prostate cancer deaths in each study group according to 
cause of death certificates and committee  
The members of the committee were in total agreement regarding the COD in 
84% (466/553). In 12% (65/553) there was minor disagreement between the 
members and in 4% (22/553) there was major disagreement. 
Paper II 
This paper investigated outcomes for men managed with AS in the Göteborg 
screening study. 
In the Göteborg screening trial, almost half (45.7%, 442/968) of all men with 
a screen-detected PC were primarily managed with active surveillance. Three 
men were excluded; two men moved to another area in Sweden and another 
man refused active treatment and follow-up, resulting in a study population 
of 439 men. Median age at diagnosis was 65.4 years and median follow-up 
from diagnosis was 6.0 years (range 0.08-15.1 years). Of all screen-detected 
cases, very low-risk and low-risk constituted 60%, and in the active 
surveillance cohort these groups constituted 78%. Men with intermediate risk 
PC were a relatively large group and amounted to 21% of those on active 
surveillance.  
During follow-up, a total of 162 men switched treatment strategy from active 
surveillance to radical prostatectomy (n=106), radiotherapy (n=32) and 
hormonal treatment (n=24). The 5- and 10-year cumulative risk of receiving 
  Follow-up until Dec 31, 
2008 
Follow-up until Dec 31, 
2012 
 Certificate Committee Certificate Committee 
Screening 
group 
45 43 83 78  
Control 
group 
77 78 120 121  
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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treatment were 38.5% and 54.6% with Kaplan Meier estimates (median time 
on active surveillance 8.2 years) and the corresponding figures for competing 
risk estimates were 37.5% and 51.4%, respectively. An increase in cancer 
involvement or Gleason grade was the most common reason for 
discontinuing active surveillance (48%), followed by an increase in PSA-
level (28%), T stage progression (4.3%) and anxiety (2.5%). Ten men (6.2%) 
had unknown reasons for switching treatment strategy and 15 (9.3%) men 
deferred treatment on their own. During follow-up, only one man died due to 
PC and 59 men died from non-PC causes, corresponding to 10-year Kaplan 
Meier estimate for overall survival of 81%. Thirty-nine men were classified 
as failures; one man died from PC, another man developed metastasized PC, 
23 men initiated hormonal treatment and 14 men experienced PSA recurrence 
after radical prostatectomy (n=10), radiotherapy (n=3) or radical 
prostatectomy plus salvage radiation (n=1). Of those who were classified as 
failures, 11 of 39 died from non-PC causes during the study-period. The 5- 
and 10-year cumulative risk of failure were 6.7% and 14% with Kaplan 
Meier estimates and the corresponding figures for competing risk estimates 
were 6.4% and 13%.  
Risk group was significantly associated with failure in both univariate and 
multivariate Cox proportional hazard models as well as in the competing risk 
model. Compared with very low-risk PC, men with low-risk PC had a HR for 
failure of 2.1 and men with intermediate risk PC had almost four times the 
risk of failure (HR 3.7). Age was significantly associated with failure in the 
univariate analysis but this associating was no longer significant in the 
multivariate analysis or the multivariate competing risk model.  
Paper III 
In this paper we investigated the effectiveness of organized compared to 
opportunistic screening in reducing PC mortality, measured as NNI, as well 
as risk of overdiagnosis, measured as NND. 
The total number of men diagnosed in the screening and control arm, and the 
method of diagnosis is listed in table 12. In the screening group, 87% were 
compliant with the recommendation of having a biopsy after a positive 
screen. Tumors detected by opportunistic screening were more advanced than 
those detected with organized screening (Table 12). Men in the screening 
group were younger at diagnosis than men in the control group (65.8 versus 
67.8 years, p<0.001). 
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Table 12. Prostate cancers diagnosed in the study groups *includes nine 
cases detected as a result of an erroneous invitation; **includes eight cases 
diagnosed at autopsy; †T1, not N1 or M1, Gleason score ≤6, and PSA < 
10ng/mL; ‡T1-2, not N1 or M1, and Gleason score ≤7 and/or PSA < 20 
ng/mL; §T1-4, not N1 or M1, and Gleason score ≥8, and/or PSA <100 
ng/mL; ¶N1 and/or M1 and/or PSA ≥100 ng/mL 
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Table 12. Prostate cancers diagnosed in the study groups *includes nine 
cases detected as a result of an erroneous invitation; **includes eight cases 
diagnosed at autopsy; †T1, not N1 or M1, Gleason score ≤6, and PSA < 
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 Screening group Control group 
Number of 
prostate cancer 
cases 
1396 962 
 Number of screen-
detected (organized 
screening) prostate 
cancer cases 
Number of 
prostate cancer 
cases, not 
screen-d tected 
Number of screen-
detected (opportunistic 
screening) prostate 
ca cer cases 
Number of 
prostate cancer 
cases, not 
screen-detected 
 1022* 374 361 601** 
 Low-risk† 613 (60%) 84 (22%) 128 (35%) 125 (21%  
 Intermediate 
risk‡ 
331 (32%) 138 (37%) 168 (47%) 192 (32%) 
 High risk§ 63 (6.2%) 73 (19%) 42 (12%) 127 (21%) 
 Advanced¶ 13 (1.3%) 54 (14%) 10 (2.8) 107 (18%) 
 Unknown 2 (0.2%) 25 (6.7%) 13 (3.6%) 50 (8.3%) 
Number of 
prostate cancer 
deaths 
79 122 
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Figure 8. Observed and expected cumulative prostate cancer incidence in the 
screening and control group 
 
 
 
 
 
 
 
 
 
 
Figure 9. Observed and expected prostate cancer mortality in the screening and 
control group 
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The observed and expected PC incidence and mortality and the 
corresponding NNI and NND for the screening and control group after 18 
years of follow-up are listed in table 13. 
Table 13. Observed and expected prostate cancer incidence and mortality 
and number needed to invite and diagnose in the screening and control arm 
at 18 years of follow-up. 
Organized screening, as performed in our screening arm, every second year 
with a PSA cut-off of 2.5-3 ng/mL for biopsy, caused a pronounced PC 
mortality reduction when compared to a situation without screening, that is 
the pre-PSA era expected PC mortality rate (absolute reduction 0.72%, 95% 
CI 0.50-0.94%, relative risk reduction of 42%, 95% CI 28-54%). In contrast, 
opportunistic screening, as performed in our control group including PSA-
testing as part of clinical routine and as part of health check-ups, was not 
associated with a statistically significant PC mortality reduction compared to 
a situation without screening, that is the pre-PSA era expected PC mortality 
rate (absolute reduction 0.20%, 95% CI 0.06-0.47%, relative risk reduction of 
12%, 95% CI -5-26%). 
Paper IV 
This paper aimed at investigating the effect of age and number of screens on 
the cumulative risk of being diagnosed with PC. With a follow-up until 30 
June, 2014 there were 3485 (38%) men who were complete attendees, 3473 
were attendees and 2107 were non-attendees. Of those with a positive screen, 
87% complied with the biopsy recommendation.  A total of 664 (19%) cases 
of PC (screen-detected and interval cancers) were detected among complete 
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the cumulative risk of being diagnosed with PC. With a follow-up until 30 
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were attendees and 2107 were non-attendees. Of those with a positive screen, 
87% complied with the biopsy recommendation.  A total of 664 (19%) cases 
of PC (screen-detected and interval cancers) were detected among complete 
 Expected 
prostate 
cancer 
incidence 
Observed 
prostate 
cancer 
incidence 
Expected 
prostate 
cancer 
mortality 
Observed 
prostate 
cancer 
mortality 
 
Screening 
group 
(organized 
screening)  
6.8% 16% 1.7% 0.98% NNI 
139 
NND 
13 
Control 
group 
(opportunistic 
screening) 
6.9% 11% 1.7% 1.5% NNI 
493 
NND 
23 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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attendees and 333 (9.6%) cancers among attendees. For the entire cohort, the 
median age at diagnosis was 65.1 years compared to 64.9 years for complete 
attendees and 65.8 years for attendees. The cumulative PC incidence 
increased steadily with age (Figure 10, Table 14). When men reached the 
upper age limit for invitation (average 69 years) there was no significant 
difference in PC incidence between age cohorts with the exception of the 
oldest cohort compared to the youngest (Table 14). The cumulative risk of 
PC reached a “steady state” after four screens and thereafter only increased 
with age and not with additional screens (Table 14). Similar results observed 
if a competing risk model was used. No obvious influence on PC incidence 
was observed when PSA threshold was lowered or the number of cores was 
increased (Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Cumulative incidences of prostate cancer for complete attendees divided 
by age cohorts (prevalent cases of prostate cancers are added to each cohort) 
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Table 14. Cumulative risks for prostate cancers at different ages and number 
of screens among complete attendees, divided in age cohorts. Number of 
screens within parenthesis. Prevalent cases are added to each cohort.  
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Table 14. Cumulative risks for prostate cancers at different ages and number 
of screens among complete attendees, divided in age cohorts. Number of 
screens within parenthesis. Prevalent cases are added to each cohort.  
 
 
Birth cohort Number 
of men in 
the 
cohort 
Cumulative  
incidence at 60 
years (number of 
screens) 
Cumulative 
incidence at 65 years 
(number of screens) 
Cumulative incidence at 70 
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5 DISCUSSION 
5.1 Paper I – Cause of death determination 
In cancer screening studies, cancer-specific mortality generally only 
constitutes a small proportion of the overall number of deaths. Therefore, 
trying to compare any differences in overall mortality would require 
extremely large sample sizes. However, using disease-specific mortality rests 
on the assumption that the COD determination is valid. It is therefore critical 
that the COD is assigned as accurately as possible and with minimal bias. To 
achieve this, many screening studies have used a COD committee reviewing 
medical records to determine the COD.[289-293] However, this method is 
expensive and time-consuming and would not be necessary if COD 
certificates were accurate. In the paper I of this thesis we therefore compared 
COD from Swedish COD certificates for men with PC in the Göteborg 
screening trial with the COD as assigned by an expert committee using a 
standardized algorithm. The results showed an excellent level of agreement at 
96% during the first 13 years of follow-up. A high level of agreement was 
seen also after 17 years (94%). Similar estimates have been reported from 
other ERSPC centers using the same algorithm. For example the Dutch and 
the Finnish centers have reported an overall accuracy between official vital 
statistics or COD certificates and a COD committee of 90.6% and 97.7% 
respectively.[294, 295] One prior Swedish study by Fall et al. has 
investigated the accuracy of COD certificates for men with PC. In this study, 
overall agreement between COD from certificates and COD as determined by 
review of medical records was 86%. Agreement was higher for younger men 
and those with localized disease.[296] The lower level of agreement in the 
study by Fall could possibly be explained by an older population compared to 
the population in paper I.        
In paper I the discordant cases were evenly distributed in the two study arms 
(15 in each group) but with the committee’s decision as reference, more cases 
were inaccurately coded as PC deaths by the certificate (n=17) than the 
number of cases that were inaccurately coded as other COD (n=13). The 
difference in the number of PC deaths between the screening and control 
arms was larger when COD was determined by the committee then when 
based on certificates (Table 11). This difference increased between 13 and 17 
years of follow-up, as evident by the decrease in sensitivity of the certificates 
(from 96% to 92%, Table 10). There are several potential explanations to 
these findings. There is obviously the possibility that this distribution has 
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occurred by chance. However, a few other studies have also investigated the 
effect of the mortality review on the main result of the trial. In the majority of 
these studies, the rate ratio of disease-specific mortality between trial arms 
has shown a larger benefit for screening when review data from a committee 
has been used compared to when data from death certificates has been 
used.[290, 292, 293] An alternative explanation, other than chance, is that the 
committee’s COD assignment could be biased towards overestimating the 
effect of screening on disease-specific mortality relative to controls. Other 
screening studies have been criticized for having trial investigators as 
members of the COD committee and for insufficient blinding of medical 
records so that it has been possible to determine the study arm of the 
participant.[234, 290] In the present study, the committee consisted of three 
experience urologists who had no other involvement or commitment in the 
Göteborg screening trial. Even with efforts trying to blind the study arm for 
the committee, complete blinding is difficult to obtain. For example, a PC 
that is diagnosed at an early stage in an asymptomatic man is naturally more 
likely to belong to the screening arm then a man who is clinically diagnosed 
due to pain from bone metastases. The use of a standardized algorithm should 
have reduced the risk of a biased COD ascertainment compared to if the COD 
was subjectively ascertained through reviewing medical records. The 
algorithm was based on a number of clear questions and criteria that were 
needed to be answered and fulfilled.[268] Also, if the information from the 
medical records were not sufficient, the COD could be assigned “pending”. 
This only occurred in one out of 553 cases.  
A third possible explanation is a phenomenon referred to as “sticky diagnosis 
bias”.[297] This bias is connected to overdiagnosis and causes disease-
specific mortality between the screened group and the control group to be 
biased against screening (reducing the benefit). With screening, more men 
will be diagnosed with PC in the screening arm compared to the control arm. 
There is a risk that the COD will be coded as PC on the certificate even 
though these men died from something else (“sticky diagnosis”). In contrast, 
men dying from PC in the control arm could be falsely attributed to having 
died from other causes as these men are less likely to have been previously 
diagnosed with PC. As screening with PSA is associated with substantial 
overdiagnosis and leads to a large increase in the number of men receiving a 
PC diagnosis this bias could potentially be problematic and lead to 
difficulties in observing a reduction in PC mortality by screening compared 
to controls. The COD committee in the present study only reviewed COD for 
men with a PC diagnosis. There could be cases in the control group with 
unknown PC whose deaths were falsely attributed to other COD. However, 
these potential cases are likely to be very few. Among the discordant cases, 
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there were 10 cases in the screening group where the COD on the certificate 
was PC but where the committee assigned death from other COD. These 
cases could potentially be the result of sticky diagnosis bias. Misattribution of 
COD has in some studied been suggested to explain part of the PC mortality 
trends. [298, 299] However, there are also studies that have not found any 
change in the COD determinations since the introduction of PSA.[300] 
Another interesting finding, which is contrasting to the results from paper I, 
was reported from the Dutch center of the ERSPC. In their report on the 
death verification process, official statistics tended to over-report PC as the 
COD for men in the control arm.[294]  
Whether the imbalance among the discordant in cases in our material is due 
to chance, inadequate blinding, sticky diagnosis or a combination of the three 
is impossible to find out. Anyhow, the most important finding is that the 
overall number of inaccurate COD certificates was small and their potential 
effect on the overall result of the Göteborg screening study would have been 
minimal.         
Another bias that can occur in COD determination, that is also connected to 
overdiagnosis and overtreatment, is “slippery-linkage bias”.[297] This bias 
would have an opposite effect; it would overestimate the positive effects of 
screening on PC mortality by not including intervention-related death in the 
definition of disease-specific mortality. As PC screening is associated with 
substantial overdiagnosis and overtreatment, it is important to try to identify 
this bias. In the Göteborg screening study, as well as in the entire ERSPC, 
intervention-related deaths are included in the definition of PC-mortality. In 
our material, there was only one case out of 553 deaths that was coded as 
intervention-related and whose death was “falsely” attributed to other COD 
on the certificate. This was a man in the control group who was diagnosed 
with a moderately differentiated PC with a PSA of 40 ng/mL at diagnosis. He 
was treated with external beam radiotherapy of a total 70Gy. Several years 
later he was diagnosed with bilateral hydronephrosis secondary to radiation 
fibrosis. He also had severe cardiovascular disease and deceased 12 years 
after the PC diagnosis in circumstances that could have been related to these 
treatment complications. One limitation with the COD determination process 
in our study is that the COD was only reviewed for men with PC. Potentially, 
there could be intervention-related deaths caused by the screening processes 
which could be missed. Consider, for instance, a man, who would have a fatal 
complication after a biopsy (e.g. sepsis) with benign result, his death would 
not be identified as intervention-related. However, fatal complications after 
prostate biopsy are very rare. Carlsson et al. investigated the possible excess 
mortality following a prostate biopsy in the Swedish, Finnish and Dutch 
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centers of the ERSPC. In their study, there was no significant difference in 
excess mortality for screening-positive men compared with screening-
negative men. Fourteen men died within 120 days of the biopsy but none died 
as an obvious complication to the biopsy.[207]      
A learning curve for the members in the COD committee was observed. With 
time, there was less usage of the more vague COD definitions such as 
“probable” and “possible PC”, and a tendency to instead report COD as 
“definitely” or “definitely not” PC (Table 9). However, when looking at the 
cases where there was major disagreement between the committee members, 
cases of disagreement appeared to be evenly distributed over time and 
showed no tendency to decrease with time. In the absolute majority of cases 
531/553(96%), the committee members were in agreement whether or not PC 
was the COD. The 22 cases (4%) for where there were major disagreement 
between the committee members tended to be cases where it was 
questionable whether PC had contributed to death or not. There was only one 
case where the committee members had reached completely opposite 
conclusions (2 members assigned death to definitely not PC 2 and 1 member 
to definitely PC).     
Paper I has several strengths such as the use of a standardized algorithm and 
an independent COD committee without any other connection with the study. 
The Swedish personal identification number enabled linkage to other 
registers and facilitated the collection of medical records from outside 
sources such as primary care facilities. In the majority of cases, the COD 
committee therefore had access to complete medical records from the time of 
PC diagnosis. Even medical records from abroad were collected. All the 
collected material was also reviewed by first author to assess potential risk 
factors for an inaccurate COD certificate. There was a relatively high autopsy 
frequency (17.3%) which should improve COD determination as autopsy is 
the golden standard, and the most thorough method for determining the COD. 
The autopsy frequency is the proportion of deaths where the COD is 
determined with a clinical or forensic autopsy. In Sweden, the autopsy 
frequency has decrease from approximately 50% in the 1970s to 11% in 
2012.[265]  
Methodological considerations 
There are some issues in paper I that deserves discussion; the compositions 
of the COD committee, the complete access to medical records, the recording 
of comorbidity status, the decision to only evaluate COD for men with PC 
and the age of the study population. First, it can be discussed whether the 
composition of the COD committee with three urologists could have affected 
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the results. Hypothetically, urologists could be biased to be pro- or against 
PC screening. However, there is no consensus regarding PSA screening in 
the Swedish urological community. Moreover, it is unclear whether a 
different composition of the committee would have changed the results. For 
example, in the Finnish section of the ERSPC the committee consisted of a 
specialist in forensic medicine, one urologist and one specialist in internal 
medicine. Yet they reached a similar level of agreement as in our study, 
between certificates and committee (97.7%). However, in 53% of cases, the 
members of the Finnish committee disagreed on the COD and consensus had 
to be reached through discussion. The corresponding figure in our material 
was 16%, indicating that COD coding in our committee was much more 
homogenous, which could be a result of the composition of the committee. 
Secondly, as previously discussed, it was difficult to accomplish complete 
blinding with respect to study arm, since the committee had access to 
complete medical records. If the COD committee was aware of trial arm 
allocation, they could, in theory, be more likely to assign PC as the final 
COD for a man in the control arm than for a man in the screening arm – or 
alternatively that the greater overdiagnosis and labeling of PC of men in the 
screening arm would lead to increased labeling of PC as COD for these men 
compared to the control arm. It has been suggested that the difficulties in 
blinding, could be improved if only records from a man’s last life-year are 
reviewed. Whether this strategy would be superior or not is unknown but it 
could also be that such a strategy would miss identifying certain PC deaths 
such as late complications from treatment performed many years before. 
Third, as the review process of medical records is very time-consuming, only 
COD for men with PC was reviewed. This could have led an underestimation 
of the rate of “sticking diagnosis bias” and “slippery-linkage bias” in the 
COD certificates, as previously discussed. Fourth, comorbidities were not 
evaluated according to a validated index or score such as the Charlson 
comorbidity index [53] or the American Society of Anesthesiologists score 
(ASA score) but was subjectively assessed. However, this should not have 
affected the conclusions drawn from paper I but makes it difficult to 
compare the degree of comorbidities in this study population with estimates 
of comorbidity in other studies. Fifth, even with an additional four years of 
follow-up the study participants were relatively young when they died 
(median age 72.9 years) compared to the median age at death from PC in 
Sweden which in approximately 80 years. Because higher age, multiple 
malignancies and comorbidities are known risk factors for difficulties in 
COD determination, [296, 299]  it can be hypothesized that the accuracy of 
COD certificates will decrease with time as the median age at death in the 
population increases.  
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In summary, the results from paper I and the additional analysis with added 
follow-up reported in the present thesis, show that COD certificate for 
Swedish men with PC are accurate, suggesting that they can be used for 
endpoint evaluation in PC screening studies with men in the same age range. 
However, in order to identify intervention-related death and for the group of 
patients lacking a death certificate (3%), having a COD committee is 
valuable. 
5.2 Paper II – Reducing overtreatment 
This paper investigated active surveillance as a management strategy to 
reduce overtreatment of screen-detected PC. The results showed that a large 
proportion of cancers that are detected by screening have very low-risk or 
low-risk features (60%) and could possibly be suitable for active surveillance. 
Almost half of all men with screen-detected PC in the Göteborg screening 
trial were primarily managed with active surveillance. For men with very 
low-risk and low-risk PC active surveillance appeared safe, at least in the 
medium-term, as no man died from PC or developed metastasized disease. 
For those with intermediate risk PC, active surveillance, came at a higher 
risk. These men had a four-fold higher risk of failure compared to those with 
very low-risk cancer. However, active surveillance could still be an option for 
some carefully selected men with intermediate risk (due to age and/or 
comorbidities) as long as they are well-informed that delaying treatment 
might risk their chance of cure. In this study of men with screen-detected PC, 
the risk of dying from unrelated causes was much higher than the risk of 
dying from PC. Only one man died from PC compared to 59 men who died 
from other causes. 
The Swedish National Board of Health and Welfare (sv. Socialstyrelsen) 
recently published its updated 2014 National Guidelines for the Treatment 
Prostate Cancer. In these guidelines, the Board recommends that active 
surveillance should be the primary treatment option for men with very low-
risk and low-risk PC. The Board set the aim that at least 95% of all men with 
very low-risk PC and a life expectancy of at least 10 years should be 
managed primarily with active surveillance.[301] The latest report from the 
NPCR showed that the usage of active surveillance in different counties (sv. 
landsting) in Sweden varied from 31% to 100% of all patients with very low- 
risk PC.[58] The same pattern was seen for men with low-risk PC. However, 
as comparing to international PC treatment trends, Sweden has a high usage 
of active surveillance and was early in adopting this management strategy. 
For example, in the US, the tradition has been to radically treat also men with 
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very low-risk and low-risk PC, and less than 10% of men with low-risk PC 
has been primarily managed with active surveillance.[27] A national survey 
among US radiation oncologists and urologists investigated the physicians’ 
perception of active surveillance and showed that the majority believed that 
active surveillance was underused, furthermore, they felt comfortable 
recommending it. Despite this, only 22.1% recommended active surveillance 
for a case of a 60 year old man with low-risk PC. The physicians felt that 
their patients were not interested in active surveillance and the majority 
(56%) of radiation oncologists recommended radiotherapy (external beam 
radiation or brachytherapy) whereas most (61%) urologists recommended 
radical prostatectomy. In addition, they were concerned about overtreatment 
with radical prostatectomy and radiotherapy but radiation oncologists and 
urologists believed that primary treatment provided by the other specialty 
was overused.[302]  From the CaPSURE register, which covers 40 urology 
practices in the US, Cooperberg et al. reported that only 6.8% of men with 
localized PC (diagnosed 1990-2008) were managed with watchful waiting or 
active surveillance and less than 9% of those with CAPRA score 0-2 (low-
risk PC).[27] However, there seems to be a growing acceptance for active 
surveillance also in the US. From a register in Michigan, it was recently 
reported that 49% of patients with low-risk PC, according to the D’Amico 
criteria, diagnosed 2012-2013, were initially managed with active 
surveillance. However, the use of active surveillance varied greatly across 
practices in the register, ranging from 27% to 80%.[303]  
There are several challenges with active surveillance, of which the first is to 
choose the right candidates. Choosing inclusion criteria for active 
surveillance is a balance between maximizing the number of men who can be 
eligible for active surveillance and thereby delaying or avoiding curative 
treatment but at the same time minimizing the number of missed potentially 
lethal tumors. The inclusion criteria of six large active surveillance-cohorts 
are listed in table 15. In a head-to-head comparison of five contemporary 
active surveillance criteria (Royal Marsden and University of Toronto not 
included) the Prostate Cancer Research International Active Surveillance 
(PRIAS) and the University of Miami criteria showed superior performance 
when it came to identifying insignificant PC and organ-confined GS 6 cancer 
in 391 radical prostatectomy patients. As expected, the most conservative 
criteria, the Johns Hopkins/Epstein criteria had the highest specificity but at 
the cost of a low sensitivity which resulted in a discriminative ability that 
what not superior to the other criteria. The PRIAS and the University of 
Miami criteria selected twice as many patients as the Johns Hopkins criteria 
but were still able to selected patients with the same pathological 
characteristics as the Johns Hopkins criteria.[304] In our study (paper II) 
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In summary, the results from paper I and the additional analysis with added 
follow-up reported in the present thesis, show that COD certificate for 
Swedish men with PC are accurate, suggesting that they can be used for 
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For example, in the US, the tradition has been to radically treat also men with 
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very low-risk and low-risk PC, and less than 10% of men with low-risk PC 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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there were no pre-defined inclusion criteria for active surveillance but 
treatment strategy was chosen at the discretion of the treating physician and 
the patient. This resulted in a population not solely consisting of very low-
risk and low-risk PC but also intermediate and high risk PC. This enabled us 
to study the effects of deferring treatment also for these groups. The results 
showed that there was a strong association between risk group and the risk of 
failure after active surveillance. The risk of failure was twice as high for men 
with low-risk tumors compared to men with very low-risk. Questions have 
been raised whether inclusion criteria for active surveillance should be 
expanded to also include men with intermediate risk.[305] So far, there is 
little data to support this. In our study, men with intermediate risk PC had a 
four-fold higher risk of failure compared to very low-risk patients. The one 
man who died from PC and the one patient who was diagnosed with 
metastasized PC in our cohort both belonged to the intermediate risk group. 
In the Toronto active surveillance cohort, 85 patients (19% of the entire 
cohort) had intermediate risk PC, and 58% (49/85) of those remained 
untreated during the study period (median 6.8 years). One man with 
intermediate risk PC developed PC metastases and died from PC.[306] The 
UCSF cohort has also reported outcomes for 90 men with CAPRA score 3-5 
(intermediate risk). These men were not significantly different from those 
with CAPRA score 0-2 (low-risk) with regards to the proportion of men who 
were upgraded at repeat biopsy, the proportion who received curative 
treatment or progression-free survival. However, men with intermediate risk 
had higher rates of adverse pathological outcomes (positive surgical margins, 
pT3 and upgrading) after radical prostatectomy.[307] From the Finnish and 
Dutch centers of the ERSPC medium term outcomes for those who had 
deferred treatment were favorable for both low- and intermediate risk PC 
although treatment-free, metastases-free and disease-specific survival were 
somewhat lower for intermediate risk PC.[308] One argument for expanding 
the inclusion criteria could be that many men that are diagnosed with Gleason 
score 3+4 today would have been classified as Gleason 3+3 before the ISUP 
modification of the Gleason score in 2005. These men probably have a better 
prognosis than those who were classified as Gleason score 3+4 a decade 
ago.[37]  
 
 
 
93
Rebecka Arnsrud Godtman 
123 
7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
 
Prostate Cancer Screening 
92 
there were no pre-defined inclusion criteria for active surveillance but 
treatment strategy was chosen at the discretion of the treating physician and 
the patient. This resulted in a population not solely consisting of very low-
risk and low-risk PC but also intermediate and high risk PC. This enabled us 
to study the effects of deferring treatment also for these groups. The results 
showed that there was a strong association between risk group and the risk of 
failure after active surveillance. The risk of failure was twice as high for men 
with low-risk tumors compared to men with very low-risk. Questions have 
been raised whether inclusion criteria for active surveillance should be 
expanded to also include men with intermediate risk.[305] So far, there is 
little data to support this. In our study, men with intermediate risk PC had a 
four-fold higher risk of failure compared to very low-risk patients. The one 
man who died from PC and the one patient who was diagnosed with 
metastasized PC in our cohort both belonged to the intermediate risk group. 
In the Toronto active surveillance cohort, 85 patients (19% of the entire 
cohort) had intermediate risk PC, and 58% (49/85) of those remained 
untreated during the study period (median 6.8 years). One man with 
intermediate risk PC developed PC metastases and died from PC.[306] The 
UCSF cohort has also reported outcomes for 90 men with CAPRA score 3-5 
(intermediate risk). These men were not significantly different from those 
with CAPRA score 0-2 (low-risk) with regards to the proportion of men who 
were upgraded at repeat biopsy, the proportion who received curative 
treatment or progression-free survival. However, men with intermediate risk 
had higher rates of adverse pathological outcomes (positive surgical margins, 
pT3 and upgrading) after radical prostatectomy.[307] From the Finnish and 
Dutch centers of the ERSPC medium term outcomes for those who had 
deferred treatment were favorable for both low- and intermediate risk PC 
although treatment-free, metastases-free and disease-specific survival were 
somewhat lower for intermediate risk PC.[308] One argument for expanding 
the inclusion criteria could be that many men that are diagnosed with Gleason 
score 3+4 today would have been classified as Gleason 3+3 before the ISUP 
modification of the Gleason score in 2005. These men probably have a better 
prognosis than those who were classified as Gleason score 3+4 a decade 
ago.[37]  
 
 
 
R
eb
ec
ka
 A
rn
sr
ud
 G
od
tm
an
 
93
 
Ta
bl
e 
15
. A
ct
iv
e 
su
rv
ei
lla
nc
e 
co
ho
rt
s a
nd
 th
ei
r c
ri
te
ri
a 
fo
r i
nc
lu
sio
n,
 fo
llo
w 
up
 a
nd
 tr
ig
ge
rs
 
fo
r i
nt
er
ve
nt
io
n.
 U
C
SF
=
U
ni
ve
rs
ity
 o
f C
al
ifo
rn
ia
 S
an
 F
ra
nc
is
co
. B
io
ps
y 
+
=
 c
or
es
 w
ith
 c
an
ce
r, 
co
re
s+
=
 p
ro
po
rt
io
n 
of
 c
or
e 
w
ith
 c
an
ce
r, 
PS
AV
=
PS
A 
ve
lo
ci
ty
, P
SA
-D
T=
 P
SA
 d
ou
bl
in
g 
tim
e 
In
st
itu
tio
n 
In
cl
us
io
n 
cr
ite
ria
 
Fo
llo
w
-u
p 
Tr
ig
ge
rs
 fo
r i
nt
er
ve
nt
io
n 
U
C
SF
[3
07
, 3
09
-3
11
] 
G
le
as
on
 sc
or
e 
≤3
+3
, P
SA
 <
10
 n
g/
m
l, 
≤T
2a
, 
≤3
3%
 b
io
ps
ie
s 
+
, ≤
50
%
 a
ny
 c
or
e+
 
D
R
E
, 
PS
A
 3
 m
on
th
s,
 T
R
U
S 
6-
12
 m
on
th
s,
 
re
pe
at
 b
io
ps
y 
ev
er
y 
12
-2
4 
m
on
th
s 
(a
ft
er
 
20
03
) 
In
cr
ea
se
d 
G
le
as
on
 s
co
re
 a
t 
re
pe
at
 b
io
ps
y 
an
d/
or
 P
SA
V
 in
cr
ea
se
 >
0.
75
 n
g/
m
L
/y
ea
r,
 
pa
tie
nt
’s
 d
es
ire
 
R
oy
al
 
M
ar
sd
en
 
H
os
pi
ta
l[3
12
, 3
13
] 
G
le
as
on
 
sc
or
e 
≤3
+
3 
(≤
3+
4 
if
 
ag
e 
>
65
 
ye
ar
s)
, 
PS
A
 
<
 
15
 
ng
/m
L
, 
T
1-
2,
 
≤ 
50
%
 
bi
op
si
es
+ 
D
R
E
 a
nd
 P
SA
 3
-6
 m
on
th
s,
 r
ep
ea
t 
bi
op
sy
 
af
te
r 
18
-2
4 
m
on
th
s 
an
d 
ev
er
y 
2 
ye
ar
 
C
an
ce
r 
pr
og
re
ss
io
n 
(G
le
as
on
 s
co
re
≤4
+3
 
or
 >
50
%
 b
io
ps
ie
s 
+
) 
an
d/
or
 P
SA
V
 >
1 
ng
/m
L
/y
ea
r 
U
ni
ve
rs
ity
 
of
 
M
ia
m
i[3
14
] 
G
le
as
on
 s
co
re
 ≤
3+
3,
 P
SA
 ≤
10
 n
g/
m
L
, 
T
1-
2,
 ≤
2 
bi
op
si
es
+
, ≤
20
%
 c
or
es
+ 
D
R
E
 a
nd
 P
SA
 3
-6
 m
on
th
s,
 a
nn
ua
l 
re
pe
at
 
bi
op
sy
  
C
an
ce
r 
pr
og
re
ss
io
n 
(a
ny
 G
le
as
on
 >
3 
or
 
in
cr
ea
se
 i
n 
nu
m
be
r 
or
 v
ol
um
e 
of
 c
or
es
),
 
pa
tie
nt
’s
 d
es
ire
 
Jo
hn
s H
op
ki
ns
[3
15
] 
G
le
as
on
 s
co
re
 ≤
3+
3,
 P
SA
 D
 <
0.
15
 n
g/
m
L
, 
T
1c
, ≤
2 
bi
op
si
es
+
, ≤
 5
0%
 c
or
es
+ 
D
R
E
 
an
d 
PS
A
 
ev
er
y 
6 
m
on
th
s,
 
an
nu
al
 
re
pe
at
 b
io
ps
y 
C
an
ce
r 
pr
og
re
ss
io
n 
(n
o 
lo
ng
er
 m
ee
ti
ng
 
bi
op
sy
 in
cl
us
io
n 
cr
ite
ri
a)
 
M
SK
C
C
[3
16
] 
G
le
as
on
 s
co
re
 ≤
3+
3,
 P
SA
 <
10
 n
g/
m
L
, 
T
1-
2a
, ≤
3 
bi
op
si
es
+
, ≤
 5
0%
 c
or
es
+ 
D
R
E
 
an
d 
PS
A
 
(f
re
e 
an
d 
to
ta
l)
 
ev
er
y 
6 
m
on
th
s,
 r
ep
ea
t 
bi
op
sy
 a
ft
er
 1
2-
18
 m
on
th
s 
th
er
ea
ft
er
 e
ve
ry
 2
-3
 y
ea
rs
 
C
an
ce
r 
pr
og
re
ss
io
n 
(n
o 
lo
ng
er
 m
ee
ti
ng
 
in
cl
us
io
n 
cr
it
er
ia
) 
PR
IA
S[
31
7]
 
G
le
as
on
 
sc
or
e 
≤3
+3
, 
PS
A
 
≤1
0 
ng
/m
L
, 
PS
A
D
 <
0.
2 
ng
/m
l/
cc
, T
1-
2,
 ≤
2 
bi
op
si
es
+
 
PS
A
 e
ve
ry
 3
-6
 m
on
th
s,
 r
ep
ea
t 
bi
op
sy
 y
ea
r 
1,
 
4 
an
d 
7 
(n
um
be
r 
of
 
co
re
s 
vo
lu
m
e 
de
pe
nd
en
t)
 
C
an
ce
r 
pr
og
re
ss
io
n 
(G
le
as
on
 4
 o
r 
5,
 >
2 
bi
op
si
es
+
) 
an
d/
or
 P
SA
-D
T
 <
3 
ye
ar
s 
U
ni
ve
rs
ity
 
of
 
To
ro
nt
o[
30
6,
 3
18
] 
G
le
as
on
 s
co
re
 ≤
3+
3,
 P
SA
 ≤
10
 n
g/
m
L
 (
up
 
to
 1
99
9 
pa
ti
en
ts
 >
70
 y
ea
rs
 w
ith
 G
le
as
on
 
3+
4 
an
d 
PS
A
 <
15
 n
g/
m
L
) 
PS
A
 
ev
er
y 
3-
6 
m
on
th
s,
 
re
pe
at
 
bi
op
sy
 
w
it
hi
n 
a 
ye
ar
 a
nd
 th
en
 e
ve
ry
 3
-4
 y
ea
rs
 
H
is
to
lo
gi
ca
l 
up
gr
ad
in
g 
an
d/
or
 
PS
A
-D
T 
<
3 
ye
ar
s 
an
d/
or
 c
lin
ic
al
 p
ro
gr
es
si
on
 
 
Prostate Cancer Screening 
94 
The second challenge with AS is to choose the “right” strategy for follow-up 
and “right” triggers for intervention. The aim should be to identify men with 
progressive disease without missing the window of curability. Similar to 
inclusion criteria, this is a balance between avoiding overtreatment of those 
who do not need treatment and identifying those who do. Most active 
surveillance protocols include an early confirmatory biopsy to identify 
potential misclassification at the first biopsy and repeat biopsies during 
follow up to detect disease progression (Table 15). The optimal number of 
biopsy cores, the location of these and the interval between repeat biopsies 
are currently unknown. The aim is trying to achieve a high degree of 
certainty that no Gleason 4 or 5 pattern has been missed. Several studies have 
shown that standard prostate biopsies often miss tumors in the anterior part of 
the prostate.[138, 319] The Swedish National Guidelines for PC Care 
therefore recommend that the anterior parts of the prostate are covered in the 
diagnostic biopsies before starting active surveillance [64]. Others advocate 
saturation biopsy (20-24 cores) or transperineal mapping biopsy (biopsies 
covering the entire gland at 5 mm interval) to rule out high-risk tumors in 
patients who are candidates for active surveillance. [138, 139]  
Triggers for interventions differ slightly between cohorts. Some cohorts 
include PSA kinetics as a trigger for intervention (Table 15). The value of 
PSA kinetics, i.e. PSA velocity or PSA doubling time (PSADT), to monitor 
disease progression for low-risk PC is uncertain, and there is increasing 
evidence that it does not add predictive information regarding disease 
progression for men on active surveillance.[130, 320, 321] Reclassification to 
higher risk disease at repeat biopsy is common (17-55%), but with most 
series reporting estimates ranging from 20-30%.[135, 319-327] From the 
PRIAS study, Bul et al. reported that a repeat biopsy within a year (10 cores) 
resulted in unfavorable biopsy outcomes (increased Gleason score and/or 
increase in number of biopsies with cancer) in 21.5%.[328] Similar results 
have been reported from the MSKCC cohort where an immediate repeat 
biopsy within 3 months resulted in 27% of patients being upgraded or 
upstaged.[134] Bearing in mind the long natural course of PC and a 
considerable lead time for many screen-detected PCs, the majority of tumors 
being upgraded or upstaged at repeat biopsy likely represent misclassification 
rather than true disease progression. A positive confirmatory biopsy, PSAD 
and cancer involvement (number of cores and % invasion any core) have 
been reported to be associated with unfavorable histological finding at later 
repeat biopsy.[326-328]  
In paper II, sextant biopsy was the standard up to 2008, thereafter a 10-core 
biopsy was used. There was no strict protocol defining re-biopsy interval. 
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These were typically performed if the first biopsy showed <2mm cancer, if 
there were signs of disease progression and every second and third year for 
men with stable disease. The most common reason for initiating treatment 
was an increase in Gleason score or cancer involvement followed by an 
increase in PSA. During follow-up approximately a third of the cohort (37%) 
discontinued active surveillance and received treatment (radical 
prostatectomy, radiotherapy, hormonal treatment). It is interesting to see that, 
despite that our study (paper II) did not have any strict inclusion or follow-
up criteria this figure is very similar to the proportion of men who has 
discontinued active surveillance in other cohorts (Table 16). During the first 
two years of follow-up, there was a high incidence of discontinuing active 
surveillance. This probably indicated undersampling at the first biopsy rather 
than true disease progression.    
Active surveillance holds many promises for the future and will most 
certainly be an important strategy to reduce to harms of overdiagnosis and 
overtreatment, at least until we have a screening method that can selectively 
identify only clinically relevant tumors, if one such strategy will ever be 
identified. Nevertheless, there are some questions remained to be answered 
regarding active surveillance. Inclusion criteria, follow-up strategies and 
triggers for intervention need to be validated and supported by evidence from 
long-term follow-up of ongoing large studies, but the most important 
question is probably: What “price” will men have to pay in order to delay or 
avoid the potential side-effects of curative treatment? There are several 
different aspects that have to be considered.  
Firstly, what are the risks with repeat biopsies including a high number of 
cores? Complications after prostate biopsies include hematospermia, 
hematuria, rectal bleeding and infectious complications.[205] The rates of 
infectious complications following transrectal prostate biopsies have 
increased over time, mainly due to a higher prevalence of antimicrobial 
resistance.[202-205] A Canadian study reported that the risk of hospital 
admission within 30 days of a prostate biopsy increased 4-fold between 1996 
and 2005.[202] The risks of repeat biopsies for men on active surveillance are 
under-studied. One study found that the number of previous biopsies was 
associated with an increased risk of infectious complications at subsequent 
biopsies (OR 1.33, 95% CI 1.01-1.74) whereas another study could not 
corroborate these findings.[329, 330] It has also been hypothesized that 
repeat biopsy can have a negative impact on potency but it has been difficult 
to separate out the negative effects of multiple biopsies from that of the 
normal ageing process on erectile function, as well as pshychological effects 
on potency of living with untreated PC.[331, 332] 
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follow up to detect disease progression (Table 15). The optimal number of 
biopsy cores, the location of these and the interval between repeat biopsies 
are currently unknown. The aim is trying to achieve a high degree of 
certainty that no Gleason 4 or 5 pattern has been missed. Several studies have 
shown that standard prostate biopsies often miss tumors in the anterior part of 
the prostate.[138, 319] The Swedish National Guidelines for PC Care 
therefore recommend that the anterior parts of the prostate are covered in the 
diagnostic biopsies before starting active surveillance [64]. Others advocate 
saturation biopsy (20-24 cores) or transperineal mapping biopsy (biopsies 
covering the entire gland at 5 mm interval) to rule out high-risk tumors in 
patients who are candidates for active surveillance. [138, 139]  
Triggers for interventions differ slightly between cohorts. Some cohorts 
include PSA kinetics as a trigger for intervention (Table 15). The value of 
PSA kinetics, i.e. PSA velocity or PSA doubling time (PSADT), to monitor 
disease progression for low-risk PC is uncertain, and there is increasing 
evidence that it does not add predictive information regarding disease 
progression for men on active surveillance.[130, 320, 321] Reclassification to 
higher risk disease at repeat biopsy is common (17-55%), but with most 
series reporting estimates ranging from 20-30%.[135, 319-327] From the 
PRIAS study, Bul et al. reported that a repeat biopsy within a year (10 cores) 
resulted in unfavorable biopsy outcomes (increased Gleason score and/or 
increase in number of biopsies with cancer) in 21.5%.[328] Similar results 
have been reported from the MSKCC cohort where an immediate repeat 
biopsy within 3 months resulted in 27% of patients being upgraded or 
upstaged.[134] Bearing in mind the long natural course of PC and a 
considerable lead time for many screen-detected PCs, the majority of tumors 
being upgraded or upstaged at repeat biopsy likely represent misclassification 
rather than true disease progression. A positive confirmatory biopsy, PSAD 
and cancer involvement (number of cores and % invasion any core) have 
been reported to be associated with unfavorable histological finding at later 
repeat biopsy.[326-328]  
In paper II, sextant biopsy was the standard up to 2008, thereafter a 10-core 
biopsy was used. There was no strict protocol defining re-biopsy interval. 
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These were typically performed if the first biopsy showed <2mm cancer, if 
there were signs of disease progression and every second and third year for 
men with stable disease. The most common reason for initiating treatment 
was an increase in Gleason score or cancer involvement followed by an 
increase in PSA. During follow-up approximately a third of the cohort (37%) 
discontinued active surveillance and received treatment (radical 
prostatectomy, radiotherapy, hormonal treatment). It is interesting to see that, 
despite that our study (paper II) did not have any strict inclusion or follow-
up criteria this figure is very similar to the proportion of men who has 
discontinued active surveillance in other cohorts (Table 16). During the first 
two years of follow-up, there was a high incidence of discontinuing active 
surveillance. This probably indicated undersampling at the first biopsy rather 
than true disease progression.    
Active surveillance holds many promises for the future and will most 
certainly be an important strategy to reduce to harms of overdiagnosis and 
overtreatment, at least until we have a screening method that can selectively 
identify only clinically relevant tumors, if one such strategy will ever be 
identified. Nevertheless, there are some questions remained to be answered 
regarding active surveillance. Inclusion criteria, follow-up strategies and 
triggers for intervention need to be validated and supported by evidence from 
long-term follow-up of ongoing large studies, but the most important 
question is probably: What “price” will men have to pay in order to delay or 
avoid the potential side-effects of curative treatment? There are several 
different aspects that have to be considered.  
Firstly, what are the risks with repeat biopsies including a high number of 
cores? Complications after prostate biopsies include hematospermia, 
hematuria, rectal bleeding and infectious complications.[205] The rates of 
infectious complications following transrectal prostate biopsies have 
increased over time, mainly due to a higher prevalence of antimicrobial 
resistance.[202-205] A Canadian study reported that the risk of hospital 
admission within 30 days of a prostate biopsy increased 4-fold between 1996 
and 2005.[202] The risks of repeat biopsies for men on active surveillance are 
under-studied. One study found that the number of previous biopsies was 
associated with an increased risk of infectious complications at subsequent 
biopsies (OR 1.33, 95% CI 1.01-1.74) whereas another study could not 
corroborate these findings.[329, 330] It has also been hypothesized that 
repeat biopsy can have a negative impact on potency but it has been difficult 
to separate out the negative effects of multiple biopsies from that of the 
normal ageing process on erectile function, as well as pshychological effects 
on potency of living with untreated PC.[331, 332] 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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Secondly, what are the psychological consequences of living with an 
untreated cancer and how does active surveillance affect QoL? Many patients 
perceive a cancer diagnosis as a death sentence. In such a scenario, it is 
understandable that being recommended an expectant management of a 
potentially lethal disease may seem unreasonable. Physicians are faced with a 
difficult task trying to explain the rationale behind active surveillance. The 
physician’s recommendation play a critical role is patient’s acceptance of 
active surveillance.[333] Estimates of the proportion of men who are eligible 
for active surveillance and who actually choose this strategy have varied 
between 10-57%.[27, 334] In paper II, 59% of men with screen-detected 
very low-risk or low-risk PC were managed with active surveillance. Men 
managed on active surveillance is a highly self-selected group, which must be 
kept in mind when analyzing the reported levels of anxiety and QoL for men 
on active surveillance. In addition, the evidence available today regarding 
psychological effects of active surveillance comes from short-term results 
from non-randomized studies. However, these studies report low and 
favorable levels of anxiety and distress and maintained or even improved, 
levels of quality of life for men on active surveillance.[335, 336] The 
proportion of men who discontinue active surveillance without signs of 
disease progression has in most series been reported to be less than 10% [60, 
306, 313, 315, 317] – but some series have reported levels of discontinuation 
of up to 20%.[337, 338] In paper II only four men (2.5%) reported that they 
came of active surveillance due to anxiety. Factors predicting adverse 
psychological effects include recent diagnosis, lack of a partner, previous 
mental health problems, consultations with fewer physicians prior to the 
treatment decision, and fewer cores at the diagnostic biopsy.[339] Strategies 
to support men and address their anxiety to improve adherence in active 
surveillance programs could be to include partners and loved ones in the 
process, working with the word “cancer” and offering patient support groups 
and contact nurses.[340] However, the evidence for these strategies is 
limited.[333]  
Thirdly, does delaying treatment affect the possibility of nerve-sparing 
surgery and do men who choose deferred treatment have “more to lose” with 
regards to HRQoL when they are eventually treated? Deferring treatment 
until signs of disease progression could hypothetically lead to a more 
extensive resection at surgery with a concomitant smaller chance of a 
successful nerve-sparing procedure. This is, so far, an under-studied area 
partly because of methodological difficulties. One small, retrospective study 
compared HRQoL and sexual function scores for men treated with delayed 
radical prostatectomy after a period of AS with a group of men who 
underwent immediate radical prostatectomy. Men on AS who received In
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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Secondly, what are the psychological consequences of living with an 
untreated cancer and how does active surveillance affect QoL? Many patients 
perceive a cancer diagnosis as a death sentence. In such a scenario, it is 
understandable that being recommended an expectant management of a 
potentially lethal disease may seem unreasonable. Physicians are faced with a 
difficult task trying to explain the rationale behind active surveillance. The 
physician’s recommendation play a critical role is patient’s acceptance of 
active surveillance.[333] Estimates of the proportion of men who are eligible 
for active surveillance and who actually choose this strategy have varied 
between 10-57%.[27, 334] In paper II, 59% of men with screen-detected 
very low-risk or low-risk PC were managed with active surveillance. Men 
managed on active surveillance is a highly self-selected group, which must be 
kept in mind when analyzing the reported levels of anxiety and QoL for men 
on active surveillance. In addition, the evidence available today regarding 
psychological effects of active surveillance comes from short-term results 
from non-randomized studies. However, these studies report low and 
favorable levels of anxiety and distress and maintained or even improved, 
levels of quality of life for men on active surveillance.[335, 336] The 
proportion of men who discontinue active surveillance without signs of 
disease progression has in most series been reported to be less than 10% [60, 
306, 313, 315, 317] – but some series have reported levels of discontinuation 
of up to 20%.[337, 338] In paper II only four men (2.5%) reported that they 
came of active surveillance due to anxiety. Factors predicting adverse 
psychological effects include recent diagnosis, lack of a partner, previous 
mental health problems, consultations with fewer physicians prior to the 
treatment decision, and fewer cores at the diagnostic biopsy.[339] Strategies 
to support men and address their anxiety to improve adherence in active 
surveillance programs could be to include partners and loved ones in the 
process, working with the word “cancer” and offering patient support groups 
and contact nurses.[340] However, the evidence for these strategies is 
limited.[333]  
Thirdly, does delaying treatment affect the possibility of nerve-sparing 
surgery and do men who choose deferred treatment have “more to lose” with 
regards to HRQoL when they are eventually treated? Deferring treatment 
until signs of disease progression could hypothetically lead to a more 
extensive resection at surgery with a concomitant smaller chance of a 
successful nerve-sparing procedure. This is, so far, an under-studied area 
partly because of methodological difficulties. One small, retrospective study 
compared HRQoL and sexual function scores for men treated with delayed 
radical prostatectomy after a period of AS with a group of men who 
underwent immediate radical prostatectomy. Men on AS who received 
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delayed treatment had more favorable HRQoL and sexual function scores 
preoperatively than men undergoing immediate surgery, however, this 
difference between the two groups could not be observed postoperatively 
suggesting that deferred radical prostatectomy had a larger unfavorable 
effect. It is interesting though, that in this small study there was no significant 
difference in the extent of nerve preservation, measured as fascia preservation 
score, between the two groups.[341] In contrast, another small, retrospective 
study reported significantly lower rates of bilateral nerve sparing surgery for 
men who deferred radical prostatectomy compared to those treated 
immediately.[342]         
And finally, the most important question: does delaying treatment reduce the 
chance of cure? Cancer-specific mortality is the ultimate end-point for active 
surveillance studies but the slow-growing nature of low-risk PC with addition 
of several years of lead time means that it will take many years before this 
endpoint can be evaluated. Therefore, this remains an unanswered question as 
of today, and while awaiting long-term data, and we will have to rely on 
current evidence relating to intermediate outcomes such as disease 
progression, adverse pathology at radical prostatectomy, PSA recurrence 
after treatment and use of hormonal treatment. As previously mentioned, 
upgrading at repeat biopsy is common (20-30%). Regarding pathology results 
after active surveillance there are only a few, small, prospective series of 
radical prostatectomy following active surveillance. From the PRIAS study, 
pathological findings of 167 men who underwent radical prostatectomy after 
a median of 1.3 years on active surveillance have been reported. The vast 
majority had organ-confined disease (80.8%) Unfavorable radical 
prostatectomy results, defined as pT3-4 and/or Gleason score ≥4+3 was 
found in 29%.[343] Similar results have been reported in other series.[313, 
344, 345]  
Another strategy has been to retrospectively compare the result of immediate 
versus delayed radical prostatectomy in men with low-risk PC. Most series 
have found no significant difference in pathological outcome at radical 
prostatectomy between immediate versus delayed radical prostatecomty. 
[310, 346, 347]   
A third strategy has been to study the outcome of radical prostatectomy in 
men who would have been eligible for active surveillance. For example, from 
the Swedish NPCR pathology outcomes of 4500 men with Gleason score 6 
and T1c-T2 disease were reviewed to identify variables associated with 
adverse pathological outcomes. Approximately 50% had adverse pathological 
outcomes (pT3 or Gleason score ≥7). Of those patients who fulfilled the 
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inclusion criteria of six common active surveillance protocols adverse 
pathological outcome ranged from 33% to 46%. As could be expected, the 
most inclusive criteria (University of Toronto) resulted in the highest rates of 
upgrading (46%), whereas the lowest rates (33%) were found with the most 
stringent criteria (Johns Hopkins). In a multivariable model, age, total PSA, 
PSAD >0.15 ng/mL/cc, extent of cancer >4 mm in biopsies and palpable 
disease were predictors of adverse pathological outcome after radical 
prostatectomy.[348] A review by van den Bergh et al. summarized the 
evidence for delaying curative treatment for PC and concluded that treatment 
delay for months or even years did not seem to affect outcome for men with 
low-risk PC but that the quality of the evidence was weak. [349] However, 
there are several different aspects that should be considered when discussion 
these results. In the reported studies the maximum time of delaying treatment 
has been short (≈2years) and treatment might be deferred for many years for 
men on active surveillance. We do not yet know which future consequences 
this will have. Also, it should be kept in mind that adverse pathological 
outcome after surgery does not have to imply a poor prognosis in the long 
run. In addition, many of these studies are retrospective, most have different 
criteria for inclusion, follow-up and triggers for intervention and none is 
randomized. There is also a high risk of selection bias at multiple levels; 
those who accept active surveillance are probably not a representative sample 
of the general population and those on active surveillance who are treated 
with radical prostatectomy have had a reason to discontinue active 
surveillance (disease progression). To compare their outcome to men who are 
primarily treated with radical prostatectomy might be misleading. The 
intention with active surveillance is to identify those with disease progression 
within the window of curability. It is difficult to know whether worse 
pathological outcome for these men, in comparison to those primarily treated, 
is a failure or if the program has actually done what it intended, i.e. ensuring 
that those with aggressive disease are not left untreated. It might also be that 
among those who discontinue active surveillance, men who are treated with 
radical prostatectomy are likely those with the most favorable disease 
characteristics, whereas those with signs of more aggressive disease are more 
likely to be treated with radiotherapy or hormonal treatment.  
Only a few series have reported PC deaths among men managed with active 
surveillance. In paper II, one man died from PC and another man developed 
PC metastases during a median follow-up of 6 years. The Toronto cohort, 
which has the longest follow-up, has reported, in a congress abstract at the 
EAU, that this cohort now has 14 PC deaths and another 16 patients who are 
alive but with PC metastases, among 840 patients managed with active 
surveillance with a median follow-up of 8.1 years. The actuarial 10-, 15-, and 
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delayed treatment had more favorable HRQoL and sexual function scores 
preoperatively than men undergoing immediate surgery, however, this 
difference between the two groups could not be observed postoperatively 
suggesting that deferred radical prostatectomy had a larger unfavorable 
effect. It is interesting though, that in this small study there was no significant 
difference in the extent of nerve preservation, measured as fascia preservation 
score, between the two groups.[341] In contrast, another small, retrospective 
study reported significantly lower rates of bilateral nerve sparing surgery for 
men who deferred radical prostatectomy compared to those treated 
immediately.[342]         
And finally, the most important question: does delaying treatment reduce the 
chance of cure? Cancer-specific mortality is the ultimate end-point for active 
surveillance studies but the slow-growing nature of low-risk PC with addition 
of several years of lead time means that it will take many years before this 
endpoint can be evaluated. Therefore, this remains an unanswered question as 
of today, and while awaiting long-term data, and we will have to rely on 
current evidence relating to intermediate outcomes such as disease 
progression, adverse pathology at radical prostatectomy, PSA recurrence 
after treatment and use of hormonal treatment. As previously mentioned, 
upgrading at repeat biopsy is common (20-30%). Regarding pathology results 
after active surveillance there are only a few, small, prospective series of 
radical prostatectomy following active surveillance. From the PRIAS study, 
pathological findings of 167 men who underwent radical prostatectomy after 
a median of 1.3 years on active surveillance have been reported. The vast 
majority had organ-confined disease (80.8%) Unfavorable radical 
prostatectomy results, defined as pT3-4 and/or Gleason score ≥4+3 was 
found in 29%.[343] Similar results have been reported in other series.[313, 
344, 345]  
Another strategy has been to retrospectively compare the result of immediate 
versus delayed radical prostatectomy in men with low-risk PC. Most series 
have found no significant difference in pathological outcome at radical 
prostatectomy between immediate versus delayed radical prostatecomty. 
[310, 346, 347]   
A third strategy has been to study the outcome of radical prostatectomy in 
men who would have been eligible for active surveillance. For example, from 
the Swedish NPCR pathology outcomes of 4500 men with Gleason score 6 
and T1c-T2 disease were reviewed to identify variables associated with 
adverse pathological outcomes. Approximately 50% had adverse pathological 
outcomes (pT3 or Gleason score ≥7). Of those patients who fulfilled the 
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inclusion criteria of six common active surveillance protocols adverse 
pathological outcome ranged from 33% to 46%. As could be expected, the 
most inclusive criteria (University of Toronto) resulted in the highest rates of 
upgrading (46%), whereas the lowest rates (33%) were found with the most 
stringent criteria (Johns Hopkins). In a multivariable model, age, total PSA, 
PSAD >0.15 ng/mL/cc, extent of cancer >4 mm in biopsies and palpable 
disease were predictors of adverse pathological outcome after radical 
prostatectomy.[348] A review by van den Bergh et al. summarized the 
evidence for delaying curative treatment for PC and concluded that treatment 
delay for months or even years did not seem to affect outcome for men with 
low-risk PC but that the quality of the evidence was weak. [349] However, 
there are several different aspects that should be considered when discussion 
these results. In the reported studies the maximum time of delaying treatment 
has been short (≈2years) and treatment might be deferred for many years for 
men on active surveillance. We do not yet know which future consequences 
this will have. Also, it should be kept in mind that adverse pathological 
outcome after surgery does not have to imply a poor prognosis in the long 
run. In addition, many of these studies are retrospective, most have different 
criteria for inclusion, follow-up and triggers for intervention and none is 
randomized. There is also a high risk of selection bias at multiple levels; 
those who accept active surveillance are probably not a representative sample 
of the general population and those on active surveillance who are treated 
with radical prostatectomy have had a reason to discontinue active 
surveillance (disease progression). To compare their outcome to men who are 
primarily treated with radical prostatectomy might be misleading. The 
intention with active surveillance is to identify those with disease progression 
within the window of curability. It is difficult to know whether worse 
pathological outcome for these men, in comparison to those primarily treated, 
is a failure or if the program has actually done what it intended, i.e. ensuring 
that those with aggressive disease are not left untreated. It might also be that 
among those who discontinue active surveillance, men who are treated with 
radical prostatectomy are likely those with the most favorable disease 
characteristics, whereas those with signs of more aggressive disease are more 
likely to be treated with radiotherapy or hormonal treatment.  
Only a few series have reported PC deaths among men managed with active 
surveillance. In paper II, one man died from PC and another man developed 
PC metastases during a median follow-up of 6 years. The Toronto cohort, 
which has the longest follow-up, has reported, in a congress abstract at the 
EAU, that this cohort now has 14 PC deaths and another 16 patients who are 
alive but with PC metastases, among 840 patients managed with active 
surveillance with a median follow-up of 8.1 years. The actuarial 10-, 15-, and 
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20-year cancer-specific survival was 97.9%, 93.5%, and 86.3%. Of the 
patients who were treated, 21% had biochemical failure.[350] Medium-term 
outcome has also been reported from the Royal Marsden active surveillance 
cohort which have had two PC death among 471 active surveillance patient 
with a median follow-up of 5.7 years.[313] It is impossible to know if any of 
these deaths would have been prevented with immediate treatment. The 
evidence for immediate surgery for men with low-risk PC is uncertain and 
surgery for men with low-risk PC is difficult to justify.[68]   
Methodological considerations 
The main limitation in paper II was the lack of a protocol detailing the 
criteria for inclusion, follow-up and triggers for intervention. This hampers 
the possibility to compare the results from paper II with the results from 
protocol-based active surveillance studies. The lack of inclusion criteria 
resulted in a heterogeneous study population where some men where 
followed with watchful waiting rather than active surveillance. This is 
evident from the fact that the population also consisted of men with 
intermediate and high risk PC who traditionally are not regarded as 
candidates for active surveillance. The fact that 24 men started hormonal 
treatment during the study period is a further indication that the study 
population was no homogenous active surveillance cohort. However, from a 
clinical perspective, there is no clear-cut boundary between active 
surveillance and watchful waiting; as men grow older and gain comorbidities, 
active surveillance gradually transcends into watchful waiting.  
The use of a sextant biopsy deserved mentioning. When the study started, this 
was the standard method, but more recent studies have shown that a sextant 
biopsy results in many false negatives and that a 10-12 core biopsy detects 
30% more cancer.[140] The risk of undersampling is an important issue as it 
may lead to delayed of the correct risk group classification. With these 
limitations, it could be questioned whether the results from paper II are 
applicable to a group of carefully selected men with very-low or low-risk PC 
followed with a protocol-based active surveillance strategy. The results 
should instead be viewed as the outcomes of active surveillance for men in 
the general population and gives a picture on how active surveillance can be 
used in everyday practice. The results indicate that even with a population 
that is not heavily selected and followed according to carefully, pre-specified 
criteria the medium-term outcomes after deferred treatment are promising. 
The lack of a pre-defined follow-up protocol was probably not very 
influential on the results as the study population was mainly followed at the 
same clinic by a small group of urologists with the same treatment policies. 
This is strengthened by the fact that the proportion of men who were 
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managed with active surveillance was relatively constant during the study 
period, indicating that similar inclusion criteria were used. It is also 
interesting to observe that the results from paper II regarding the proportion 
of men discontinuing active surveillance and the reason for discontinuing are 
in line with results reported from cohorts with stricter criteria for inclusion 
and follow-up (Table 15 and 16). Despite having a follow-up that was longer 
than many other active surveillance cohorts, a median follow-up of six years 
is far too short to conclude that active surveillance is safe in the long term. 
The long-term findings from the Johansson cohort showed that localized PC 
can become lethal after having been stable for many years.[351] 
5.3 Paper III and IV – Drivers of 
overdiagnosis 
The results of paper III and paper IV have contributed with knowledge 
concerning factors that drive overdiagnosis and how screening can possibly 
be organized in order to reduce overdiagnosis. The results of paper III 
showed that opportunistic screening was far less effective in reducing PC 
mortality than organized screening and was associated with even more 
overdiagnosis when measured as NND. Organized screening resulted in a 
substantial mortality reduction (relative reduction of 42%) but there was no 
significant difference in PC mortality from opportunistic screening as carried 
out in Sweden at this time compared to pre-PSA era rates. In paper IV, the 
risk of being diagnosed with PC was heavily affected by age at screening but 
the number of screens had a minor effect. Furthermore, we could not identify 
any obvious association between changes in the PSA threshold during the 
course of the Göteborg trial or increase in the number of biopsy cores over 
time with the risk of PC diagnosis.  
Drivers of overdiagnosis can be found both in the screened population and in 
the screening algorithm. As there is no easy way to directly measure 
overdiagnosis it is also difficult to measure the effects of various risk factors. 
The evidence is therefore, to a large extent, based on simulations from 
modeling studies.  
Populations factors 
Ethnicity, age and comorbidities affect the risk of PC and the risk of 
overdiagnosis. A recent review of international autopsy studies among men 
without a clinical diagnosis of PC confirmed previous findings that the 
prevalence of histological cancer increases with age, ranging from 2% from 
white men in their 20’s to 69% of men above 90 years. African Americans 
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had the highest prevalence of PC and Asian men had the lowest prevalence 
when compared to white men. The size of the pool of prevalent cases 
indicates the upper bound of overdiagnosis, that is, how much additional 
cancer can potentially be detected.[20] In addition to having a high PC 
incidence, African American men are younger at diagnosis, are more likely to 
present with higher grade and stage and have an higher risk of dying from 
PC, compared to Caucasians.[352] Based on these findings, one would 
hypothesized that the risk of overdiagnosis should be lower among African 
American men. In contrast, several studies have reported that the 
overdiagnosis rate is, in fact, higher among blacks than whites.[163, 164]  
Another population factor that is an important driver for overdiagnosis is age. 
Several studies, mainly modeling studies, suggest that age is a very 
important, perhaps the most important, driver of overdiagnosis.[19, 165, 172, 
173, 198] Gulati et al. used a microsimulation model based on data from an 
American population, and modeled individual men’s life histories in a virtual 
population. Subsequently, the data was fitted to a logistic regression model to 
construct a nomogram that could predict the risk of overdiagnosis based on 
age, Gleason score and PSA. Age at diagnosis was the most important 
predictor of overdiagnosis; for each additional year of age the odds of 
overdiagnosis increased by 12.9%. Gleason score ≥7 was associated with a 
decrease in the odds (19.5% compared to Gleason score ≤6) as was a higher 
PSA (16.6% for each unit increase, 1 ng/mL, in PSA-levels).[172]  
The results from paper IV confirm that age is an important driver for 
overdiagnosis. For instance, the cumulative risk of being diagnosed with PC 
after 5 screens at the age of 60 years was 8%, compared to 13% at 65 years 
and 21% at 70 years. There are several explanations as to why the risk of 
overdiagnosis increases with age. As illustrated in autopsy studies, the 
prevalence of PC increases heavily with age and the pool of latent cancers 
that can potentially be detected by screening is larger.[20] Another reason as 
to why age is an important driver of overdiagnosis is that the risk of dying 
from other competing causes increases with age.[353-355] Therefore, even 
aggressive cancers can be considered overdiagnosed if diagnosed in older 
men with limited life-expectancy, who are more likely to die of something 
else. A study by Albertsen et al. showed that despite having an aggressive 
cancer (T1c, Gleason score 8-10), a man with comorbidities was up to five 
times more likely to die from other causes than his PC.[353] A study by 
Landsdorp-Voogelar et al. used seven different microsimulation models to 
investigate the benefits and harms of screening and to assess individual 
cessation ages for breast, colorectal and PC screening based on comorbidity 
status. The models simulated a U.S cohort of individuals aged 66 to 90 years 
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who had been screened regularly from 50 years and followed for a lifetime. 
The model suggested that the “optimal” age for screening cessation, based on 
comorbid conditions, varied with a 10 year interval around the age cut-point 
of 74. For example, a person who had been regularly screened since age 50 
years, with no comorbid conditions, could continue to be screened until age 
74 and still have the same ratio of benefits to harms as someone with average 
health until age 72 years or as someone with severe comorbid conditions 
screened until age 66 years.[356] Similar findings were reported from a 
simulation model using ERSPC data, where screening until the age of 75 in 
men with low comorbidity had almost the same adjustment for QoL as 
screening until the age of 69 years in the general population.[170]  
Screening factors 
Screening factors such as the number of screens, the screening interval, the 
PSA threshold for biopsy and number of biopsies are also drivers of 
overdiagnosis. As with age, the association between these risk factors and 
overdiagnosis has mainly been studied in modeling studies.[19, 165, 170, 
171, 173] These studies have found that overdiagnosis is associated with the 
screening interval, and that a shorter screening interval increases risk of 
overdiagnosis. However, the screening interval and the PSA threshold appear 
to have a smaller effect on risk of overdiagnosis than age. De Carvalho et al. 
investigated 83 different screening policies in a US population with the 
MISCAN model and compared these policies to a base model defined as 
annual screening from 50 to 74 years with a PSA threshold of 3 ng/mL. 
Decreasing the age of screening cessation had a larger effect on reducing 
overdiagnosis than increasing the screening interval or the PSA 
threshold.[173] Similar finding was reported from the modeling study based 
on ERSPC data, mentioned above, where decreasing the cessation age from 
74 years to 69 years led to a larger reduction in overdiagnosis than increasing 
the screening interval from one to four years. Screening annually up to the 
age of 74 years led to the largest reduction (-32%) in life-years gained due to 
negative QoL effects, whereas this figure was almost identical between 
screening annually (-23%) or every four years (-21%) from 55-69 years, 
implying that annual screening up to the age of 74 had the largest negative 
effect on QoL.[170]  
The risk of overdiagnosis and the screening interval is not straightforward. 
The screening interval is linked to the number of screens and each screening 
visit implies a certain risk of overdiagnosis. Moreover, natural fluctuations in 
the PSA-levels add to the complexity, as the PSA-level fluctuates also for 
men without prostatic diseases. For example, in the Göteborg screening trial, 
17% of men who had an elevated PSA (≥3 ng/mL) but a benign biopsy, had 
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normalized PSAs during a follow-up of four years.[357] With frequent 
screens, there is a risk that one of these normal fluctuations results in a 
positive screening test and subsequent biopsies with detection of an 
insignificant cancer, that was unrelated to the temporary PSA increase. For 
example, in the Göteborg screening study, 24% of those with a PSA-level 
above threshold had PC in subsequent biopsy[119] and of these, 34% were 
very-low-risk (paper II) which is presumed to be clinically insignificant. 
This implies that among those who had a positive screening test, the risk of 
being overdiagnosed was 8% (0.24x0.34=0.08).  
A long screening interval theoretically exposes the individual to fewer 
screens over time which would thus reduce overdiagnosis. However, an 
overly long screening interval may also risk missing the more aggressive, 
fast-growing tumors and instead diagnose the more slow-growing and less 
aggressive tumors (length-time bias). This would act in the opposite 
direction, and result in a larger proportion of less aggressive tumors, that 
have a higher probability of being overdiagnosed. A shorter screening 
interval would instead theoretically be associated with a higher likelihood of 
diagnosing the more fast-growing tumors, which are less likely to be 
overdiagnosed. Wu et al. investigated the risk of overdiagnosis and the 
“number of screens for overdetection” (NSO) in the Finnish center of the 
ERSPC. NSO indicates the expected number of men screened to result in one 
overdiagnosed man (a lower NSO indicates more overdiagnosis).There was a 
large difference in NSO depending on the age at starting screening, for 
example NSO was 104 for men starting at age 55 compared to 44 for starting 
at age 67, i.e. more overdiagnosis if screening started at a higher age. NSO 
also decreased with the number of screens and with a shorter screening 
interval (i.e. more overdiagnosis with more screens and higher screening 
frequency). However, the effect of the screening interval on risk of 
overdiagnosis was most pronounced when the screening interval was 
shortened from 8 to 4 years, NSO was identical for a 1-year and a 2-year 
screening interval.[165] In paper IV we found that the risk of being 
diagnosed with PC increased with each screen up to four screens but 
thereafter reached “steady-state”. It appeared as if the effect of the prevalent 
cases was “washed out” after four screens and the number of screens had a 
smaller effect on the risk of being diagnosed with PC, than age. The results 
from paper IV also suggest that men can start screening at a young age (≈50 
years) without substantially increasing their risk of overdiagnosis. This is an 
important finding as the age at start of screening has been shown to be 
important for screening to effectively reduce PC mortality.[2] However, the 
optimal age to start screening has yet to be established.    
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The PSA threshold is also important for risk of overdiagnosis, but perhaps 
less so than age and comorbidities.[171, 173] When Gulati et al. modeled the 
outcome of 35 different screening strategies they found that lowering the 
PSA threshold from 4 ng/mL to 2.5 ng/mL generated substantial harms in the 
form of false-positive screening tests and overdiagnosis, relative to the 
increase in averted deaths from PC.[171] A study by Vickers et al. 
investigated empirical estimates of overdiagnosis based on age and PSA-
level. They found that for men at the age of 60 years the risk of overdiagnosis 
was relatively low for those with a PSA above 4 ng/mL. The ratio of the risk 
of clinically detected PC to the risk for biopsy-detected PC for this group of 
men was close to one. For lower PSA-levels this ratio increased to slightly 
above two, indication more overdiagnosis.[198]  
In paper IV, lowering the PSA threshold in the Göteborg screening study 
was not associated with any apparent change in the cumulative PC incidence 
for the study population. The PSA threshold was lowered on two occasions 
(to 2.9 ng/mL in year 1999 and to 2.5 ng/ML in 2005). When analyzing the 
cumulative PC incidence curve for the entire study population, there was no 
sharp increase in incidence during the years following the two occasions at 
which the PSA threshold was lowered; rather, the slope of the curve was 
relatively constant during the entire follow-up (Figure 11).  
The number of biopsy cores sampled at each biopsy affects the detection rate 
of PC and therefore, most likely, the risk of overdiagnosis. Theoretically, 
increasing the number of cores should increase the risk of, by chance, 
detecting very small, potentially insignificant, tumors. During the last 30 
years, there has been a trend towards an increasing number of cores, from 2-4 
cores in the early 1980’s to today’s recommendation of 8-12 cores.[11] With 
the aim of minimizing sampling error some even advocate biopsy schemes 
including up to 30-40 cores. In the Göteborg screening trial, the number of 
biopsy cores was increased from 6 to 10 cores in 2009, which potentially 
could have augmented the risk of overdiagnosis. However, in paper IV, we 
could not identify any discernible increase in the cumulative PC incidence 
after changing the number of sampled cores (Figure 11). To the best of our 
knowledge, no study has investigated the number of biopsy cores and risk of 
overdiagnosis, but several studies have reported that increasing the number of 
cores detects more insignificant cancers. In the majority of these studies, no 
statistically significant difference has been observed in the detection of 
insignificant cancer when comparing sextant biopsies and extended biopsy 
schemes (10-12 cores), whereas extending the number of cores beyond 12 
appears to increase risk of finding insignificant cancer, while having only 
marginal effect on the overall detection rate.[132] 
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In summary, population factors such as age and comorbidity appear to be 
some of the strongest drivers of overdiagnosis. Factors that indicate screening 
intensity such as the PSA threshold, the number of sampled cores and the 
screening interval and/or the number of screens probably also affect risk of 
overdiagnosis, but perhaps not as strongly as the population factors. 
Organized versus opportunistic screening  
As previously described, screening for PC is a careful balance of benefits and 
harms. While trying to minimize overdiagnosis, a screening program must 
simultaneously aim at maximizing the benefits in the form of a reduced 
morbidity and mortality from advanced PC. In paper III we found that 
organized, biennial screening was more effective in reducing PC mortality 
than opportunistic screening, at least in the way it has been performed in the 
Göteborg male population the last 20 years. The participants in the screening 
arm of the Göteborg screening study have been screened intensively; every 
second year with a PSA threshold of 2.5-3 ng/mL, and the vast majority 
(87%) has complied with the biopsy recommendation following a positive 
screening test. Unfortunately, we did not have data on exactly how 
opportunistic screening had been carried out in the Göteborg area during the 
last 20 years; however, we find it unlikely that it has been as rigorous and 
intense as the organized screening in the screening arm of the study. For 
example, in the Dutch center of the ERSPC, only 7-8% of those with a PSA 
≥3 ng/mL in the control arm had a biopsy within six months following the 
PSA-test.[358] The results from paper III are in line with several studies 
from breast- and cervical cancer screening, which have shown that organized 
screening performs better and is more cost-effective than opportunistic 
screening.[257, 359, 360] The Council of the European Union has therefore, 
during several years, recommended that screening for breast, cervical and 
colorectal cancer should be conducted in organized programs.[361] There is 
no such recommendation for PC and with the exception of Lithuania,[362] no 
country in Europe has implemented a national organized PC screening 
program. The fascinating question is: why is organized screening more 
effective in reducing PC mortality, and associated with less overdiagnosis (in 
relation to every averted PC death) than opportunistic screening? What are 
the differences between these two screening strategies? There are several 
potential explanations, including screening intensity, the population being 
screened, compliance with biopsy and time to biopsy following a positive 
screen, adequacy of the follow-up of a positive screen and different treatment 
patterns.       
The intensity of a screening strategy consists of several different components 
as previously described (screening interval, PSA-threshold, number of 
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sampled cores). A comparison between the Dutch center (4 year interval) and 
the Swedish center (2 year interval) in the ERSPC found that a 2-year interval 
significantly reduced the incidence of advanced cancers but at the cost of an 
increased risk of low-risk PC diagnosis, compared to the 4-year interval.[363] 
These results are supported by the findings of a study from the Finnish 
ERSPC center, in which the screening interval had a large effect risk of 
advanced PC and PC mortality. Annual screening reduced risk of advanced 
PC by 40% compared to 24% for biennial screening and the reduction in PC 
mortality declined steadily as the screening interval increased.[364] The 
importance of screening intensity is also supported by a study by Stattin et al. 
who found that more intense opportunistic screening resulted in lower PC 
mortality as compared to less intense opportunistic screening. The relative 
risk of PC mortality in high versus low incidence counties in Sweden, 
adjusted for time period, was 0.81.[365] A higher screening intensity and 
over a longer period of time (started earlier in time) is likely also an 
explanation to why opportunistic screening has been effective in reducing the 
age-adjusted PC mortality in the US but not in Sweden. Since the 
introduction of PSA, the age-adjusted PC mortality in the US has fallen by 
more than 40% from its peak in 1993.[366] Sweden, which has one of the 
highest PC mortality rates in the world, has had an almost stable PC mortality 
since the 1960s.[15]  
There are no studies that have randomized men to screening with different 
PSA cut-offs for biopsy but from the PCPT trial it became clear that PSA 
could not be treated as a dichotomous variable; instead there was a 
continuum of risk of PC, and PC was present at all PSA-levels. Of these men 
with a PSA <4 ng/mL and a normal DRE, 15% harbored cancer. However, 
only 15% of these were Gleason score 7 or higher (corresponding to 2.5% of 
the entire population) indicating that the majority of tumors detected in these 
low PSA-levels are low-risk PC with a high risk of being 
overdiagnosed.[122] Nevertheless, there was no PSA-level where high risk 
PC was not present and there was no threshold associated with high 
sensitivity and specificity simultaneously.[121] The Göteborg screening 
study, which has had the most intense screening algorithm of all the ERSPC 
centers, with a screening interval of 2 years and a PSA threshold lowered to 
of 2.5 ng/mL during the course of the trial, is also the center that has reported 
the largest reduction in PC mortality. These results are a further indication of 
the importance of screening interval and PSA threshold. The Göteborg 
screening study is also unique in that it screened younger men, starting at age 
50. [2, 179, 180] Another factor that may play a role in the effectiveness of 
PSA-testing in reducing PC mortality is the time elapsed between a raised 
PSA to PC diagnosis, and treatment. Although we did not have information 
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on this, it can be hypothesized that this time period was longer for cases 
detected with opportunistic screening, which could have led to a worse 
prognosis and a smaller chance of cure, compared to cases detected with 
organized screening with a study protocol recommending biopsy for all 
screen-positive above 2.5-3 ng/mL.   
Other possible, theoretical, reasons why opportunistic screening may be less 
effective than organized screening may be inadequate treatment together with 
screening of a population who is unlikely to benefit from due to age or 
comorbidities. However, these factors are unlikely to explain the difference 
in effectiveness between organized and opportunistic screening in paper III 
because of the reasons discussed below, these factors may be influential 
when discussing screening in the general population. In the Göteborg 
screening study, which is a randomized trial, the screening and control arm 
had the same age distribution. In addition, the majority of men diagnosed 
with PC, in both the screening and control arm, have been handled by a small 
group of urologists at the same urology department in Göteborg, where the 
same treatment strategies apply. Therefore, it is unlikely that differences in 
age distribution or differential treatment can explain the large difference in 
the ability to reduce PC mortality. As regards opportunistic screening in the 
general population, there is room for improvement when it comes to focusing 
screening efforts on men who can potentially benefit from it. Drazer et al. 
reported from the National Health Interview Survey during years 2000-2005 
in the US that PSA-testing rates were highest for men 70-74 years, among 
which 45.5% reported being screened in the previous year and screening rates 
for men 85 years or older was as high as 24.6%. These men are unlikely to 
reap any benefits from PSA-testing due to competing risks and lower 
likelihood of being fit for curative treatment at such high age. Although PSA 
screening rates were lower for men with short life expectancy, 30% of those 
with the shortest life expectancy (>48% probability of death within 5 years) 
reported being screened in the previous year.[367] Similar finding have been 
reported in Sweden from the Stockholm area, were PSA-testing was most 
common in the age group 70-79 years. In this age group, almost half (45.7%) 
had undergone PSA-testing within the last two years. In addition, re-testing 
was common, regardless of the PSA-level. For example, almost half of men 
70-79 years who had a PSA <1ng/mL were re-tested within 2 years, despite 
that their risk of lethal cancer should be very low at such low PSA-levels. 
[34, 270]   
In summary, the results from paper III and paper IV suggest that screening 
should ideally be performed with a certain intensity to effectively reduce PC 
mortality and that opportunistic screening in Göteborg, Sweden during the 
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last 20 years does not seem to have reached this level. It also suggests that 
screening can be relatively intense for “younger” (<60-65 years) men, but in 
order to reduce overdiagnosis screening ought to be performed more 
selectively in older men and those with comorbidities. Drivers for 
overdiagnosis are found both in the population screened, as well as in the 
screening algorithm. By identifying these and by estimating their relative 
independent and interactive effects, we can create “smarter” screening 
strategies that minimize the harms while maintaining, or even improving, the 
benefits.  
Methodological considerations paper II and IV 
In both paper III and IV we drew conclusions regarding overdiagnosis based 
on PC incidence estimates. In paper III we assumed that the PC incidence 
trends in both the screening and control group were largely affected by 
screening (organized versus opportunistic). The optimal study design would 
be to have access to data regarding the extent of opportunistic screening in 
the control group; i.e. the number of PSA-tests, the proportion of PSA-tests 
that resulted in a biopsy etc. Had we had access to such data, we could have 
performed a direct comparison of the effects on organized and opportunistic 
screening on PC mortality, and we could also have evaluated which features 
of the opportunistic screening that made it less effective in reducing PC 
mortality. The historical comparison has weaknesses and it is impossible to 
rule out that there have been changes in the recording, treatment and 
prognosis of PC. In addition, it is impossible to rule out that there have been 
no changes in the background risk of PC. Nevertheless, as the Göteborg 
screening study is a randomized study, any changes would have influenced 
both arms in similar fashion, and should not have affected the conclusion.  
It can be questioned whether NND is the best estimate of overdiagnosis. 
There is no universally agreed upon method to estimate overdiagnosis.  The 
results from paper III showed that screening, regardless if it is organized or 
opportunistic resulted in an increased number of men diagnosed with PC 
compared to a situation without screening. This increase in incidence was 
smaller for opportunistic screening than for organized screening (Figure 8). 
Therefore, if overdiagnosis had instead been measured as the excess 
incidence, opportunistic screening would have appeared as the more 
favorable alternative. Screening results in four groups of patients; those who 
are overdiagnosed (not detected in the absence of screening), those who are 
detected earlier but still too late and will develop symptoms but not die from 
PC, those who are diagnosed earlier but still too late and would die from PC 
anyway and those who are saved from PC due to early detection through 
screening (Figure 12). The only group of these four who benefit from 
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screening is the last, the other three groups are harmed. The results from 
paper III showed that organized screening was much more effective in 
reducing PC mortality than opportunistic screening. The primary aim of 
screening is not to minimize the number of men with the diagnosis but to 
reduce disease-specific mortality. We therefore believe the group of men 
whose PC death has been prevented with screening men should be related to 
those who constitute the extra cases (Figure 12). We therefore choose to 
estimate overdiagnosis with NND which relates the mortality reduction to the 
excess incidence.  
Figure 12. Distribution of patient categories with different methods of diagnosis. 
 
In paper IV, as mentioned above, we also used PC incidence to estimate the 
effect of the number of screens and age at diagnosis on the risk of PC.  We 
assumed that a higher risk of PC diagnosis overall was a reflection of a 
higher risk of overdiagnosis. Although it can be presumed that an increase in 
the risk of PC diagnosis reflects an increased risk of overdiagnosis we do not 
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know how risk of overdiagnosis was distributed among different ages. 
Furthermore, we were unable to investigate the effect of different screening 
intervals, but instead estimated the effect of number of screens on incidence. 
Another limitation is that we were unable to measure the individual effect of 
each variable (age, number of screens, number of biopsy cores, PSA 
threshold) on the risk of PC diagnosis. This could possibly be analyzed in the 
form of a regression analysis, but such an analysis is not straightforward as 
several of the variables interact and are also time-dependent.  
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6 GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES 
Shifting the ratio of benefits to harm for PC will require “smarter” screening 
strategies. While awaiting future discoveries we must make the best out of 
tools we have available today. There are several strategies that can be applied 
to screen “smarter” and reduce the harms of overdiagnosis and overtreatment. 
The aim should be to identify those men who have an elevated risk of 
developing potentially life-threatening PC. Carlsson and Vickers et al. 
recently suggested five “golden rules” to improve the benefit to harm ratio 
for PC screening.[113, 368] To a large extent, these rules summarize what 
will be discussed below: 
- “Get consent” 
- “Don’t screen men who won’t benefit” 
- “Don’t biopsy without a compelling reason” 
- “Don’t treat low-risk disease” 
- “If you do have to treat, do so at a high-volume center”   
6.1 Risk stratified, individualized screening: 
finding the “right” tumor in the “right” 
patient 
Identifying those with an elevated risk of developing a life-threatening PC 
and those whom screening should be focused on can be based on age, 
comorbidities, ethnicity, family history and baseline PSA.  
As previously discussed, men of African American origin and men with a 
family history of PC are at higher risk of PC diagnosis and PC death and are 
more likely to benefit from screening.[10, 352] For example, in the Swedish 
National Guidelines for PC care it is recommended that men with hereditary 
PC (defined as ≥2 close relatives with PC of whom one was diagnosed <75 
years of age and/or men who test positive for BRCA2 mutation) start 
screening at the age 40-50 years and are screened with a 1-2 years 
interval.[64]  
Evidence regarding which age group to screen comes mainly from RCTs 
restricted to men 50-69 years.[2, 59] In addition, treatment benefits for 
radical prostatectomy is mainly limited to men <65 years, whereas individual 
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estimations of benefit apply.[67, 369] The results form paper IV and 
abundant evidence from other studies show that overdiagnosis increases with 
age.[19, 165, 172, 173, 198] Therefore, there is little evidence for continuing 
screening above the age of 70 years. On the other hand, there is also evidence 
indicating that older unscreened men have a higher risk of being diagnosed 
with higher risk PC with concomitant poorer prognosis, compared to younger 
men.[370, 371] Nevertheless, in order to minimize overdiagnosis, screening 
ought to be performed in a more selective manner for men above the age of 
70 years. Instead of applying a universal stopping age, an individualized 
stopping age is probably preferable as comorbidity and remaining life-
expectancy can vary greatly.[356] For men above 70 years but with an 
excellent health, who might have up to 30 years of remaining life-expectancy, 
screening can still be an alternative. Following the same argument, screening 
may be less valuable for certain younger men with a high level of 
comorbidity. Alternative strategies to reduce overdiagnosis in older men 
would be applying a higher PSA threshold for biopsy and/or increasing 
screening interval.[171] Several studies from the Malmö Preventive Project 
and the ERSPC have shown that the PSA-level in midlife is a strong 
predictor for future risk of clinical PC, PC metastases and PC death [32, 34, 
372-375] For instance, one of these studies which compared the screening 
group in the Göteborg screening study to an unscreened cohort in Malmö, 
reported that a baseline PSA at age 60 could be useful for identifying those 
who might benefit from screening. In the 26% of men who had a PSA ≥2 
ng/mL continued regular screening led to a large reduction in mortality with a 
NNS of 23 and NND of 6. The two thirds of men who had a baseline PSA-
level at 60 years of < 1ng/mL had very low-risks of PC metastases and death 
within 15 years.[373] Another study from the same group, showed that the 
risk of dying from PC at age 85 was very low (≤ 0.2%) for those with a PSA 
below the median (≤ 1 ng/mL) at age 60.[34] These findings suggests that the 
baseline PSA-level in midlife can be used to risk-stratify men, such that those 
with the lowest PSA can be screened less frequently and those with a PSA <1 
ng/mL at the age of 60, i.e. the majority of men, can possibly be exempted 
from further screening.        
In order to risk stratify men for screening, nomograms and risk calculators 
can help find patients at higher risk of PC whom are candidates for biopsy. 
These instruments are multivariate prediction tools, that have been developed 
with the aim of reducing unnecessary biopsies and overdiagnosis. Three 
commonly used risk calculators are the PCPT-risk calculator, the ERSPC risk 
calculator and the Sunnybrook risk calculator. They are all easily available 
online. 
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The PCPT risk calculator is a continuous multivariable risk calculator that 
was developed based on the 5519 men in the control arm of the trial.[116] 
The “basic” risk calculator uses race, age, PSA-level, family history, DRE 
and any previous prostate biopsy to assess the risk of PC if a biopsy is 
performed.[116] An updated 2.0 version has also been released which can 
predict low- versus high-risk cancer.[376] The calculator can be used for men 
above the age of 55 years and who have been screened with PSA and DRE. 
The calculator has an AUC between 0.56 and 0.72 for predicting a positive 
biopsy in different cohorts.[377] One limitation with this calculator is that it 
was based on men of whom the majority had PSA<3 ng/mL and the risk 
calculator can therefore overestimate the risk of cancer for men with a PSA 
above this level.  
The Dutch arm of the ERSPC has developed a risk calculator in six levels 
based on six different multivariable logistic regression analyses. Level 1 and 
2 are aimed at non-medical persons and do not require any medical 
knowledge; the remaining levels are for urologists. Level 3 predicts the 
presence of cancer in sextant biopsy and the degree of aggressiveness for 
previously unscreened men. Level 4 is for previously screened men but non-
biopsied men or those with a prior benign biopsy. Level 5 calculates the 
chance of harboring indolent cancer. Level 6 predicts future risk of PC.[378] 
These risk calculators use age, PSA, prostate volume, DRE findings, TRUS 
result, previous biopsy result and family history. The AUC for level 3-5, 
which have also been externally validated [379], ranges between 0.68 and 
0.79. Using a PSA threshold of 3 ng/mL, sextant biopsy and probability cut-
off of 12.5% for a positive biopsy Robool et al. showed that 33% of all 
biopsies could have been avoided using the risk calculator, compared to a 
using PSA only.[380] In a head-to-head comparison, the ERSPC risk 
calculator outperformed the PCPT risk calculator.[381]     
The Sunnybrook risk calculator uses age, family history, ethnicity, LUTS, 
total PSA, F/T PSA ratio and DRE to calculate an individual’s risk for PC. 
The AUC for the nomogram predicting any PC is 0.74 and 0.77 for high-risk 
cancer.[382] In head-to-head comparisons, the Sunnybrook risk calculator 
performed better than the PCPT risk calculator but neither one added clinical 
benefit for risk thresholds of PC diagnosis below 30% [383].  
Another possible theoretical strategy to reduce overdiagnosis is primary 
prevention trough chemoprevention with 5-alfa reductase inhibitors. 
Finasteride and duasteride have shown to reduce the risk of PC Gleason score 
≤6.[384-386] In addition, these agents reduce the symptoms from BPH and 
decrease the risk of urine retention. Duasteride have shown to improve 
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sensitivity and specificity of PSA for diagnosing Gleason score 7-10. 
However, these agents do not reduce the risk of high-risk cancer, or PC 
death, and concerns have been raised whether finasteride may even increase 
risk of high-grade cancer.[387] The costs and side-effects should also be 
considered and the exact role for these agents in the prevention of PC remains 
to be established.       
6.2 Reduce the harms of diagnosis 
Today, a large proportion of men with screen-detected PC are treated for a 
cancer that in the absence of screening would never have been diagnosed. 
These men have very little to gain from being diagnosed or treated and only 
risk having to live with side effects from treatment. When Heijnsdijk et al. 
performed a computer simulation study, modeling the effects of introducing 
annual screening, the beneficial effects of screening in terms of reducing PC 
mortality were reduced by 23% of QALYs gained, due to the downstream 
side effects of overdiagnosis and overtreatment. This can be compared to 
breast cancer screening where the corresponding figure is a reduction by 
8%.[170] 
The results from paper II in the present thesis, showed that a large 
proportion of men screen-detected PC are potential candidates for active 
surveillance. Active surveillance holds many promises for the future and it is, 
and will continue to be, an important strategy to reduce overtreatment. 
However, as discussed in chapter 5.2 in this thesis, some challenges need to 
be faced before active surveillance can be widely accepted. The limited 
follow-up of the reported active surveillance series and the lack of evidence 
from RCTs make it questionable to recommend active surveillance to the 
youngest patients who might have a remaining life-expectancy of more than 
30 years. On the other hand, these patients are probably those who have the 
most to gain when it comes to avoiding or delaying the side-effects from 
curative treatment. For these men, active surveillance is more about delaying 
treatment for some years rather than avoiding it completely. Therefore, 
discontinuing active surveillance and receiving curatively aiming treatment 
cannot be regarded as failure of active surveillance. 
Avoiding overtreatment is as important as avoiding undertreatment in men 
with potentially life-threatening PC. Akre et al. reported from PCBaSe that 
only 18% of men with locally advanced PC received curative treatment. PC 
mortality for those who were not treated was high (8-year PC mortality 28-
64%).[388] These figures can be compared to data from SEER-Medicare in 
the US, where 49% of men with locally advanced PC received curative 
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treatment within six months from diagnosis.[389] These figures, together 
with the fact that opportunistic screening in Sweden has not been as intense 
as in the US, may in part explain why PC mortality in Sweden has been 
relatively stable since 1960, while in the US, PC mortality has decreased by 
more than 40%. Curative treatment should be delivered with highest possible 
quality in men who are likely to benefit and the aim should be to minimize 
the side-effects from curative treatment, which have profound negative 
effects on HRQoL.[170] Several studies have shown that oncologic and 
functional outcome after radical prostatectomy vary between surgeons to a 
greater extent than what can be explained by chance. For example, Carlsson 
et al. showed that the individual surgeon’s experience was related to the risk 
of urinary incontinence.[75] A recent review, mostly based on US studies, 
reported a strong association between hospital volume and outcomes such as 
perioperative mortality and length of stay and surgeon volume with 
functional and oncologic outcomes.[390] In Sweden, there has been a 
centralization of urologic cancer surgery during recent years. For example, in 
the Western Region (sv.”Västra Götalands Regionen”), radical prostatectomy 
has been centralized to be performed at the three largest hospitals in the 
region, as compared to being performed at six hospitals earlier. A US study 
reported that, in 2005, 25% of surgeons performing radical prostatectomy in 
the US, performed only one procedure per year, and 80% performed less than 
10 procedures annually.[391] 
6.3  Other strategies to reduce the harms 
The results from paper III showed that opportunistic screening, the way it 
has been performed in Göteborg, Sweden during the last 20 years, has 
increased PC incidence but has had, little, or no effect on PC mortality. 
Opportunistic screening consumes a fair amount of health care resources, 
which could be questioned from an ethical perspective. On the other hand, 
introducing an population-based, organized PSA screening program today 
seems premature. The levels of overdiagnosis and overtreatment are 
unacceptable with current screening. “Smarter” screening strategies to reduce 
the harms are needed before organized screening can be implemented. 
Nevertheless, the ongoing opportunistic screening needs to be somehow 
addressed. Possible ways forward could be changing national guidelines 
together with educational efforts directed at primary care providers and other 
health care facilities which deliver opportunistic screening. An alternative 
strategy could be to build specialized screening clinics to which men who are 
interested in PC screening can be directed. These clinics would then take care 
of the entire chain of events from PSA-testing, to prostate biopsy to referrals 
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to urology or oncology clinics. The National Board of Health and Welfare in 
Sweden currently do not recommend organized PSA screening for men of 
any age, but state that men aged 50 to 70, who has received written 
information regarding the pros and cons of PSA screening, and who wish to 
have a PSA test should have the possibility. The Board also recognizes the 
need of improving the way current opportunistic PSA screening is carried out 
and recommend that methods of organizing opportunistic screening, such as 
standardized routines for delivering PSA and biopsy test results, as well as 
predetermined screening intervals, should be systematically evaluated. 
Informed decision-making is a key feature in screening recommendations 
from a number of organizations. However, this is also an area that can be 
improved. A study from the NPCR showed that only 14% of Swedish men 
had received written information before being tested and 10% were unaware 
that a PSA-test had been ordered.[392] A Swedish study in Region Skåne 
investigated the feasibility of organized information and voluntary screening 
by sending out the Board’s brochure “About the PSA-test” (sv.“Om PSA-
prov”), together with a questionnaire and information about the possibility to 
have a PSA test, to Swedish men aged 50-70. Men were well aware of the 
possibilities of PSA-testing, but the awareness varied with educational level; 
from 78% among men with a high-school education to 90% among those 
with college/university education. There were larger differences regarding the 
awareness of negative aspects of PSA-testing across educational levels. Of 
those with college or university education, 72% were aware of the negative 
aspects of PSA screening, compared to only 42% of those with primary 
education. These figures suggest that today’s Swedish guidelines, under 
which organized screening is discouraged, but no man can be denied testing 
if well-informed, risks leading to health care disparities, if well-educated men 
are those that best can take an informed decision regarding PSA-testing. 
Whether or not a man is entitled to a PSA-test should not be dependent on the 
personal beliefs of the treating physician or whether this man is someone who 
can speak for his rights. Equal health care is a fundamental right in Sweden 
regulated by the Health care act (sv. “Hälso- och sjukvårdslagen”). From this 
perspective, it might be better with an organized program that can reach the 
broader population in a more equal manner. 
The concept of overdiagnosis has been introduced relatively slowly over 
time, also among the medical profession. However, there is a growing 
awareness of this terminology and in 2012, the American National Cancer 
Institute organized a meeting specifically aimed at evaluate the challange 
with overdiagnosis in cancer screening. A working group from this meeting 
constructed a set of recommendations to form a strategy to address the issues 
surrounding overdiagnosis in cancer screening and prevention. First, it must 
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be recognized that overdiagnosis occurs, and that it is common. Second, a 
change in cancer terminology was recommended such that lesions with very 
low likelihood of progression would not be called “cancer” but instead be 
labeled “indolent lesions of epithelial origin” (IDLE). For PC, IDLE could be 
represented by Gleason score 6, according to some authors.[393] This change 
in taxonomy could help clinicians and patients choosing less aggressive 
treatment. Third, it was recommended that observational registers be created 
for low malignant lesions to gain more knowledge regarding these lesions. 
Fourth, the working group recommended that overdiagnosis should be 
mitigated with strategies such as avoiding diagnostic assessment when it is 
not truly necessary, reducing the screening frequency, raising the threshold 
for what constitutes a positive screen, and focusing screening on high-risk 
individuals. Fifth and lastly, they recommended that new strategies for 
determining what defines cancer progression and new screening strategies 
should be embraced.[394]           
There is an urgent need to improve the screening tools and diagnostic tools 
for PC. We are continuously gaining new knowledge and the future will 
hopefully bring us better tools such as biomarkers, genetic tests and novel 
imaging techniques that can help us identify and treat only those men who 
will actually benefit. Until then, we can do a lot by using the currently 
available tools in a “smarter” way. 
6.3.1 Novel screening markers, biomarkers 
The optimal biomarker for screening should be non-invasive, non-expensive, 
specific for PC and be able to differentiate between aggressive and non-
aggressive PC. However, this marker is yet to be found.  
Work is ongoing aiming at further improving the widely used PSA assays. 
The four kallikrein panel (4K score) [395] and the prostate heath index (PHI) 
are amongst the biomarkers that are the furthest ahead but both need 
additional evaluation.[396] The four kallikrein panel (total PSA, free PSA, 
intact PSA, and hK2) appear to have an improved predictive accuracy for 
diagnosing PC and high risk PC and have the potential to reduce the number 
of biopsies.[395] PHI combines total PSA, free PSA and -2proPSA into a 
single score and is calculated as PHI=[-2proPSA/free PSA] x √PSA. 
Catalona et al. reported, from a prospective multicenter study, that for men 
with a PSA 2-10 ng/mL, at a sensitivity of 80-95%, PHI performed better 
(specificity and AUC) than PSA and free/total PSA alone.[397] There are 
also several urinary markers based on RNA, DNA or proteins under 
investigation. The RNA-based urine markers such as the Prostate cancer 
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antigen 3 gene (PCA3) and TMPRSS2:ERG are amongst the most developed. 
However, urinary tests are less feasible than blood tests, since they must be 
preceded by prostatic massage by DRE to obtain enough cells to be analyzed. 
PCA3 is a prostate-specific gene and PCA3 mRNA is overexpressed in many 
PC cells. PCA3 score measures the amount of non-coding PCA3 mRNA in 
relation to normal PSA mRNA. Currently, the main use of PCA3 is in 
determining the need of repeat biopsy in men with an initial negative 
biopsy.[11] Detection of the gene fusion of TMPRSS2:ERG in urine may 
have the potential to better distinguish low-risk tumors from more aggressive 
ones.[398] 
Genetic and epigenetic markers of PC risk and prognosis is also an area of 
intense research. Genome-wide association studies (GWAS) have tried to 
identify markers of increased PC risk but the genetics behind PC is 
heterogeneous and so far, no single gene has been identified. Certain single 
nucleotide polymorphisms (SNP) have been linked to PC risk but the change 
in risk associated with each SNP is small. However, risk of PC appears to 
increase with increasing number of risk alleles.[399] Epigenetic changes in 
PCs are also a promising area of research. DNA methylation, for example, 
can lead to silencing or amplification of genes resulting in gene-expression 
alteration without changing the DNA sequence. For example, methylation 
status of the GSTP1 gene may be associated with PC risk.[400]  
6.3.2 Magnetic Resonance Imaging 
Multiparametric Magnetic Resonance Imaging (mp-MRI) has emerged as a 
promising adjunct to PSA in the diagnosis and follow-up of PC. MRI has the 
advantages of being a non-invasive procedure that does not expose the 
individual to ionizing radiation and can image the entire prostate in 3-5 mm 
sections. It builds on the principle that atomic nuclei in a strong magnetic 
field absorb pulses of radiofrequency energy and emit them as radio waves.  
These radio waves can then be received and reconstructed into 3D-images. 
[401] mpMRI includes T2-weighted imaging (T2WI), diffusion weighted 
imaging (DWI) and dynamic contrast enhanced imaging (DCEI). Some 
centers also perform magnetic resonance spectroscopy (MRS), which 
measures concentrations of metabolites (choline and creatine) in suspicious 
areas.  
T2WI can define the prostate anatomy with its different zones. Areas of low 
signal can, especially in the peripheral zone, indicate cancer. DWI measures 
the diffusion of water molecules. Areas of PC exhibit reduced diffusion of 
water. With this information, an apparent diffusion coefficient (APC) map of 
the prostate is built. In the contrast enhanced series a bolus of gandolinium 
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T2WI can define the prostate anatomy with its different zones. Areas of low 
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the prostate is built. In the contrast enhanced series a bolus of gandolinium 
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contrast is given followed by many rapid scans at short intervals. With this 
information it is possible to calculate time-against-perfusion curves.[401] It 
has been suggested that, in these curves, high-grade PC exhibit early and 
intense contrast enhancement and a rapid wash-out, in contrast to lower grade 
PC  
The European Society of Urogenital Radiology (ESUR) recommends that 
findings on prostate MRI are reported in a structure manner according to the 
Prostate Imaging-Reporting and Data System (PI-RAD). A score is given for 
each parameter within each region of interest. Presence of clinically 
significant cancer is indicated as 1=extremely unlikely, 2=unlikely and so on 
up to 5=extremely likely.[401, 402] T2WI, DWI and MRS can be helpful in 
estimating tumor grade and volume. These abilities could help reducing 
overdiagnosis by more selectively choosing candidates for biopsy and AS 
and for following men on AS.[401] mpMRI also has the potential to improve 
the way prostate biopsies are performed. Today, there are at least three main 
techniques to perform MRI-guided biopsies[401, 403, 404]:  
1. “MRI-informed free-hand” (cognitive) technique, during 
which the operator reviews the MRI images, and with this 
information performs a TRUS-guided biopsy directed 
towards the MRI-suspicious area. This technique has the 
advantages of being cheap and not requiring any specific 
equipment other than TRUS, but is limited by the obvious 
difficulties in guaranteeing that the “right” area is sampled. 
2. “MRI-TRUS-fusion biopsy”, where a particular software 
program downloads the information from the MRI and 
transfers it over to the ultrasound machine, and a fused 
image is built. Biopsies can then be directed towards the 
MRI-suspicious area. The advantages include a short 
learning curve for the examiner and possibly more accurate 
sampling. However, today’s equipment cannot compensate 
for any potential movement and deformation of the prostate 
by the probe and biopsy gun since the fusion between the 
MRI and ultrasound images cannot be performed in real 
time. 
3. “Real-time MRI-guided biopsy”. This technique is the most 
advanced and includes a MRI-compatible biopsy device, 
which allows biopsy sampling within the MRI machine, 
under the guidance of real-time MRI images. This technique 
can guarantee sampling from the area of interest, but it 
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limited by being time-consuming, costly and requiring the 
need for anesthesia  
Standard TRUS-guided biopsies (10-14 cores) are limited by sampling errors, 
as previously described, with both undersampling (false negatives or missing 
the foci with the highest Gleason score) and oversampling (diagnosis of 
clinically insignificant cancer). Undersampling is especially common in the 
anterior parts of the prostate. MRI-guided targeted biopsies have the potential 
to address several of these limitations. Among men with no previous biopsy, 
MRI may increase cancer detection with 50% for low-risk men and 70% for 
high-risk men. For low-risk men with previously negative biopsies, a 
negative MRI has a NPV which reaches 98%, implying that biopsies can be 
avoided and overdiagnosis decreased. For men with a previous negative 
biopsy, 72-87% of tumors detected under MRI-guidance are clinically 
significant.[403]   
mp-MRI also seems promising for the selection and follow-up of men on 
active surveillance. Turkbey et al. investigated the ability of a 3 Tesla (a 
measure of field strenght) mP-MRI and different clinical inclusion criteria 
(D’Amico, Epstein, CAPRA) to select appropriate candidates for active 
surveillance by comparing the results with findings at radical prostatectomy. 
mp-MRI outperformed clinical criteria and had a sensitivity of 93%, a PPV 
of 57% and an overall accuracy of 92% for finding clinically significant 
cancer, defined as tumor volume <0.5 ml, no Gleason pattern 4 or 5 or 
extracapsular or seminal vesicle involvement.[405] Stamatakis et al. reported 
on 85 patients who met the Johns Hopkins active surveillance criteria and 
who subsequently underwent a mp-MRI. After a confirmatory MRI/TRUS-
fusion-biopsy, 29% were no longer candidates for active surveillance.[406] 
This figure is similar to the figures of upgrading from standard TRUS-guided 
biopsies and radical prostatectomy. In a study of 388 men with low-risk PC 
who underwent MRI and a confirmatory biopsy, Vargas et al. found that 
findings on MRI correlated well with findings on confirmatory biopsy with a 
high NPV (86-100%), specificity (95-100%) and sensitivity (87-98%).[407]  
These and other studies, indicate that MRI has a high NPV for intermediate 
outcomes (upgrading) for men on AS and that a high-quality MRI can be of 
value for patient selection and follow-up to reduce the need for repeat biopsy. 
Much work remains before we know what constitutes significant radiological 
disease and radiological progression for men on active surveillance.  
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
 
Prostate Cancer Screening 
122 
The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
Rebecka Arnsrud Godtman 
123 
7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
 
Prostate Cancer Screening 
124 
ACKNOWLEDGEMENT 
The work behind this thesis was conducted at the Urology Department at the 
Sahlgrenska Academy at University of Göteborg between 2009 and 2014. 
Many people have been involved in this work and I would like to especially 
express my gratitude to the following people:     
Jonas Hugosson, M.D., Professor of Urology at the Sahlgrenska Academy at 
University of Göteborg, my main supervisor, who introduced me to the world 
of research. Thank you for believing in me and for giving me this fantastic 
opportunity to conduct my PhD work within the Göteborg screening study. 
Although there have been times when finalizing this thesis have felt 
impossible, I have always left our meetings filled with energy and optimism. 
You are a true inspiration!    
Johan Stranne, M.D., Associate Professor at the Sahlgrenska Academy at 
University of Göteborg, and my co-supervisor. Thank you for your 
enthusiasm and for always making me feel welcome; no matter how 
overloaded with work you are, you always take time to help and assist in 
every possible way.    
Jan-Erik Damber, M.D., Professor at the Sahlgrenska Academy at 
University of Göteborg Thank you for giving me the possibility to be a PhD 
student at your department. 
Ali Khatami, M.D. PhD, head of the Department of Urology at the 
Sahlgrenska University Hospital and co-author of paper II. Thank you for 
hiring me as a junior doctor, fresh out of medical school, for introducing me 
to the wonderful world of urology and giving me the opportunity to conduct 
my research at your clinic.   
Erik Holmberg, PhD, statistician. Thank you for your fantastic help with 
many of the statistical analysis of this thesis, for being patient with short 
deadlines and the numerous e-mails from me even late at night, during week-
ends and holidays.  
Sigrid Carlsson, M.D., PhD, MPH, Associate Professor the the Sahlgrenska 
Academy at University of Göteborg. Thank you for being my unofficial 
mentor during these years, for helping me with everything from revising 
manuscript (and this thesis) to giving advice on dress codes for various 
research events.   
 
125 
Helén Ahlgren, database manager. Thank you for your kind assistance with 
the study database and for all the fun we have had during our work. Without 
you, this thesis would not have been possible.  
Maria Nyberg, research nurse and my roommate during the last six months. 
Thank you for all your help and patience. Being roommate with a “klok 
gumma” has been invaluable! 
Lars Rex, M.D. and Hans Boman, M.D., PhD former and present head of 
the Surgery Department at Södra Älvsborgs sjukhus. Thank you for enabling 
this thesis by giving me time off from clinical work to conduct my PhD 
work. 
Hans Lilja, M.D., Professor of Clinical Biochemistry. Thank you for 
invaluable work with the Göteborg screening study and for co-authoring of 
paper III.  
The members of the cause of death committee of the Göteborg screening 
study; Silas Pettersson, Professor Emeritus in Urology, Eberhard 
Varenhorst, Professor Emeritus in Urology, Per Folmerz, specialist in 
urology and the late Bo Johan Norlén, Professor Emeritus in Urology. 
Thank you for your hard work and for charing your enormous knowledge and 
experience.   
Anna Grenbo Bergdahl, Maria Frånlund and Kimia Kohestani my fellow 
PhD students. Thank you for all the fun we have had in our research team and 
for the numerous trips around Europe. Anna, I owe you a trip to Italy!  
All my Colleagues at the Urology Department at Sahlgrenska University 
Hospital. Thank you for always making me feel welcome and for generously 
charing your knowledge and experience.   
To my mom, my dad and my brother Markus, thank you for your 
unconditional love and for your support, both emotionally and financially.  
Thank you for always believing in me, yet never putting pressure on me. 
To Martin, the love of my life, my fantastic husband. Thank you for your 
patience, love and support and for encouraging me to do thing for the right 
reasons. To Josefina, my beautiful, intelligent daughter, thank you for every 
day reminding me what is truly important.  
 
Prostate Cancer Screening 
124 
ACKNOWLEDGEMENT 
The work behind this thesis was conducted at the Urology Department at the 
Sahlgrenska Academy at University of Göteborg between 2009 and 2014. 
Many people have been involved in this work and I would like to especially 
express my gratitude to the following people:     
Jonas Hugosson, M.D., Professor of Urology at the Sahlgrenska Academy at 
University of Göteborg, my main supervisor, who introduced me to the world 
of research. Thank you for believing in me and for giving me this fantastic 
opportunity to conduct my PhD work within the Göteborg screening study. 
Although there have been times when finalizing this thesis have felt 
impossible, I have always left our meetings filled with energy and optimism. 
You are a true inspiration!    
Johan Stranne, M.D., Associate Professor at the Sahlgrenska Academy at 
University of Göteborg, and my co-supervisor. Thank you for your 
enthusiasm and for always making me feel welcome; no matter how 
overloaded with work you are, you always take time to help and assist in 
every possible way.    
Jan-Erik Damber, M.D., Professor at the Sahlgrenska Academy at 
University of Göteborg Thank you for giving me the possibility to be a PhD 
student at your department. 
Ali Khatami, M.D. PhD, head of the Department of Urology at the 
Sahlgrenska University Hospital and co-author of paper II. Thank you for 
hiring me as a junior doctor, fresh out of medical school, for introducing me 
to the wonderful world of urology and giving me the opportunity to conduct 
my research at your clinic.   
Erik Holmberg, PhD, statistician. Thank you for your fantastic help with 
many of the statistical analysis of this thesis, for being patient with short 
deadlines and the numerous e-mails from me even late at night, during week-
ends and holidays.  
Sigrid Carlsson, M.D., PhD, MPH, Associate Professor the the Sahlgrenska 
Academy at University of Göteborg. Thank you for being my unofficial 
mentor during these years, for helping me with everything from revising 
manuscript (and this thesis) to giving advice on dress codes for various 
research events.   
 
125 
Helén Ahlgren, database manager. Thank you for your kind assistance with 
the study database and for all the fun we have had during our work. Without 
you, this thesis would not have been possible.  
Maria Nyberg, research nurse and my roommate during the last six months. 
Thank you for all your help and patience. Being roommate with a “klok 
gumma” has been invaluable! 
Lars Rex, M.D. and Hans Boman, M.D., PhD former and present head of 
the Surgery Department at Södra Älvsborgs sjukhus. Thank you for enabling 
this thesis by giving me time off from clinical work to conduct my PhD 
work. 
Hans Lilja, M.D., Professor of Clinical Biochemistry. Thank you for 
invaluable work with the Göteborg screening study and for co-authoring of 
paper III.  
The members of the cause of death committee of the Göteborg screening 
study; Silas Pettersson, Professor Emeritus in Urology, Eberhard 
Varenhorst, Professor Emeritus in Urology, Per Folmerz, specialist in 
urology and the late Bo Johan Norlén, Professor Emeritus in Urology. 
Thank you for your hard work and for charing your enormous knowledge and 
experience.   
Anna Grenbo Bergdahl, Maria Frånlund and Kimia Kohestani my fellow 
PhD students. Thank you for all the fun we have had in our research team and 
for the numerous trips around Europe. Anna, I owe you a trip to Italy!  
All my Colleagues at the Urology Department at Sahlgrenska University 
Hospital. Thank you for always making me feel welcome and for generously 
charing your knowledge and experience.   
To my mom, my dad and my brother Markus, thank you for your 
unconditional love and for your support, both emotionally and financially.  
Thank you for always believing in me, yet never putting pressure on me. 
To Martin, the love of my life, my fantastic husband. Thank you for your 
patience, love and support and for encouraging me to do thing for the right 
reasons. To Josefina, my beautiful, intelligent daughter, thank you for every 
day reminding me what is truly important.  
 
Rebecka Arnsrud Godtman 
123 
7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
 
Prostate Cancer Screening 
126 
Thank you!  
This thesis was made possible by the financial support by: 
• Swedish Cancer Society (Cancerfonden) 
• Percy Falk’s foundation for prostate and breast cancer 
research 
• Märta and Gustaf Ågren’s foundation 
• Anna-Lisa and Bror Björnsson’s foundation 
     
REFERENCES 
1. Dorlands Medical Dictionary; Available from: 
http://www.dorlands.com/.[ Accessed 6 Oct 2014] 
2. Hugosson J, Carlsson S, Aus G, et al. Mortality results from 
the Goteborg randomised population-based prostate-cancer screening trial. 
Lancet Oncol. 2010;11(8):725-32. 
3. Walsh CP, Retik BA, Vaughan DE, Wein A. Campbell's 
Urology. 7th ed. Philadelphia: W.B. Saunders Company; 1998. 
4. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific 
antigen. J Clin Oncol. 2003;21(2):383-91. 
5. The National Board of Health and Welfare S. Cancer 
incidence in Sweden 2012. 2013; Available from: 
http://www.socialsty elsen.se/publikationer2013/2013-12-17.[Accessed 6 Oct 
2014] 
6. Leitzmann MF, Rohrmann S. Risk factors for the onset of
prostatic cancer: age, location, and behavioral correlates. Clinical 
epidemiology. 2012;4:1-11. 
7. National Prostate Cancer Register. Annual report 2012. 2013; 
Available from: http://npcr.se/wp-content/uploads/2013/04/20131121-NPCR-
Rapport-2012.pdf. 
8. Sakr WA, Grignon DJ, Crissman JD, et al. High grade 
prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma 
between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 
1994;8(3):439-43. 
9. Soos G, Tsakiris I, Szanto J, Turzo C, Haas PG, Dezso B. The 
prevalence of prostate carcinoma and its precursor in Hungary: an autopsy 
study. Eur Urol. 2005;48(5):739-44. 
10. Hemmi ki K. Famili l risk and familial surviv l in prostate
cancer. World J Urol. 2012;30(2):143-8. 
11. Mottet N, Bastian PJ, Bellmunt J, et al. EAU Guidelines on 
Prostate Cancer. European Association of Urology. 2014. 
12. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J 
Cancer. 2010;127(12):2893-917. 
13. Center MM, Jemal A, Lortet-Tieulent J, et al. International 
variation in prostate cancer incidence and mortality rates. Eur Urol. 
2012;61(6):1079-92. 
14. Cancer incidence in Sweden 2011. The National Board of 
ealth and Welfare. Available from: 
http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/18919/2012-
12-19.pdf. [Accessed 6 Oct 2014] 
127
Rebecka Arnsrud Godtman 
3 
7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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Those who have had a PSA-test will then be randomized into one of three 
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ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
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the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
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the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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mortality, can be increased and overdiagnosis reduced (relative to the gain).  
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but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
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promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
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in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
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most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
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trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
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screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
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the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
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ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
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order to minimize overdiagnosis, screening should be focused on younger 
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that can selectively diagnose only clinically relevant tumors. A large 
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the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
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in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
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Those who have had a PSA-test will then be randomized into one of three 
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ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
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targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
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The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
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for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
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for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
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with a suspicious lesion on MRI, an extra 4 cores directed towards 
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ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
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the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
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for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
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ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
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This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
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7 CONCLUSION 
This thesis aimed at exploring different aspects of overdiagnosis in screening 
for PC. In paper I, we concluded that death certificates for men with PC in 
Sweden are of high quality and can be used for endpoint evaluation of PC 
screening studies. Overdiagnosis in the screening arm was not associated 
with any larger effect on the COD determination. In paper III and paper IV 
we investigated drivers of overdiagnosis. By organizing screening within the 
frameworks of a program the effectiveness, in terms of reducing PC 
mortality, can be increased and overdiagnosis reduced (relative to the gain).  
If a screening program were to be introduced, our results indicate that, in 
order to minimize overdiagnosis, screening should be focused on younger 
men and only performed carefully in selected older men. The intensity of 
screening appears important for screening to effectively reduce PC mortality, 
but seem to be of less important for the risk of overdiagnosis than age at 
termination of screening. In paper II, we explored how overtreatment, 
following overdiagnosis, can be reduced. Active surveillance appears to be a 
promising management strategy, at least until we have a screening strategy 
that can selectively diagnose only clinically relevant tumors. A large 
proportion of men diagnosed with screen-detected PC are candidates for 
active surveillance. With active surveillance these men can avoid or postpone 
the side-effects of curative treatment without risking the chance of cure, at 
least in the medium-term.   
We now have evidence that screening with PSA can reduce the burden of PC 
in terms of reduced morbidity and PC mortality [2, 59, 148, 149] but is 
associated with considerable harms, of which overdiagnosis and 
overtreatment are the major concerns. Does this mean we should stop the use 
of PSA as a screening test? The obvious answer for me personally is: “No”. 
By no means would we would want to turn back time to the pre-PSA era and 
most would probably agree that it would not be desirable. So, what options 
do we have? Until alternative screening tools or strategies are developed we 
must stop using a “one-size fits all” strategy for screening and instead 
develop individualized screening strategies where focus is on the individual 
patient.[408] Guided by factors such as the PSA-value, age, comorbidities 
and life expectancy, we can screen “smarter” and reduce overdiagnosis. 
Hopefully, in the near future, MRI will be a valuable and integrated part of 
the screening algorithm that may further reduce the harms of screening. 
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The GÖTEBORG-2 trial 
Several of these, new, promising features of mp-MRI will be investigated in 
the GÖTEBORG-2 trial which will be launched in late 2014/early 2015. The 
trial is a 3-arm RCT, which will be a collaboration between the Depertment 
of Urology and the Department of Radiology at the Sahlgrenska Academy, 
the Regional Cancer Center and Chalmers University of Technology, in 
Göteborg, Sweden. In the first phase, 40000 men in the Western Region will 
be randomized in a 1:1 ratio to a screening or control group. The 20,000 men 
in the screening group will, after informed consent, be offered a PSA-test. 
Those who have had a PSA-test will then be randomized into one of three 
study arms.  
• Arm 1 (the reference arm). In this arm, the PSA threshold is 3 
ng/mL. Screen-positive men will be invited to a mpMRI followed by 
TRUS-guided standard (10-core) biopsy for all men, and for those 
with a suspicious lesion on MRI, an extra 4 cores directed towards 
the suspicious area/s (targeted biopsies).  
• Arm 2 (experimental arm I). In this arm, the PSA threshold is again 3 
ng/mL. Screen-positive men will be invited to mpMRI, but only 
targeted biopsies, and no systematic biopsies, will be performed. 
Men with a negative MRI will not be biopsied. 
• Arm 3 (experimental arm II). In this arm, the PSA threshold is 1.8 
ng/mL, and otherwise identical to arm 2.  
The hypothesis is that PSA+mp-MRI will reduce the number of men biopsied 
unnecessarily, and increase specificity and reduce overdiagnosis by reducing 
the number of men diagnosed with insignificant cancer, without 
compromising sensitivity or detection rate.  
Several side-studies will also be performed, including studies on technical 
aspects of mp-MRI, feasibility and logistics, costs and cost-effectiveness, 
QoL, biomarkers, equitable care and health care disparities. 
403. Bjurlin MA, Meng X, Le Nobin J, et al. Optimization of 
Prostate Biopsy: the Role of Magnetic Resonance Imaging Targeted Biopsy 
in Detection, Localization and Risk Ass sment. J Urol. 2014;192(3):648-58. 
404. Lee DJ, A med HU, Moore CM, Emberton M, Ehdaie B.
Multiparametric magnetic resonance imaging in the management and 
diagnosis of prostate cancer: current applications and strategies. Current 
urology reports. 2014;15(3):390. 
405. Turkbey B, Mani H, Aras O, et al. Prostate cancer: can 
multiparametric MR imaging help identify patients who are candidates for 
active surveillance? Radiology. 2013;268(1):144-52. 
406. Stamatakis L, Siddiqui MM, Nix JW, et al. Accuracy of 
multiparametric magnetic resonance imaging in confirming eligibility for 
active surveillance for men with prostate cancer. Cancer. 2013;119(18):3359-
66. 
407. Vargas HA, Akin O, Afaq A, et al. Magnetic resonance 
imaging for predicting prostate biopsy findings in patients considered for 
active surveillance of clinically low risk prostate cancer. J Urol. 
2012;188(5):1732-8. 
408. M Naughton-Collins MF, Barry MJ. One man at a time--
resolving the PSA controversy. N Engl J Med. 2011;365(21):1951-3. 
 
 
R
eb
ecka A
rnsrud
 G
o
d
tm
an 
 
P
ro
state C
ancer S
creening
 – A
sp
ects o
f O
verd
iag
no
sis
Prostate Cancer Screening
Aspects of Overdiagnosis
2014
Rebecka Arnsrud Godtman
Institute of Clinical Sciences
at Sahlgrenska Academy
University of Gothenburg
ISBN 978-91-628-9224-1
Printed by Ale Tryckteam AB, Bohus
